

South Africa Country Operational Plan FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

		Funding Source				
Agency	GAP	GHP-State	GHP-USAID	Total		
HHS/CDC	3,450,000	83,459,062		86,909,062		
HHS/HRSA		8,290,207		8,290,207		
HHS/NIH		1,800,000		1,800,000		
PC		2,375,000		2,375,000		
State		2,941,014		2,941,014		
State/AF		1,490,000		1,490,000		
USAID		155,194,717	0	155,194,717		
Total	3,450,000	255,550,000	0	259,000,000		

Summary of Planned Funding by Budget Code and Agency

		Agency								
Budget Code	State	HHS/CDC	HHS/HRS	HHS/NIH	PC	State/AF	USAID	AllOther	On Hold Amount	Total
CIRC	69,065	12,223,76 6					16,781,34 6	0	0	29,074,17 7
НВНС	120,669	3,997,549			469,935	345,000	11,625,02 8	0	0	16,558,18 1
HKID	533,527	123,140			590,535	1,145,000	14,669,74 7		0	17,061,94 9
HLAB	69,065	3,570,634					18,101		0	3,657,800
HMBL		0								0
HMIN		0								0
HTXD	69,065	0					28,962		0	98,027
HTXS	69,065	23,730,59 8		300,000			38,006,06 4	0	0	62,105,72 7
HVAB	69,065	458,972			517,735		6,169,493	0	0	7,215,265
HVCT	69,065	3,421,801					4,987,455	0	0	8,478,321



	2,941,014	86,909,06 2	8,290,207	1,800,000	2,375,000	1,490,000	155,194,7 17	0	0	259,000,0 00
PDTX	69,065	6,390,149					9,155,117		0	15,614,33 1
PDCS	69,065	900,865					3,692,790		0	4,662,720
OHSS	72,946	3,894,230	6,837,707				9,663,691	0	0	20,468,57
МТСТ	69,065	3,159,880					8,292,420		0	11,521,36 5
IDUP		116,013							0	116,013
HVTB	69,065	8,678,980	750,000	1,500,000			15,645,45 2		0	26,643,49 7
HVSI	72,946	2,318,232					3,665,347		0	6,056,525
HVOP	69,065	5,081,827	702,500		517,737		7,003,891	0	0	13,375,02 0
HVMS	1,381,211	8,842,426			279,058		5,789,813	0	0	16,292,50 8



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	14,971,184	0
HKID	15,429,228	0
HVTB	25,764,908	0
PDCS	4,229,150	0
Total Technical Area Planned Funding:	60,394,470	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	3,093,068	0
HVSI	4,363,312	0
OHSS	19,479,326	0
Total Technical Area Planned Funding:	26,935,706	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	28,173,706	0
HVAB	5,997,891	0
нуст	7,771,247	0
HVOP	11,842,213	0



Funding:	04,023,483	"
Total Technical Area Planned	64,623,483	0
MTCT	10,738,426	0
IDUP	100,000	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	0	0
HTXS	60,818,508	0
PDTX	14,995,379	0
Total Technical Area Planned	75 042 007	
Funding:	75,813,887	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
	Number of unique sites supported by PEPFAR	4,859	
	By program area/support type: HTC Direct Service Delivery (DSD)	825	
	By program area/support type: HTC Technical Assistance-only (TA)	2,795	
	By program area/support type: Treatment Direct Service Delivery (DSD)	825	
	By program area/support type: Treatment Technical Assistance-only (TA)	2,795	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	825	
	By program area/support type: Care and Support Technical Assistance-only (TA)	2,795	
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	825	
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	2,795	



By program area/support type: PMTCT Direct Service	805	
Delivery (DSD)		
By program area/support type: PMTCT Technical	2,695	
Assistance-only (TA)		
By program area/support type: TB/HIV Direct Service	825	
Delivery (DSD)		
By program area/support type: TB/HIV Technical	2,795	
Assistance-only (TA)		
By program area/support type: VMMC Direct Service Delivery (DSD)	525	
By program area/support type: VMMC Technical Assistance-only (TA)	25	
By program area/support type: General Population Prevention Direct Service Delivery (DSD)	47	
By program area/support type: General Population Prevention Technical Assistance-only (TA)	87	
By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	162	
By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	110	
By program area/support	76	



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	186	
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	805	
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	2,795	
	By program area/support type: Lab Direct Service Delivery (DSD)	21	
	By program area/support type: Lab Technical Assistance-only (TA)	2,759	
	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	n/a	
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		2,800
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		2,800
	By site support type: Direct Service Delivery (DSD):		336



	Number of		
	PEPFAR-supported sites		
	achieving 90% ARV or ART coverage for HIV+ pregnant		
	women		
	By site support type:		
	Technical Assistance-only		
	(TA): Number of		0.404
	PEPFAR-supported sites		2,464
	achieving 90% ARV or ART		
	coverage for HIV+ pregnant		
	women		
	Sum of Numerator Support		2,800
	Type disaggregates		2,000
	By site support type: Direct		
	Service Delivery (DSD):		
	Total number of PEPFAR		220
	supported sites providing		336
	PMTCT services (HTC and		
	ARV or ART services)		
	By site support type:		
	Technical Assistance-only		
	(TA): Total number of		
	PEPFAR supported sites		2,464
	providing PMTCT services		
	(HTC and ARV or ART		
	services)		
	Sum of Denominator Support		
	Type disaggregates		2,800
	PMTCT_STAT_DSD		
	Number and percentage of		
	pregnant women with known		
PMTCT_STAT_DSD	status (includes women who	100 %	
I MIOI_OIAI_DOD	were tested for HIV and		
	received their results) (DSD)		
	Number of pregnant women	230,000	96,000
	radified of pregnant women	230,000	30,000



with known HIV status		
(includes women who were		
tested for HIV and received		
their results)		
Number of new ANC and	230,000	96,000
L&D clients	200,000	33,333
By: Known positives at entry		
By: Number of new positives		
identified		
Sum of Positives Status		
disaggregates		
Required only for DREAMS		
Countries - By Number of		
new positives: <15		
Required only for DREAMS		
Countries - By Number of		
new positives: 15-19		
Required only for DREAMS		
Countries - By Number of		
new positives: 20-24		
Required only for DREAMS		
Countries - By Number of		
new positives: 25+		
Required only for DREAMS		
Countries - By Number of		
known positives: <15		
Required only for DREAMS		
Countries - By Number of		
known positives: 15-19		
Required only for DREAMS		
Countries - By Number of		
known positives: 20-24		
Required only for DREAMS		
Countries - By Number of		
known positives: 25+		
<u> </u>	l .	



	Required only for DREAMS Countries - Denominator: <15 Required only for DREAMS Countries - Denominator:		
	<15-19 Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
	PMTCT_STAT_NA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (Neither)	n/a	
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients		
	By: Known positives at entry By: Number of new positives identified		
	Sum of Positives Status disaggregates		
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received	100 %	



	their results) (NGI)		
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,000,000	800,000
	Number of new ANC and L&D clients	1,000,000	800,000
	By: Known positives at entry		
	By: Number of new positives identified		
	Sum of Positives Status disaggregates		
	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	100 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	770,000	704,000
PMTCT_STAT_TA	Number of new ANC and L&D clients	770,000	704,000
	By: Known positives at entry		
	By: Number of new positives identified		
	Sum of Positives Status disaggregates		
	Required only for DREAMS countries - By known positives: <15		_
	Required only for DREAMS		



	1		
	countries - By known		
	positives: 15-19		
	Required only for DREAMS		
	countries - By known		
	positives: 20-24		
	Required only for DREAMS		
	countries - By known		
	positives: 25+		
	Required only for DREAMS		
	countries - By new positives:		
	<15		
	Required only for DREAMS		
	countries - By new positives:		
	15-19		
	Required only for DREAMS		
	countries - By new positives:		
	20-24		
	Required only for DREAMS		
	countries - By new positives:		
	25+		
	Required only for DREAMS		
	countries - Denominator: <15		
	Required only for DREAMS		
	countries - Denominator:		
	15-19		
	Required only for DREAMS		
	countries - Denominator:		
	20-24		
	Required only for DREAMS		
	countries - Denominator: 25+		
	PMTCT_ARV_DSD		
	Percentage of HIV-positive		
PMTCT_ARV_DSD	pregnant women who	100 %	
	received antiretrovirals to		
	reduce risk for		
			<u>L</u>



mother-to-child-transmission		
(MTCT) during pregnancy		
and delivery (DSD)		
Number of HIV-positive		
pregnant women who		
received antiretrovirals to		
reduce risk of	63,250	26,400
mother-to-child-transmission		
(MTCT) during pregnancy		
and delivery		
Number of HIV- positive		
pregnant women identified in		
the reporting period	63,250	26,400
(including known		
HIV-positive at entry)		
Life-long ART (including		
Option B+)	63,250	26,400
Sub-Disag of Life-long ART:		
Newly initiated on treatment	50,600	21,120
during the current pregnancy	,	
Sub-Disag of Life-long ART:		
Already on treatment at the		
beginning of the current	12,650	5,280
pregnancy		
Maternal triple ARV		
prophylaxis (provided with		
the intention to stop at the		
end of the breastfeeding		
period)		
Maternal AZT (prophylaxis		
component of WHO Option A		
during pregnancy and		
delivery)		
Single-dose nevirapine (with		
or without tail)		
or without tail)		



	Sum of Regimen Type		
	disaggregates	63,250	26,400
	Sum of New and Current disaggregates	63,250	26,400
	PMTCT_ARV_NA		
	Percentage of HIV-positive		
	pregnant women who		
	received antiretrovirals to		
	reduce risk for	n/a	
	mother-to-child-transmission		
	(MTCT) during pregnancy		
	and delivery (Neither)		
	Number of HIV-positive		
	pregnant women who		
	received antiretrovirals to		
	reduce risk of		
	mother-to-child-transmission		
	(MTCT) during pregnancy		
	and delivery		
PMTCT_ARV_NA	Number of HIV- positive		
	pregnant women identified in		
	the reporting period		
	(including known		
	HIV-positive at entry)		
	Life-long ART (including		
	Option B+)		
	Sub-Disag of Life-long ART:		
	Newly initiated on treatment		
	during the current pregnancy		
	Sub-Disag of Life-long ART:		
	Already on treatment at the		
	beginning of the current		
	pregnancy		
	Maternal triple ARV		
	prophylaxis (provided with		



	1		
	the intention to stop at the		
	end of the breastfeeding period)		
	Maternal AZT (prophylaxis		
	component of WHO Option A		
	during pregnancy and		
	delivery)		
	Single-dose nevirapine (with		
	or without tail)		
	Sum of Regimen disaggregates		
	Sum of New and Current		
	disaggregates		
	PMTCT_ARV_NGI		
	Percentage of HIV-positive		
	pregnant women who		
	received antiretrovirals to	100 %	
	reduce risk for		
	mother-to-child-transmission		
	(MTCT) during pregnancy and delivery (NGI)		
	Number of HIV-positive		
	pregnant women who		
DIATOT ADV NO	received antiretrovirals to		
PMTCT_ARV_NGI	reduce risk of	275,000	
	mother-to-child-transmission		
	(MTCT) during pregnancy		
	and delivery		
	Number of HIV- positive		
	pregnant women identified in		
	the reporting period	275,000	
	(including known		
	HIV-positive at entry)		
	Life-long ART (including	275,000	
	Option B+)		



		i -	ı
	Sub-Disag of Life-long ART:		
	Newly initiated on treatment	220,000	
	during the current pregnancy		
	Sub-Disag of Life-long ART:		
	Already on treatment at the	FF 000	
	beginning of the current	55,000	
	pregnancy		
	Maternal triple ARV		
	prophylaxis (provided with		
	the intention to stop at the		
	end of the breastfeeding		
	period)		
	Maternal AZT (prophylaxis		
	component of WHO Option A		
	during pregnancy and		
	delivery)		
	Single-dose nevirapine (with		
	or without tail)		
	Sum of Regimen	275 000	
	disaggregates	275,000	
	Sum of New and Current	075 000	
	disaggregates	275,000	
	PMTCT_ARV_TA		
	Percentage of HIV-positive		
	pregnant women who		
	received antiretrovirals to	100 %	
	reduce risk for	100 %	
	mother-to-child-transmission		
PMTCT_ARV_TA	(MTCT) during pregnancy		
	and delivery (TA)		
	Number of HIV-positive		
	pregnant women who		
	received antiretrovirals to	211,750	193,600
	reduce risk of		
	mother-to-child-transmission		



(MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in	
Number of HIV- positive	
pregnant women identified in	
the reporting period 211,750 1	193,600
(including known	
HIV-positive at entry)	
Life-long ART (including	102 600
Option B+) 211,750 1	193,600
Sub-Disag of Life-long ART:	
Newly initiated on treatment 169,400 1	154,880
during the current pregnancy	
Sub-Disag of Life-long ART:	
Already on treatment at the	
beginning of the current	38,720
pregnancy	
Maternal triple ARV	
prophylaxis (provided with	
the intention to stop at the	
end of the breastfeeding	
period)	
Maternal AZT (prophylaxis	
component of WHO Option A	
during pregnancy and	
delivery)	
Single-dose nevirapine (with	
or without tail)	
Sum of Regimen Type	
disaggregates 211,750 1	193,600
Sum of New and Current	
disaggregates 211,750 1	193,600
KP_MAT_DSD Percentage	
of people who inject drugs	
KP_MAT_DSD (PWID) on medication n/a	
assisted therapy (MAT) for at	



		ſ	
	least 6 months		
	Number of people who inject		
	drugs (PWID) on medication	120	240
	assisted therapy (MAT) for at		
	least 6 months		
	Sex: Male	60	120
	Sex: Female	60	120
	Sum of Sex disaggregates	120	240
	Number of males		
	circumcised surgically or by		
	medical device that	42.000	
	experienced at least one	12,000	
	moderate or severe adverse		
	event(s) (AEs)		
	By AE type: Number of		
	VMMC clients with one or		
	more moderate or severe		
	surgical intra-operative AE(s)		
	Sub-Disag: Surgical		
	intra-operative AE(s) by		
	maximum severity category:		
VMMC_AE_DSD	Number of clients with one or		
	more moderate surgical		
	intra-operative AE(s), but no		
	severe surgical		
	intra-operative AE(s)		
	Sub-Disag: Surgical		
	intra-operative AE(s) by		
	maximum severity category:		
	Number of clients with one or		
	more severe surgical		
	intra-operative AE(s)		
	By AE Type: Number of		
	VMMC clients with one or		
	more moderate or severe		



	curgical post operative AE(a)		
	surgical post-operative AE(s)		
	Sub-Disag: By Surgical		
	post-operative AE(s) by		
	maximum severity category:		
	Number of clients with one or		
	more moderate surgical		
	post-operative AE(s), but no		
	severe surgical		
	post-operative AE(s)		
	Sub-Disag: By Surgical		
	post-operative AE(s) by		
	maximum severity category:		
	Number of clients with one or		
	more severe surgical		
	intra-operative AE(s)		
	By AE Type: Number of		
	VMMC clients with one or		
	more moderate or severe		
	medical device-related AE(s)		
	Sub-Disag: By Medical		
	device-based AE(s) by		
	maximum severity category:		
	Number of clients with one or		
	more moderate medical		
	device-related AE(s), but no		
	severe medical		
	device-related AE(s)		
	Sub-Disag: By Medical		
	device-based AE(s) by		
	maximum severity category:		
	Number of clients with one or		
	more severe medical		
	device-related AE(s)		
	Number of males		
VMMC_CIRC_DSD	circumcised as part of the	438,000	216,930
A IMUMO OUTO DOD	·	430,000	210,930
	voluntary medical male		



singuing sision ()/BABAO) for LUI/		
circumcision (VMMC) for HIV		
prevention program within		
the reporting period		
By Age: <1	0	
By Age: 1-9	0	
By Age: 10-14	65,800	32,540
By Age: 15-19	174,800	86,772
By Age: 20-24	87,600	43,386
By Age: 25-29		
By Age: 30-49		
By Age: 50+	22,400	10,846
Sum of age disaggregates	438,000	216,930
By HIV status: Number of		
HIV-positive clients (tested		
HIV positive at VMMC site)		
By HIV status: Number of		
HIV-negative clients (tested		
HIV negative at VMMC		
program)		
By HIV status: Number of		
clients with		
undocumented/indeterminate		
HIV status or not tested for		
HIV at site		
By circumcision technique:		
Surgical VMMC		
By circumcision technique:		
Device-based VMMC		
By follow-up status: Number		
of surgically circumcised		
clients who returned at least		
once for follow-up care within		
14 days of circumcision		
 surgery		



	By follow-up status: Number		
	of surgically circumcised		
	clients who did NOT return		
	for follow-up care within 14		
	days of circumcision surgery		
	Number of males		
	circumcised as part of the		
	voluntary medical male	439,090	
	circumcision (VMMC) for HIV	100,000	
	prevention program within		
	the reporting period		
	By Age: <1	0	
	By Age: 1-9	0	
	By Age: 10-14	66,000	
	By Age: 15-19	175,500	
	By Age: 20-24	87,880	
	By Age: 25-49	87,780	
	By Age: 50+	21,930	
	Sum of Age disaggregates	439,090	
VMMC_CIRC_NGI	By HIV status: Number of		
	HIV-positive clients (tested		
	HIV positive at VMMC site)		
	By HIV status: Number of		
	HIV-negative clients (tested		
	HIV negative at VMMC		
	program		
	By HIV status: Number of		
	clients with		
	undocumented/indeterminate		
	HIV status or not tested for		
	HIV at site		
	By circumcision technique:		
	Surgical VMMC		
	By circumcision technique:		
	, , , , , , , , , , , , , , , , , , , ,		



	Device-based VMMC		
	By follow-up status: Number		
	of surgically circumcised		
	clients who returned at least		
	once for follow-up care within		
	14 days of circumcision		
	surgery		
	By follow-up status: Number		
	of surgically circumcised		
	clients who did NOT return		
	for follow-up care within 14		
	days of circumcision surgery		
	Number of males		
	circumcised as part of the		
	voluntary medical male		
	circumcision (VMMC) for HIV	1,090	8,000
	prevention program within		
	the reporting period		
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	200	1,468
	By Age: 15-19	300	2,202
	By Age: 20-24	280	2,055
VMMC_CIRC_TA	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	30	220
	Sum of Age disaggregations	1,090	8,000
	By HIV status: Number of		
	HIV-positive clients (tested		
	HIV positive at VMMC site)		
	By HIV status: Number of		
	HIV-negative clients (tested		
	HIV negative at VMMC		
	program		



	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site By circumcision technique: Surgical VMMC		
	By circumcision technique: Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention	n/a	
	including the minimum components during the reporting period (DSD)		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during	900,000	3,565,038
	the reporting period. Total number of people in the target population		



	Age/sex: 10-14 Male	104,854	495,633
	Age/sex: 15-19 Male	158,901	605,810
	Age/sex: 20-24 Male	160,523	540,828
	Age/sex: 25-49 Male	86,132	30,626
	Age/sex: 50+ Male	27,726	92,699
	Age/sex: 10-14 Female	70,018	409,944
	Age/sex: 15-19 Female	105,239	441,398
	Age/sex: 20-24 Female	111,635	379,114
	Age/sex: 25-49 Female	55,947	229,968
	Age/sex: 50+ Female	19,025	63,383
	Sum of Age/Sex disaggregates	900,000	3,289,403
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only) Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. Total number of people in the	n/a 100,000	6,136,571
	target population Age/sex: 10-14 Male	10,313	1,176,154
	Age/sex: 15-19 Male	15,335	940,644
	Age/sex: 20-24 Male	15,477	535,116
	Age/sex: 25-49 Male	10,786	362,196
	Age/sex: 50+ Male	4,116	135,449
	Age/sex: 10-14 Female	7,022	1,243,874
		·	
	Age/sex: 15-19 Female	10,825	872,914



	Age/sex: 20-24 Female	12,244	414,793
	Age/sex: 25-49 Female	9,666	320,797
	Age/sex: 50+ Female	4,216	134,633
	Sum of Age/Sex	100,000	6,136,570
	disaggregates	·	
	KP_PREV_DSD Percentage		
	of key populations reached		
	with individual and/or small		
	group level HIV preventive	n/a	
	interventions that are based	11/4	
	on evidence and/or meet the		
	minimum standards required (DSD)		
	Number of key populations		
	reached with individual		
	and/or small group level HIV		
	preventive interventions that	26,831	30,463
	are based on evidence		
	and/or meet the minimum		
	standards required		
KP_PREV_DSD	Total estimated number of		
	key population in the		
	catchment area		
	By key population type:		
	Female sex workers (FSW)		
	(Numerator: Number of key		
	populations reached with		
	individual and/or small group	12,000	14,000
	level HIV preventive	,	,
	interventions that are based		
	on evidence and/or meet the		
	minimum standards required)		
	By key population type:		
	Males who inject drugs (1,500	3,000
	Male PWID) (Numerator:	1,300	3,000
	IVIAIC F VVID) (INUITICIATOL.		



T T	<u> </u>	T
Numb	er of key populations	
reache	ed with individual	
and/or	small group level HIV	
prevei	ntive interventions that	
are ba	sed on evidence	
and/or	meet the minimum	
standa	ırds required)	
By key	population type:	
Femal	es who inject drugs	
(Fema	le PWID) (Numerator:	
Numb	er of key populations	
reache	ed with individual	0,000
and/or	small group level HIV 3,000	6,000
prevei	ntive interventions that	
are ba	sed on evidence	
and/or	meet the minimum	
standa	ards required)	
By key	population type: Men	
	ave sex with	
men/T	ransgender (MSM/TG)	
	erator: Number of key	
popula	itions reached with	
individ	ual and/or small group	27,212
level H	IIV preventive	
interve	entions that are based	
on evi	dence and/or meet the	
minim	um standards required)	
By ke	population type:	
	ΓG who are male sex	
	rs (subset MSM/TG)	
	erator: Number of key	
	ations reached with 221	370
	ual and/or small group	
	IIV preventive	
	entions that are based	
	dence and/or meet the	
0.107.		l



	minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment		
	area) By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with	n/a	



		1
individual and/or small group		
level HIV preventive		
interventions that are based		
on evidence and/or meet the		
minimum standards required		
(TA-only)		
Number of key populations		
reached with individual		
and/or small group level HIV		
preventive interventions that	10,070	12,140
are based on evidence		
and/or meet the minimum		
standards required		
Total estimated number of		
key population in the		
catchment area		
By key population type:		
Female sex workers (FSW)		
(Numerator: Number of key		
populations reached with		
individual and/or small group	70	140
level HIV preventive	, ,	110
interventions that are based		
on evidence and/or meet the		
minimum standards required)		
By key population type:		
Males who inject drugs (
Male PWID) (Numerator:		
Number of key populations		
reached with individual	0	0
and/or small group level HIV		
preventive interventions that		
are based on evidence		
and/or meet the minimum		
standards required)		
By key population type:	0	0



Females who inject drugs		
(Female PWID) (Numerator:		
Number of key populations		
reached with individual		
and/or small group level HIV		
preventive interventions that		
are based on evidence		
and/or meet the minimum		
standards required)		
By key population type: Men		
who have sex with		
men/Transgender (MSM/TG)		
(Numerator: Number of key		
populations reached with		
individual and/or small group	10,000	12,000
level HIV preventive		
interventions that are based		
on evidence and/or meet the		
minimum standards required)		
By key population type:		
MSM/TG who are male sex		
workers (subset MSM/TG)		
(Numerator: Number of key		
populations reached with		
individual and/or small group	0	600
level HIV preventive		
interventions that are based		
on evidence and/or meet the		
minimum standards required)		
By key population type:		
Female sex workers (FSW)		
(Denominator: Total		
estimated number of key		
population in the catchment		
area)		
,		
By key population type:		



	Males who inject drugs (
	Male PWID) (Denominator:		
	Total estimated number of		
	key population in the		
	catchment area)		
	By key population type:		
	Females who inject drugs		
	(Female PWID)		
	(Denominator: Total		
	estimated number of key		
	population in the catchment		
	area)		
	By key population type: Men		
	who have sex with		
	men/Transgender (MSM/TG)		
	(Denominator: Total		
	estimated number of key		
	population in the catchment		
	area)		
	By key population type:		
	MSM/TG who are male sex		
	workers (subset MSM/TG)		
	(Denominator: Total		
	estimated number of key		
	population in the catchment		
	area)		
	Number of individuals who		
	received T&C services for		
	HIV and received their test	2,394,000	1,440,000
	results during the past 12		
HTC_TST_DSD	months		
	By Test Result: Negative		
	By Test Result: Positive		
	Sum of Test Result		
	disaggregates		



Test Result by Age and Sex: Positive: <1 Male	
Test Result by Age and Sex: Positive: 1-4 Male	
Test Result by Age and Sex: Positive: 5-9 Male	
Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male	
Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: <1 Female	
Test Result by Age and Sex: Positive: 1-4 Female	
Test Result by Age and Sex: Positive: 5-9 Female	
Test Result by Age and Sex: Positive: 10-14 Female	
Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: <1 Male	



Test Result by Age and Sex:		
Negative: 1-4 Male		
Test Result by Age and Sex: Negative: 5-9 Male		
Test Result by Age and Sex: Negative: 10-14 Male		
Test Result by Age and Sex: Negative: 15-19 Male		
Test Result by Age and Sex: Negative: 20-24 Male		
Test Result by Age and Sex: Negative: 25-49 Male		
Test Result by Age and Sex: Negative: 50+ Male		
Test Result by Age and Sex: Negative: <1 Female		
Test Result by Age and Sex: Negative: 1-4 Female		
Test Result by Age and Sex: Negative: 5-9 Female		
Test Result by Age and Sex: Negative: 10-14 Female		
Test Result by Age and Sex: Negative: 15-19 Female		
Test Result by Age and Sex: Negative: 20-24 Female		
Test Result by Age and Sex: Negative: 25-49 Female		
Test Result by Age and Sex: Negative: 50+ Female		
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	87,055	52,364
Aggregated Age/sex - USE	870,545	523,636



	H HQ PERMISSION Y: 15+ Male		
Aggi WITI	regated Age/sex - USE H HQ PERMISSION Y: <15 Female	130,582	78,546
WITI	regated Age/sex - USE H HQ PERMISSION Y: 15+ Female	1,305,818	785,454
Sum <15	of Aggregated Age/Sex	217,637	130,910
Sum 15+	of Aggregated Age/Sex	2,176,363	1,309,090
	of Aggregated Age/Sex ggregates	2,394,000	1,440,000
	rice Delivery Point by ult: Antenatal Clinic - All lts		
	rice Delivery Point by ult: Antenatal Clinic - tive		
Resu	rice Delivery Point by ult: Antenatal Clinic - ative		
Serv	rice Delivery Point by ult: Labor & delivery - All		
	rice Delivery Point by ult: Labor & delivery - tive		
Resu	rice Delivery Point by ult: Labor & delivery - ative		
	rice Delivery Point by ult: Under 5 Clinic – All Its		



Service Delivery Point by	
Result: Under 5 Clinic -	
Positive	
Service Delivery Point by	
Result: Under 5 Clinic -	
Negative	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic – All Results	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Positive	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Negative	
Service Delivery Point by	
Result: Tuberculosis – All	
results	
Service Delivery Point by	
Result: Tuberculosis -	
Positive	
Service Delivery Point by	
Result: Tuberculosis -	
Negative	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections – All Results	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Positive	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Negative	
Service Delivery Point by	
Result: Outpatient	



1	
Department – All Results	
Service Delivery Point by	
Result: Outpatient	
Department - Positive	
Service Delivery Point by	
Result: Outpatient	
Department - Negative	
Service Delivery Point by	
Result: Inpatient – All	
Results	
Service Delivery Point by	
Result: Inpatient - Positive	
Service Delivery Point by	
Result: Inpatient - Negative	
Service Delivery Point by	
Result: HIV care and	
treatment clinic – All Results	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Positive	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Negative	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision – All	
Results	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Positive	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Negative	
Service Delivery Point by	
Result: Voluntary Counseling	



1	1	
& Testing (co-located) - All		
Results		
Service Delivery Point by		
Result: Voluntary Counseling		
& Testing (co-located) -		
Positive		
Service Delivery Point by		
Result: Voluntary Counseling		
& Testing (co-located) -		
Negative		
Service Delivery Point by		
Result: Voluntary Counseling		
& Testing (stand alone) – All		
Results		
Service Delivery Point by		
Result: Voluntary Counseling		
& Testing (stand alone) –		
Positive		
Service Delivery Point by		
Result: Voluntary Counseling		
& Testing (stand alone) -		
Negative		
Service Delivery Point by		
Result: Mobile – All Results		
Service Delivery Point by		
Result: Mobile - Positive		
Service Delivery Point by		
Result: Mobile - Negative		
Service Delivery Point by		
Result: Home-based – All		
Results		
Service Delivery Point by		
Result: Home-based -		
Positive		
Service Delivery Point by		



	Result: Home-based -
	Negative
	Service Delivery Point by
	Result: Other – All Results
	Service Delivery Point by
	Result: Other - Positive
	Service Delivery Point by
	Result: Other - Negative
	Number of individuals who
	received T&C services for
	HIV and received their test
	results during the past 12
	months
	By Test Result: Negative
	By Test Result: Positive
	Sum of Test Result
	disaggregates
	Age/sex: <1 Male
	Age/sex: 1-4 Male
	Age/sex: 5-9 Male
HTC_TST_NA	Age/sex: 10-14 Male
	Age/sex: 15-19 Male
	Age/sex: 20-24 Male
	Age/sex: 25-49 Male
	Age/sex: 50+ Male
	Age/sex: <1 Female
	Age/sex: 1-4 Female
	Age/sex: 5-9 Female
	Age/sex: 10-14 Female
	Age/sex: 15-19 Female
	Age/sex: 20-24 Female
	Age/sex: 25-49 Female Age/sex: 50+ Female



	Sum of Age/Sex		
	disaggregates Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex disaggregates		
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,650,000	4,800,000
	By Test Result: Negative	5,652,500	4,080,000
	By Test Result: Positive	997,500	720,000
	Sum of Test Result disaggregates	6,650,000	4,800,000
HTC_TST_NGI	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		



	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex: <15 Male	241,818	174,546
	Aggregated Age/sex: 15+ Male	2,418,182	1,745,454
	Aggregated Age/sex: <15 Female	362,727	261,818
	Aggregated Age/sex: 15+ Female	3,627,273	2,618,182
	Sum of Aggregated Age/Sex <15	604,545	436,364
	Sum of Aggregated Age/Sex 15+	6,045,455	4,363,636
	Sum of Aggregated Age/Sex disaggregates	6,650,000	4,800,000
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,256,000	3,360,000
HTC_TST_TA	By Test Result: Negative		
	By Test Result: Positive		
	Sum of Test Result disaggregates		
	Test Result by Age and Sex: Positive: <1 Male		



Test Result by Age and Sex: Positive: 1-4 Male	
Test Result by Age and Sex: Positive: 5-9 Male	
Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male	
Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: <1 Female	
Test Result by Age and Sex: Positive: 1-4 Female	
Test Result by Age and Sex: Positive: 5-9 Female	
Test Result by Age and Sex: Positive: 10-14 Female	
Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: <1 Male	
Test Result by Age and Sex: Negative: 1-4 Male	



Task Dassik har Assault C		
Test Result by Age and Sex:		
Negative: 5-9 Male		
Test Result by Age and Sex:		
Negative: 10-14 Male		
Test Result by Age and Sex:		
Negative: 15-19 Male		
Test Result by Age and Sex:		
Negative: 20-24 Male		
Test Result by Age and Sex:		
Negative: 25-49 Male		
Test Result by Age and Sex:		
Negative: 50+ Male		
Test Result by Age and Sex:		
Negative: <1 Female		
Test Result by Age and Sex:		
Negative: 1-4 Female		
Test Result by Age and Sex:		
Negative: 5-9 Female		
Test Result by Age and Sex:		
Negative: 10-14 Female		
Test Result by Age and Sex:		
Negative: 15-19 Female		
Test Result by Age and Sex:		
Negative: 20-24 Female		
Test Result by Age and Sex:		
Negative: 25-49 Female		
Test Result by Age and Sex:		
Negative: 50+ Female		
Aggregated Age/sex - USE		
WITH HQ PERMISSION	154,764	122,182
ONLY: <15 Male		
Aggregated Age/sex - USE		
WITH HQ PERMISSION	1,547,636	1,221,818
ONLY: 15+ Male		



		Т	1
V	Aggregated Age/sex - USE WITH HQ PERMISSION DNLY: <15 Female	232,145	183,272
V	Aggregated Age/sex - USE VITH HQ PERMISSION DNLY: 15+ Female	2,321,455	1,832,728
	Sum of Aggregated Age/Sex	386,909	305,454
	Sum of Aggregated Age/Sex 5+	3,869,091	3,054,546
	Sum of Aggregated Age/Sex	4,256,000	3,360,000
R	Service Delivery Point by Result: Antenatal Clinic - All esults		
R	Service Delivery Point by Result: Antenatal Clinic - Positive		
R	Service Delivery Point by Result: Antenatal Clinic - Negative		
R	Service Delivery Point by Result: Labor & delivery - All esults		
R	Service Delivery Point by Result: Labor & delivery - Positive		
R	Service Delivery Point by Result: Labor & delivery - Negative		
R	Service Delivery Point by Result: Under 5 Clinic – All esults		
	Service Delivery Point by Result: Under 5 Clinic -		



Decition	
Positive	
Service Delivery Point by	
Result: Under 5 Clinic -	
Negative	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic – All Results	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Positive	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Negative	
Service Delivery Point by	
Result: Tuberculosis – All	
results	
Service Delivery Point by	
Result: Tuberculosis -	
Positive	
Service Delivery Point by	
Result: Tuberculosis -	
Negative	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections – All Results	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Positive	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Negative	
_	
Service Delivery Point by	
Result: Outpatient	
Department – All Results	
Service Delivery Point by	



	1	
Result: Outpatient		
Department - Positive		
Service Delivery Point by		
Result: Outpatient		
Department - Negative		
Service Delivery Point by		
Result: Inpatient – All		
Results		
Service Delivery Point by		
Result: Inpatient - Positive		
Service Delivery Point by		
Result: Inpatient - Negative		
Service Delivery Point by		
Result: HIV care and		
treatment clinic – All Results		
Service Delivery Point by		
Result: HIV care and		
treatment clinic - Positive		
Service Delivery Point by		
Result: HIV care and		
treatment clinic - Negative		
Service Delivery Point by		
Result: Voluntary Medical Male Circumcision – All		
Results		
Service Delivery Point by Result: Voluntary Medical		
Male Circumcision - Positive		
Service Delivery Point by		
Result: Voluntary Medical		
Male Circumcision - Negative		
Service Delivery Point by		
Result: Voluntary Counseling		
& Testing (co-located) – All		
Results		



1	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (standalone) - All	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (standalone) -	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (standalone) -	
Negative	
Service Delivery Point by	
Result: Mobile – All Results	
Service Delivery Point by	
Result: Mobile - Positive	
Service Delivery Point by	
Result: Mobile - Negative	
Service Delivery Point by	
Result: Home-based – All	
Results	
Service Delivery Point by	
Result: Home-based -	
Positive	
Service Delivery Point by	
Result: Home-based -	
Negative	
Service Delivery Point by	



	Result: Other – All Results		
	Service Delivery Point by		
	Result: Other - Positive		
	Service Delivery Point by		
	Result: Other - Negative		
	Number of people receiving	16,240	20,360
	post-GBV care	10,210	20,000
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
GEND_GBV_DSD	Age/Sex: 18-24 Female		
020_02202	Age/Sex: 25+ Female		
	Sum of Age/Sex		
	Disaggregates		
	By type of service: Physical		
	and/or Emotional Violence		
	(Other Post-GBV Care)		
	By type of service: Sexual		
	Violence (Post-Rape Care)		
	By PEP service provision		
	(related to sexual violence		
	services provided)		
	Number of people		
	completing an intervention		1,400,000
GEND_NORM_DSD	pertaining to gender norms,		
	that meets minimum criteria		
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		



		1	
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		500,000
	By Age: 20-24		500,000
	By Age: 25+		400,000
	Sum of Age disaggregates		1,400,000
	Number of active		
	beneficiaries receiving		
	support from PEPFAR OVC	37,632	31,698
	programs to access HIV		
	services		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
OVC_ACC_DSD	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18+ Female		



	A 70 / O 200 40 24 5 2 2 2 4		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex		
	disaggregates		
	Number of active		
	beneficiaries served by		
	PEPFAR OVC programs for	105,655	90,854
	children and families affected		
	by HIV/AIDS		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
OVC_SERV_DSD	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex		
	disaggregates		
	Required only for DREAMS		
	countries - By service, age		
	and sex: Education Support		
	Female <1		
	Required only for DREAMS		
	countries - By service, age		
	and sex: Education Support		
	Female 1-4		



1	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
and sex. Education Support	



1	
Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female <1	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 15-17	
Required only for DREAMS	
countries - By service, age	
countiles - by service, age	



and sex: Parenting/Caregiver	
Programs Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 25+	
Required only for DREAMS	



<u> </u>		1
countries - By service, age		
and sex: Social Protection		
Female <1		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male <1		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male 1-4		



1		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Male 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female <1		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
	·	I



	T	
Strengthening Female 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male <1		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male 15-17		
Required only for DREAMS		
countries - By service, age		



	and sex: Economic		
	Strengthening Male 18-24		
	Required only for DREAMS		
	countries - By service, age		
	and sex: Economic		
	Strengthening Male 25+		
	Number of active		
	beneficiaries served by		
	PEPFAR OVC programs for	446,322	361,911
	children and families affected		
	by HIV/AIDS		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By age/sex: 18-24 Male		
	By age/sex: 25+ Male		
	Age/Sex: <1 Female		
OVC_SERV_TA	Age/Sex: 1-4 Female		
OVO_SERV_TA	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By age/sex: 18-24 Female		
	By age/sex: 25+ Female		
	Sum of Age/Sex		
	disaggregates		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Education		
	Support Female <1		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Education		



Support Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 5-9	
Required only for DREAMS	
countries: By Service Area,	



age and sex: Education	
Support Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 10-14	
Required only for DREAMS	
	Support Male 10-14 Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24 Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+ Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1 Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4 Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4 Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9 Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9 Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9 Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14



1 1	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
Journal Dy Corrido / II Cu,	



age and sex:	
Parenting/Caregiver Program	
Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
ocultures. By Corvice Area,	



age and sex: Social	
Protection Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social Protection Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 25+	
Required only for DREAMS	



1	1	
countries: By Service Area,		
age and sex: Economic		
Strengthening Female <1		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Female 1-4		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Female 5-9		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Female 10-14		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Female 15-17		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Female 18-24		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic Strengthening Female 25+		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Male <1		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Economic		
Strengthening Male 1-4		



1	1
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female <1	
Required only for DREAMS countries: By Service Area,	
age and sex: Other Service	
Areas Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	



	Arosa Famala 40 44		
	Areas Female 10-14		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service Areas Female 25+		
	Number of HIV-positive individuals receiving a		
	minimum of one clinical	897,000	
	service		
	By Age/Sex: <15 Female	26,910	
	By Age/Sex: <15 Male	26,910	
	By Age/Sex: 15+ Female	505,908	
	By Age/Sex: 15+ Male	337,272	
C2.1.D_DSD	Sum of Age/Sex	897,000	
	disaggregates	097,000	
	By Age: <15	53,820	
	By Age: 15+	843,180	
	Sum of Age disaggregates	897,000	
	By Sex: Female	532,818	
	By Sex: Male	364,182	
	Sum of Sex disaggregates	897,000	
	Number of HIV-positive		
	individuals receiving a		
C2.1.D_NA	minimum of one clinical		
	service		
	By Age/Sex: <15 Female		



	By Age/Sex: <15 Male	
	By Age/Sex: 15+ Female	
	By Age/Sex: 15+ Male	
	Sum of Age/Sex	
	disaggregates	
	By Age: <15	
	By Age: 15+	
	Sum of Age disaggregates	
	By Sex: Female	
	By Sex: Male	
	Sum of Sex disaggregates	
	Number of HIV-positive	
	individuals receiving a	0.000.000
	minimum of one clinical	3,900,000
	service	
	By Age/Sex: <15 Female	
	By Age/Sex: <15 Male	
	By Age/Sex: 15+ Female	
	By Age/Sex: 15+ Male	
C2.1.D_NGI	Sum of Age/Sex	
	disaggregates	
	By Age: <15	975,000
	By Age: 15+	2,925,000
	Sum of Age disaggregates	3,900,000
	By Sex: Female	2,535,000
	By Sex: Male	1,365,000
	Sum of Sex disaggregates	3,900,000
C2.1.D_TA	Number of HIV-positive	
	individuals receiving a	3,003,000
	minimum of one clinical service	
	By Age/Sex: <15 Female	90,090
	By Age/Sex: <15 Male	90,090
	Dy /190/00x. < 10 Maic	00,000



	By Age/Sey: 15± Female	1 603 603	
	By Age/Sex: 15+ Female	1,693,692	
	By Age/Sex: 15+ Male	1,129,128	
	Sum of Age/Sex disaggregates	3,003,000	
	By Age: <15	180,180	
	By Age: 15+	2,822,820	
	Sum of Age disaggregates	3,003,000	
	By Sex: Female	1,783,782	
	By Sex: Male	1,219,218	
	Sum of Sex disaggregates	3,003,000	
	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	90 %	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	807,300	
	Number of HIV-positive individuals receiving a minimum of one clinical service	897,000	
	C2.5.D_DSD Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment	n/a	
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment		
	Number of HIV-positive individuals receiving a minimum of one clinical service	897,000	



	Number of HIV positive	
	adults and children who	
	received at least one of the	
	following during the reporting	449,280
	period: clinical assessment	
	(WHO staging) OR CD4	
	count OR viral load	
	Age/sex: <1 Male	
	Age/sex: 1-4 Male	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: <1 Female	
	Age/sex: 1-4 Female	
CARE_CURR_DSD	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sun of Age/Sex	
	disaggregates	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	15,725
	ONLY: <15 Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	167,132
	ONLY: 15+ Male	,
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	15,725
	ONLY: <15 Female	



	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	250,698
	Sum of Aggregated Age/Sex disaggregates	449,280
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,294,719
	Age/sex: <1 Male	
	Age/sex: 1-4 Male	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
CARE_CURR_TA	Age/sex: 50+ Male	
	Age/sex: <1 Female	
	Age/sex: 1-4 Female	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex	
	disaggregates	
	Aggregated Age/sex - USE WITH HQ PERMISSION	115,315
	ONLY: <15 Male	



	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,225,636
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	115,315
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,838,453
	Sum of Aggregated Age/Sex disaggregates	3,294,719
	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	96,000
	Age/sex: <1 Male	
	Age/sex: 1-4 Male	
CARE_NEW_DSD	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: <1 Female	
	Age/sex: 1-4 Female	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	



	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/sex disaggregates		
	Aggregated Age/sex: <15 Male		3,360
	Aggregated Age/sex: 15+ Male		35,712
	Aggregated Age/sex: <15 Female		3,360
	Aggregated Age/sex: 15+ Female		53,568
	Sum of Aggregated Age/sex disaggregates		96,000
CARE_SITE	CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	n/a	
	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND		2,355



	1	
3) if eligible, cotrimoxazole		
Total number of PEPFAR		
supported sites providing		2,944
clinical care services		
By site support type: Direct		
Service Delivery (DSD):		
Number of		
PEPFAR-supported HIV		
clinical care sites at which at		
least 80% of PLHIV received		
all of the following during the		282
reporting period: 1) clinical		
assessment (WHO staging)		
OR CD4 count OR viral load,		
AND 2) TB screening at last		
visit, AND 3) if eligible,		
cotrimoxazole		
By site support type:		
Technical Assistance-only		
(TA): Number of		
PEPFAR-supported HIV		
clinical care sites at which at		
least 80% of PLHIV received		
all of the following during		2,073
the reporting period: 1)		,
clinical assessment (WHO		
staging) OR CD4 count OR		
viral load, AND 2) TB		
screening at last visit, AND		
3) if eligible, cotrimoxazole		
Sum of Numerator Site		
Support Type disaggregates		2,355
By site support type: Direct		
Service Delivery (DSD):		354
Total number of PEPFAR		
supported sites providing		



	clinical care services		
	By site support type:		
	Technical Assistance-only		
	(TA): Total number of		2,590
	PEPFAR supported sites		2,390
	providing clinical care		
	services		
	Sum of Denominator Site		0.044
	Support Type disaggregates		2,944
	FN_SITE Percentage of		
	PEPFAR-supported sites		
	achieving 90% of nutrition		
	assessments that result in an	n/a	
	accurate categorization of		
	malnutrition		
	Number of		
	PEPFAR-supported sites		
	achieving 90% nutrition		
	assessments that result in		356
	accurate categorization of		
	malnutrition		
	Total number of		
FN_SITE	PEPFAR-supported sites		
N_0112	providing nutrition		681
	assessment, counseling and		
	support (NACS) services		
	By site support type: Direct		
	Service Delivery (DSD):		
	Number of		
	PEPFAR-supported sites		
	achieving 90% nutrition		16
	assessments that result in		
	accurate categorization of		
	malnutrition		
	By site support type:		340
	Technical Assistance-only		



	(TA): Number of		
	PEPFAR-supported sites		
	achieving 90% nutrition		
	assessments that result in		
	accurate categorization of		
	malnutrition		
	Sum of Numerator Support		050
	Type disaggregates		356
	By site support type: Direct		
	Service Delivery (DSD):		
	Total number of		
	PEPFAR-supported sites		32
	providing nutrition		
	assessment, counseling and		
	support (NACS) services		
	By site support type:		
	Technical Assistance-only		
	(TA): Total number of		
	PEPFAR-supported sites		649
	providing nutrition		
	assessment, counseling and		
	support (NACS) services		
	Sum of Denominator Support		681
	Type disaggregates		001
	FN_THER_DSD Proportion		
	of clinically undernourished		
	PLHIV who received	n/a	
	therapeutic or supplementary		
	food		
EN THED DOD	Number of clinically		
FN_THER_DSD	malnourished PLHIV who		
	received therapeutic and/or		
	supplementary food during		
	the reporting period.		
	Number of PLHIV who were		
	rtainbor or r Eritt Who word	500	600



	found to be clinically		
	undernourished.		
	Age: <1		
	Age: 1-4		
	Age: 5-14		
	Age: 15-17		
	Age: 18+		
	Sum of Age disaggregates		
	Aggregated Age: <18		
	Aggregated Age: 18+		
	Sum of Aggregated Age		
	disaggregates		
	By Pregnancy/Postpartum		
	Status: Pregnant		
	By Pregnancy/Postpartum		
	Status: Postpartum		
	TB_ART_DSD Percentage of		
	HIV-positive new and	n/a	
	relapsed registered TB cases	11/4	
	on ART during TB treatment		
	The number of registered		
	new and relapse TB cases		
	with documented		145,600
	HIV-positive status whoare		143,000
TD 457 505	on ART during TB treatment		
TB_ART_DSD	during the reporting period		
	The number of registered		
	new and relapse TB cases		
	with documented		400,000
	HIV-positive status during TB		182,000
	treatment during the		
	reporting period		
	Age: <1		
	Age: 1-4		



			<u> </u>
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male		
	Female		
	Sum of Sex disaggregates		
	Newly tested		
	Known HIV-positive		
	Sum of Test Status		
	disaggregates		
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age		
	disaggregates		
	Timeliness: Art initiation <8		
	weeks of start of TB		
	treatment		
	Timeliness: Art initiation >8		
	weeks of start of TB		
	treatment		
	TB_ARTSITE Proportion of PEPFAR-supported TB basic		
	management units at which		
	80% of registered TB cases	n/a	
	who are HIV-positive are on		
TD ADTOITE	ART		
TB_ARTSITE	The number of		
	PEPFAR-supported TB basic		
	management units at which		2,355
	80% of registered TB cases		_,300
	who are HIV-positive are on		
	ART, during the reporting		



period	
The number of PEPFAR-supported TB basic management units	2,944
By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	282
By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2,073
Sum of Numerator Site Support Type disaggregates	2,355
By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	354
By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	2,590
Sum of Denominator Site Support Type disaggregates	2,944



		Г	
	TB_SCREEN_DSD		
	Percentage of PLHIV who		
	were screened for TB	n/a	
	symptoms at the last clinical	II/a	
	visit to an HIV care facility		
	during the reporting period.		
	The number of PLHIV who		
	were screened for TB		
	symptoms at the last clinical		426,816
	visit to an HIV care facility		
	during the reporting period		
	Number of HIV positive		
	adults and children who		
	received at least one of the		
	following during the reporting		449,280
	period: clinical assessment		
	(WHO staging) OR CD4		
	count OR viral load		
TB_SCREEN_DSD	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		29,877
	<15		
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		396,939
	15+		
	Sum of Aggregated Age		
	disaggregates		426,816
	Sex: Male		170,726
	Sex: Female		256,090
	1		,



	Sum of Sex disaggregates		426,816
	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	100 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	63,250	26,400
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	63,250	26,400
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth		
	By infants who received their first virologic HIV test between 2 and 12 months of age		
	Sum of Infant Age disaggregates		
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and	690,000	345,600



	children receiving antiretroviral therapy (ART)		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	259,440	128,563
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	389,160	192,845
	Sum of Aggregated Age/Sex <15	41,400	24,192
	Sum of Aggregated Age/Sex 15+	648,600	321,408
	Sum of Aggregated Age/Sex disaggregates	690,000	345,600
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)		



	<u> </u>		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15+ Female		
	Sum of Age/Sex		
	disaggregates		
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: <15 Male		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: <15 Female		
	Aggregated Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex disaggregations		
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,000,000	
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		



	Age/Sex: 5-14 Male		
	Age/Sex: 15+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15+ Female		
	Sum of Age/Sex		
	disaggregates		
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: <15 Male	90,000	
	Aggregated Age/Sex: 15+ Male	1,128,000	
	Aggregated Age/Sex: <15 Female	90,000	
	Aggregated Age/Sex: 15+ Female	1,692,000	
	Sum of Aggregated Age/Sex disaggregates	3,000,000	
	Sum of Aggregated Age/Sex <15	180,000	
	Sum of Aggregated Age/Sex 15+	2,820,000	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,310,000	2,534,400
	Age/Sex: <1 Male		
IN_OURN_IA	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
1	Age/Sex: 15-19 Male		



	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex		
	disaggregations		
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	868,560	942,797
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	1,302,840	1,414,195
	Sum of Aggregated Age/Sex <15	138,600	177,408
	Sum of Aggregated Age/Sex 15+	2,171,400	2,356,992
	Sum of Aggregated Age/Sex disaggregates	2,310,000	2,534,400
	TX_DIST Percentage of Districts that are PEPFAR		
TX_DIST	supported with documented routine supportive	n/a	
	supervision visits to 75% of ART sites in District		
	Number of Districts with documented routine		30



T		Г	
	supportive supervision visits		
	to 75% of HIV care and		
	treatment sites supported by		
	the District		
	Total number of PEPFAR		
	supported District Health		42
	Offices		
	Number of adults and		
	children newly enrolled on	138,000	57,600
	antiretroviral therapy (ART)		
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		
	By Age/Sex: 20-24 Male		
	By Age/Sex: 25-49 Male		
	By Age/Sex: 50+ Male		
	By Age/Sex: <1 Female		
TV NEW 505	By Age/Sex: 1-4 Female		
TX_NEW_DSD	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		
	By Age/Sex: 25-49 Female		
	By Age/Sex: 50+ Female		
	Sum of Age/Sex		
	disaggregates		
	Aggregated Grouping by		
	Age: <1 Male		
	Aggregated Grouping by		
	Age/Sex: 1-14 Male		
	Aggregated Grouping by	51,888	21,428



	Age/Sex: 15+ Male		
	Aggregated Grouping by		
	Age/Sex: <1 Female		
	Aggregated Grouping by		
	Age/Sex: 1-14 Female		
	Aggregated Grouping by		
	Age/Sex: 15+ Female	77,832	32,140
	Sum of Aggregated Age/Sex		
	disaggregates	138,000	57,600
	Pregnancy status		
	Breastfeeding status		
	TX_RET_DSD Percent of		
	adults and children known to		
	be alive and on treatment 12	80 %	
	months after initiation of	80 %	
	antiretroviral therapy		
	Number of adults and		
	children who are still alive		
	and on treatment at 12	94,944	46,080
	months after initiating ART		
	Total number of adults and		
	children who initiated ART in		
TX_RET_DSD	the 12 months prior to the		
	beginning of the reporting	118,680	57,600
	period, including those who		
	have died, those who have		
	stopped ART, and those lost		
	to follow-up		
	Age/Sex: <5 Male		
	(Numerator: Number of		
	adults and children who are		
	still alive and on treatment at		
	12 months after initiating		
	ART)		
	Age/Sex: 5-14 Male		



	(Numerator: Number of	
ļ.	adults and children who are	
	still alive and on treatment at	
	12 months after initiating	
ļ	ART)	
Į.	Age/Sex: 15-19 Male	
	(Numerator: Number of	
	adults and children who are	
	still alive and on treatment at	
	12 months after initiating	
	ART)	
Ī	·	
	Age/Sex: 20+ Male	
	(Numerator: Number of	
	adults and children who are	
	still alive and on treatment at	
	12 months after initiating	
ļ	ART)	
,	Age/Sex: <5 Female	
	(Numerator: Number of	
ŀ	adults and children who are	
	still alive and on treatment at	
	12 months after initiating	
ļ	ART)	
	Age/Sex: 5-14 Female	
	(Numerator: Number of	
	adults and children who are	
	still alive and on treatment at	
	12 months after initiating	
	ART)	
	,	
	Age/Sex: 15-19 Female	
	(Numerator: Number of	
	adults and children who are	
	still alive and on treatment at	
	12 months after initiating	
	ART)	



1	1	
(Numerator: Number of		
adults and children who are		
still alive and on treatment at		
12 months after initiating		
ART)		
Age/Sex: <5 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 5-14 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 15-19 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 20+ Male		
rigorock. Zur Maie		



(Denominator: Total number
of adults and children who
initiated ART in the 12
months prior to the beginning
of the reporting period,
including those who have
died, those who have
stopped ART, and those lost
to follow-up)
Age/Sex: <5 Female
(Denominator: Total number
of adults and children who
initiated ART in the 12
months prior to the beginning
of the reporting period,
including those who have
died, those who have
stopped ART, and those lost
to follow-up)
Age/Sex: 5-14 Female
(Denominator: Total number
of adults and children who
initiated ART in the 12
months prior to the beginning
of the reporting period,
including those who have
died, those who have
stopped ART, and those lost
to follow-up)
Age/Sex: 15-19 Female
(Denominator: Total number
of adults and children who
initiated ART in the 12
months prior to the beginning
of the reporting period,
including those who have



stopped ART, and those lost to follow-up) Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART Initiation Total number of PEPFAR-supported ART Initiation Total number of PEPFAR-supported ART		died, those who have		
to follow-up) Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Pregnant TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART STATION TOTAL number of PEPFAR-supported ART Initiation Total number of PEPFAR-supported ART STATION TOTAL number of PEPFAR-supported ART				
Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART initiation Total number of PEPFAR-supported ART initiation Total number of PEPFAR-supported ART 2,944				
of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART initiation Total number of PEPFAR-supported ART initiation Total number of PEPFAR-supported ART initiation Total number of PEPFAR-supported ART 2,944		_		
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		`		
months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		- = -		
stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		* *		
Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		.,		
Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
Denominator by Status: Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		=		
Pregnant Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
Denominator by Status: Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944				
Breastfeeding TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		Pregnant		
TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		-		
PEPFAR-supported ART sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		Breastfeeding		
sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		TX_SITE Percentage of		
sites achieving a 75% ART retention rate Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		PEPFAR-supported ART	n/a	
Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,208		sites achieving a 75% ART	11/a	
TX_SITE PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,208		retention rate		
TX_SITE sites with a retention rate of 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,208 2,208		Number of		
TX_SITE 75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,208 2,208 2,208		PEPFAR-supported ART		
75% or greater for patients 12 months after ART initiation Total number of PEPFAR-supported ART 2,944		sites with a retention rate of		2 200
initiation Total number of PEPFAR-supported ART 2,944	IX_SHE	75% or greater for patients		2,208
Total number of PEPFAR-supported ART 2,944		12 months after ART		
PEPFAR-supported ART 2,944		initiation		
		Total number of		
		PEPFAR-supported ART		2,944
		sites		
By support type: Direct 265		By support type: Direct		265



	Service Delivery (DSD):		
	Number of		
	PEPFAR-supported ART		
	sites with a retention rate of		
	75% or greater for patients		
	12 months after ART		
	initiation		
	By support type: Technical		
	Assistance (TA-only):		
	Number of		
	PEPFAR-supported ART		4.040
	sites with a retention rate of		1,943
	75% or greater for patients		
	12 months after ART		
	initiation		
	Sum of Numerator Site		
	Support Type disaggregates		2,208
	By support type: Direct		
	Service Delivery (DSD):		
	Total number of		354
	PEPFAR-supported ART		
	sites		
	By support type: Technical		
	Assistance (TA-only): Total		
	number of		2,590
	PEPFAR-supported ART		_,000
	sites		
	Sum of Denominator Site		
	Support Type disaggregates		2,944
	Number of		
	PEPFAR-supported testing		
	facilities (laboratories) that		
LAB_ACC_DSD	are recognized by national,	12	12
	regional, or international		
	standards for accreditation or		
	have achieved a minimal		
	navo aomovoa a minima		



	acceptable level towards		
	acceptable level towards attainment of such		
	accreditation		
	Number of		
	PEPFAR-supported testing facilities with capacity to	2.700	2 024
	perform clinical laboratory	2,780	3,024
LAB_CAP_DSD	tests		
		10	42
	By clinical laboratories	16	13
	By Point-of-care testing sites	2,764	3,011
	Number of new HCW who		
	graduated from a pre-service		
	training institution or program		
	as a result of	6,852	11,268
	PEPFAR-supported	0,002	11,200
	strengthening efforts, within		
	the reporting period, by		
	select cadre		
	By Graduates: Doctors	189	398
HRH_PRE	By Graduates: Nurses	148	165
	By Graduates: Midwives	130	145
	By Graduates: Social service	202	0.050
	workers	383	2,953
	By Graduates: Laboratory		
	professionals	0	0
	By Graduates: Other	6,002	7,607
	Sum of Graduates	0.050	44.000
	disaggreagtes	6,852	11,268
	FPINT_SITE_DSD Family		
	Planning and HIV		
	Integration: Percentage of		
FPINT_SITE_DSD	HIV service delivery points	n/a	
	supported by PEPFAR that		
	are directly providing		
	integrated voluntary family		



	planning services		
	Number of service delivery points supported by PEPFAR		
	for HIV services that are		2,800
	directly providing integrated voluntary family planning		,
	services		
	Total number of PEPFAR-supported HIV service delivery points:		2,800
	PMTCT, Care and Treatment Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality		
	improvement activities implemented that address clinical HIV program	n/a	
QI_SITE	processes or outcomes and have documented process results in the last 6 months		
	Number of		
	PEPFAR-supported clinical		
	service sites with a quality		2,944
	improvement activity		,,,,,,
	completed that addresses clinical HIV programs and		



has documented process	
results in the last 6 months	
Total number of PEPFAR-supported sites for	
any HIV clinical service	2,944
Treatment, TB care, PMTCT,	
VMMC, and HTC	
By site support type: Direct Service Delivery (DSD):	
Number of	
PEPFAR-supported clinical	
service sites with a quality	354
improvement activity	357
completed that addresses	
clinical HIV programs and	
has documented results in	
the last 6 months	
By site support type:	
Technical Assistance-only	
(TA): Number of	
PEPFAR-supported clinical	
service sites with a quality	2,590
improvement activity	2,090
completed that addresses	
clinical HIV programs and	
has documented results in	
the last 6 months	
Sum of Numerator Site	2.04
Support Type disaggregates	2,944
By site support type: Direct	
Service Delivery (DSD):	
Total number of	25.
PEPFAR-supported sites for	354
any HIV clinical service	
including HIV Care, HIV	



Treatment, TB care, PMTCT, VMMC, HTC	
By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	2,590
Sum of Denominator Site Support Type disaggregates	2,944



Partners and Implementing Mechanisms

Partner List

Partner		Organization			
Mech ID	Partner Name	Туре	Agency	Funding Source	Planned Funding
	University		U.S. Agency for		
7221	Research	Private Contractor		GHP-State	0
	Corporation, LLC		Development		
7000	South Africa	Host Country Government	U.S. Department	GHP-State	0
7223	Military Health Service	Agency	of Defense	GnP-State	0
	Service	Agency	U.S. Department		
			of Health and		
	South African		Human		
7225		NGO	Services/Centers	GHP-State	0
	Teachers Union		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
9464	Africare	NGO	Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Yetrata Coal SA &		Human		
9496	Xstrata Coal SA & Re-Action!	NGO	Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
9497	UNIVERSITY OF	University	U.S. Department	GHP-State	0



	KWAZULU-NATA		of Health and		
	L INNOVATIONS		Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	0.14		Human		
9509	St. Mary's	FBO	Services/Centers	GHP-State	0
	Hospital		for Disease		
			Control and		
			Prevention		
			U.S. Department		
	SOUTHERN		of Health and		
	AFRICAN		Human		
9521	CATHOLIC	FBO	Services/Centers	GHP-State	0
	BISHOP'S		for Disease		
	CONFERENCE		Control and		
	(SACBC)		Prevention		
	Partnership for		U.S. Agency for		
9526	Supply Chain	Private Contractor		GHP-State	4,562,674
	Management		Development		
			U.S. Department		
			of Health and		
	South Africa		Human		
9529	National Blood	NGO	Services/Centers	GHP-State	0
	Service		for Disease		
			Control and		
			Prevention		
			U.S. Department		
	National Alliance		of Health and		
0500	of State and	NOO	Human	OUD OU	
9562	Territorial AIDS	NGO	Services/Centers	GHP-State	0
	Directors		for Disease		
			Control and		



			Prevention		
9569	TBD	TBD	Redacted	Redacted	Redacted
9590	Lifeline Mafikeng	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9610	International Organization for Migration	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
9816	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	0
9821	University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
11498	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	425,000
11500	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	1,490,000
12509	WamTechnology	Private Contractor	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
12510	South Africa	NGO	Services/Centers	GHP-State	0
	Partners		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
12840	Pathfinder	NGO		GHP-State	433,352
	International		for Disease		,
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
12887	AIDS Foundation	NGO		GHP-State	0
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	COUNCIL OF	Host Country	Human		
13000	SCIENTIFIC AND	Government		GHP-State	555,313
	INDUSTRIAL	Agency	for Disease		333,013
	RESEARCH	, g,	Control and		
			Prevention		
			U.S. Department		
	Human Science		of Health and		
13558		Private Contractor		GHP-State	0
					-
	of South Africa		Services/Centers for Disease		



	<u> </u>				1
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	University of		Human		
13567	California at San	University	Services/Centers	GHP-State	0
	Francisco		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Population		Human		
13570	Services	NGO	Services/Centers	GHP-State	500,000
	International		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	LUV/ Mara a see al		Human		
13577	HIV Managed Care Solutions	NGO	Services/Centers	GHP-State	800,000
	Care Solutions		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13585	Shout It Now	NGO	Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
10000	University of	I lair caraite	Human	CUD Chat-	4 420 000
13608	Washington	University	Services/Centers	GHP-State	1,120,000
			for Disease		
			Control and		



			Prevention		
13618	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,655,112
13619	JHPIEGO	University	U.S. Department of Health and Human	GHP-State	1,200,000
13644	University of Cape Town	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13682	Health Information Systems Program	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13688	Health and Development Africa	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



				1	T
			U.S. Department		
			of Health and		
	Epicentre AIDS		Human		
13695	Risk Management	NGO	Services/Centers	GHP-State	0
	Nisk Management		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Liniversity of		Human		
13709	University of Washington	University	Services/Health	GHP-State	6,515,207
	Washington		Resources and		
			Services		
			Administration		
			U.S. Department		
			of Health and		
	University of		Human		
13750	Stellenbosch, South Africa	University	Services/Centers	GHP-State	249,000
			for Disease		
			Control and		
			Prevention		
	University of the		U.S. Agency for		
13760	University of the Western Cape	University	International	GHP-USAID	0
	western Cape		Development		
13761	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
			of Health and		
			Human		
13767	Re-Action!	NGO	Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
40774	Harris and Harris and Y	I lais canaite :	of Health and	CLID Ctots	500,000
13771	Howard University	University	Human	GHP-State 50	500,000
			Services/Centers		



	1	1			1
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	South African		Human		
13789	Clothing & Textile	NGO	Services/Centers	GHP-State	5,600,000
	Workers' Union		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13793	TB/HIV Care	Implementing	Services/Centers	GHP-State	3,338,141
		Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13797	Health Systems	NGO	Services/Centers	GHP-State	5,109,118
	Trust		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13798	Soul City	NGO	Services/Centers	GHP-State	0
			for Disease	J. II State	
			Control and		
			Prevention		
			U.S. Department		
	Columbia		of Health and		
13800	University	University	Human	GHP-State	600,000
	Mailman School	Cilivoroity	Services/Centers	J. II State	000,000
	of Public Health		for Disease		
			וטו טוטבמטב		



			Control and		
13888	Population Services International	NGO	Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department	GHP-State	0
13902	Human Sciences Research Council	Private Contractor	of Health and Human	GHP-State	0
13903	Community Media Trust	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13904	TB/HIV Care	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13923	International Center for AIDS Care and Treatment Programs, Columbia	University	U.S. Department of Health and Human Services/Health Resources and Services	GHP-State	600,000



	University		Administration		
13938	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0
14126	South Africa Partners	NGO	Prevention U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	324,412
14291	Hospice and Palliative Care Assn. Of South Africa	NGO	U.S. Agency for International Development	GHP-State	2,488,023
14294	University Research South Africa	Private Contractor	U.S. Agency for International Development	GHP-State	0
14295	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,850,000
14450	Society for Family Health - South Africa	NGO	U.S. Department of Defense	GHP-State	0
14616	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	4,250,000
14617	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,423,000
14623	Foundation for	NGO	U.S. Agency for	GHP-State	0



	Professional		International		
	Development		Development		
14631	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	8,960,939
14667	Tulane University	University	U.S. Agency for International Development	GHP-State	0
14846	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	2,227,976
14847	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	0
16372	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	13,427,788
16583	Aurum Health Research	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,168,830
16584	Institute for Youth Development SA (IYDSA)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,992,884
16746	Emory University	University	U.S. Department of Health and	GHP-State	0



					=
			Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Columbia		Human		
16759	University	University	Services/Centers	GHP-State	160,167
	Mailman School		for Disease		
	of Public Health		Control and		
			Prevention		
			U.S. Department		
			of Health and		
	National	Implementing Agency	Human		
16772	Department of		Services/Centers	GHP-State	0
	Health		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	South African	Host Country	Human		
16773	National AIDS	Government	Services/Centers	GHP-State	0
10773	Council	Agency	for Disease	GIT-State	
	Courien	Agency	Control and		
			Prevention		
			U.S. Department		
			of Health and		
40===	Aurum Health		Human		
16775	Research	NGO	Services/Centers	GHP-State	9,200,000
			for Disease		
			Control and		
			Prevention		
16807	TBD	TBD	Redacted	Redacted	Redacted
16808	University of	University	U.S. Department	GHP-State	3,660,000
10000	Kwazulu-Natal,	Officeroity	of Health and	GHF-State	3,000,000



16980	University	Private Contractor	U.S. Agency for	GHP-State	0
16979	Regional Psychosocial Support Initiative, South Africa	NGO	U.S. Agency for International Development	GHP-State	0
16976	TBD	TBD	Redacted	Redacted	Redacted
16932	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16929	TBD	TBD	Redacted	Redacted	Redacted
16835	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	130,000
16810	Results for Development	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
	Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS		Human Services/Centers for Disease Control and Prevention		



	Research		International		
	Corporation, LLC		Development		
16981	Africa Health Placements	NGO	U.S. Agency for International Development	GHP-State	539,424
16982	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	4,383,398
16984	South Africa Partners	NGO	U.S. Agency for International Development	GHP-State	0
16985	ICF Macro	Private Contractor	U.S. Agency for International Development	GHP-State	257,520
16987	Childline Mpumalanga	NGO	U.S. Agency for International Development	GHP-State	512,609
16988	Kheth'Impilo	NGO	U.S. Agency for International Development	GHP-State	0
16989	Childwelfare Bloemfontein & Childline Free State	NGO	U.S. Agency for International Development	GHP-State	465,000
16990	Children in Distress	NGO	U.S. Agency for International Development	GHP-State	462,791
16991	Future Families	Implementing Agency	U.S. Agency for International Development	GHP-State	233,249
16992	HIVSA	Implementing Agency	U.S. Agency for International Development	GHP-State	0
16993	NACOSA (Networking AIDS	Implementing Agency	U.S. Agency for International	GHP-State	211,572



	Community of		Development		
	South Africa)		Вотогорителя		
17017	National	NGO	U.S. Agency for International Development	GHP-State	459,738
17018	AgriAIDS	NGO	U.S. Agency for International Development	GHP-State	0
17019	Anova Health Institute	NGO	U.S. Agency for International Development	GHP-State	1,673,312
17020	Anova Health Institute	NGO	U.S. Agency for International Development	GHP-State	3,497,291
17021	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	9,055,322
17022	The South-to-South Partnership for Comprehensive Family HIV Care and Treatment Program (S2S)	Private Contractor	U.S. Agency for International Development	GHP-State	998,790
17023	Broadreach	NGO	U.S. Agency for International Development	GHP-State	13,536,898
17024	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	0
17025	Wits Health Consortium, Health Economics and Epidemiology Research Office	Implementing Agency	U.S. Agency for International Development	GHP-State	1,686,968



	1	1	1	T .	
17026	Mothers to Mothers (M2M)	Implementing Agency	U.S. Agency for International Development	GHP-State	3,452,035
17027	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	633,383
17028	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	225,971
17029	Witkoppen Health & Welfare Centre (WHWC)	NGO	U.S. Agency for International Development	GHP-State	1,761,039
17030	Wits Health Consortium (Pty) Limited	Private Contractor	U.S. Agency for International Development	GHP-State	0
17033	Medical Research Council	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17036	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	13,015,684
17037	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	10,606,327
17038	Maternal, Adolscent and Child Health (MatCH)	Implementing Agency	U.S. Agency for International Development	GHP-State	3,013,474
17039	Broadreach	NGO	U.S. Agency for International Development	GHP-State	3,672,622



				1	
	Wits Reproductive		U.S. Agency for		
17043	Health& HIV	NGO	International	GHP-State	0
	Institute		Development	1	
			U.S. Agency for		
17046	Kheth'Impilo	NGO	International	GHP-State	9,361,890
			Development		
			U.S. Agency for		
17047	FHI 360	NGO	International	GHP-State	1,894,466
			Development		
			U.S. Department		
			of Health and		
	American		Human		
17452	International	NGO	Services/Health	GHP-State	1,175,000
	Health Alliance		Resources and		, ,
			Services		
			Administration		
	Human Sciences Research Council	Private Contractor	U.S. Department		
			of Health and		
			Human		
17459				GHP-State	0
			for Disease		
			Control and		
			Prevention		
17493	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
			of Health and		
			Human		
17505	United Nations	Multi-lateral		GHP-State	100,000
	Children's Fund	Agency	for Disease		,
			Control and		
			Prevention		
			U.S. Department		
	Institute for Youth Development SA (IYDSA)	NGO	of Health and		
17506			Human	GHP-State	2,520,000
			Services/Centers		,,
	(,		for Disease		
		l	Diocase		l



	1	1		1	
			Control and		
			Prevention		
17507	Kheth'Impilo	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,520,000
17508	TBD	TBD	Redacted	Redacted	Redacted
17509	TBD	TBD	Redacted	Redacted	Redacted
17510	Macro Atlanta	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17511	United Nations Office on Drugs and Crime		U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17512	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
17528	TBD	TBD	Redacted	Redacted	Redacted
17533	TBD	TBD	Redacted	Redacted	Redacted
17536	FHI 360	NGO	U.S. Agency for	GHP-State	76,749



			latamatia : -!		
			International		
	Johns Hopkins		U.S. Agency for		
17537	Health and Education in South Africa	NGO	International Development	GHP-State	2,630,285
17538	Johns Hopkins Health and Education in South Africa	NGO	U.S. Agency for International Development	GHP-State	6,193,604
17539	TBD	TBD	Redacted	Redacted	Redacted
17540	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	5,200,000
17564	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
17604	Universitaet Bern	University	U.S. Department of Health and Human Services/National Institutes of Health	GHP-State	300,000
17606	CRDF Global	NGO	U.S. Department of Health and Human Services/National Institutes of Health	GHP-State	1,500,000
17767	Broadreach	NGO	U.S. Department of Health and	GHP-State	1,000,000



			Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department of Health and		
	Columbia University Mailman School of Public Health	University	Human		
17768			Services/Centers	GHP-State	750,000
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	I limit to maintain af		Human		
17769	University of Washington	University	Services/Centers	GHP-State	400,000
			for Disease		
			Control and		
			Prevention		



Implementing Mechanism(s)

Implementing Mechanism Details

implementing incontanion betane				
Mechanism ID: 17769	Mechanism Name: GH001197			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: University of Washingto	on			
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: Yes			
Global Fund / Multilateral Engagement: No				
G2G: No Managing Agency:				

Total All Funding Sources: 400,000	Total Mechanism Pipeline: Redacted					
Applied Pipeline Amount: 0						
FY 2013 Burn Rate: Redacted						
Funding Source Funding Amount						
GHP-State	400,000					

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17769

Mechanism Name: GH001197

Prime Partner Name: University of Washington



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0

(No data provided.)

Implementing Mechanism Details

mpromortung moortunem potane				
Mechanism ID: 17768	Mechanism Name: GH001194			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Columbia University Mailman S	School of Public Health			
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: Yes			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 750,000	Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 0					
FY 2013 Burn Rate: Redacted					
Funding Source	Funding Amount				
GHP-State	750,000				

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000



Key Issues

(No data provided.)

Budget Code Information

Budget Gode information					
Mechanism ID:	17768				
Mechanism Name:	GH001194				
Prime Partner Name:	Columbia University Mailman School of Public Health				
Strategic Area	Budget Code Planned Amount On Hold Amount				
Treatment	HTXS	750,000	0		

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17767	Mechanism Name: GH001202	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Broadreach		
Agreement Start Date: Redacted	ate: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	1,000,000	

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Ì		
	Human Resources for Health	800,000

Key Issues

(No data provided.)

Budget Code Information

Badget Code information			
Mechanism ID:	17767		
Mechanism Name:	GH001202		
Prime Partner Name:	Broadreach		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17606 Mechanism Name: RePORT TB Sout		
Funding Agency: HHS/NIH	Procurement Type: Cooperative Agreement	
Prime Partner Name: CRDF Global		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	



FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	1,500,000	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Badget Gode information			
Mechanism ID:	17606		
Mechanism Name:	RePORT TB South Africa		
Prime Partner Name:	: CRDF Global		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17604 Mechanism Name: NIAIID/NIH Registr	
Funding Agency: HHS/NIH	Procurement Type: Grant
Prime Partner Name: Universitaet Bern	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	300,000	

Sub Partner Name(s)

National Health and Laboratory	
Services	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17604		
Mechanism Name:	NIAIID/NIH Registry Match		
Prime Partner Name:	Universitaet Bern		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17564	Mechanism Name: NIH CT Development		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Population Services International			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: Yes		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 200,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	200,000	

Sub Partner Name(s)

Perinatal HIV Research Unit,	
South Africa	

Cross-Cutting Budget Attribution(s)

<u> </u>	
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Operation Research
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Operation Research

Key Issues

TB End-of-Program Evaluation Family Planning

Budget Code Information

Daagot Coao iinoiini			
Mechanism ID:	17564		
Mechanism Name:	NIH CT Development		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	4,000		Redacted



	test results during the past 12 months		
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,600	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,400	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,600	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	2,400	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	4,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,000	Redacted

Implementing Mechanism Details

Mechanism ID: 17540	Mechanism Name: TB Care - 2	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 5,200,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 1,666,804		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	5,200,000	

Sub Partner Name(s)



Johns Hopkins University/Jhpiego	Partners in Health	Project HOPE
Johns Hopkins Offiversity/Jriplego	r artifers in ricaltif	FIUJECTIOFL

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation

Budget Code Information

Budget Code information			
Mechanism ID:	17540		
Mechanism Name:	TB Care - 2		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HVTB	5,200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17539	TBD: Yes
REDACTED	

implementing meentament betane	
	Mechanism Name: Community-Based
Mechanism ID: 17538	Comprehensive HIV Prevention, Counseling and
	testing Program to Reduce HIV Incidence



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins Health and Education in South Africa	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 6,193,604 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 526,396	
FY 2013 Burn Rate: Redacted	
Funding Source Funding Amount	
GHP-State	6,193,604

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

<u> </u>	- \-/
Gender: GBV	1,819,864
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	2,183,837
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Monitoring and Evaluation
Condom programming	242,649



Key Issues

(No data provided.)

Budget Code Information

Budget Code Inform	ation			
Mechanism ID: Mechanism Name: Prime Partner Name:	17538 Community-Based Comprehensive HIV Prevention, Counseling and testing Program to Reduce HIV Incidence			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Prevention	CIRC 405,000		0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVAB	2,686,640	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	3,101,964	0	

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,974,078	2,715,622
PP_PREV_DSD	Age/sex: 15-19 Male	415,026	555,468
PP_PREV_DSD	Age/sex: 20-24 Male	481,728	555,468
PP_PREV_DSD	Age/sex: 25-49 Male	235,510	277,734
PP_PREV_DSD	Age/sex: 50+ Male	80,503	92,578



PP_PREV_DSD	Age/sex: 10-14 Female	32,591	246,875
PP_PREV_DSD	Age/sex: 15-19 Female	232,873	370,312
PP_PREV_DSD	Age/sex: 20-24 Female	326,563	370,312
PP_PREV_DSD	Age/sex: 25-49 Female	115,615	185,156
PP_PREV_DSD	Age/sex: 50+ Female	53,669	61,719
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,974,078	2,715,622

Implementing Mechanism Details

implementing mechanism betails		
Mechanism ID: 17537	Mechanism Name: Strategic, Evidence-Based Communication Interventions Systematically Applied at Multiple Levels for Greater Effectiveness of HIV Prevention Programs	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins Health and Education in South Africa		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 2,630,285 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 2,229,715		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	2,630,285	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

	1 /
Key Populations: MSM and TG	384,244
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and
	operational research among MSM/TG and their sex



	partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: Gender Equality	720,458
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	576,367
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Condom programming	191,122

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID:	17537 : Strategic, Evidence-Based Communication Interventions Systematically : Applied at Multiple Levels for Greater Effectiveness of HIV Prevention : Programs Johns Hopkins Health and Education in South Africa		
Strategic Area	Budget Code Planned Amount On Hold Amount		On Hold Amount
Governance and Systems	HVSI	282,724	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	728,411	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	619,150	0

(No data provided.)

Mechanism ID: 17536	Mechanism Name: Accelerating Strategies for Practical Innovation & Research in Economic Strengthening (ASPIRES)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	



Total All Funding Sources: 76,749	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,000,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	76,749

Sub Partner Name(s)

ACDI/VOCA	Development & Training Services, Inc.	Economic Policy Research Institute
Freedom from Hunger	Human Sciences Research Council	Innovations for Poverty Action
Integral Science Institute	Living Goods	Microfinance Opportunities
The SEEP Network	The William Davidson Institute at the University of Michigan	World Council of Credit Unions

Cross-Cutting Budget Attribution(s)

Economic Strengthening	76,749	

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	Accelerating Strategies for Practical Innovation & Research in Economic Strengthening (ASPIRES)		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HKID	76,749	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17533	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 17528	TBD: Yes
REDA	CTED

Implementing Mechanism Details

Mechanism ID: 17512	Mechanism Name: WHO HIV Prevention	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 150,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 312,282		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	150,000	

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Cross carming bunger, the location	-(-)
Key Populations: MSM and TG	30,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues

(No data provided.)

Budget Code Information

Budget Code Informa	ation		
Mechanism ID:	17512		
Mechanism Name:	WHO HIV Prevention		
Prime Partner Name:	World Health Organizat	ion	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17511	Mechanism Name: UNODC Capacity Development for PWID	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: United Nations Office on Drugs and Crime		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 100,000 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source Funding Amount	
	i e e e e e e e e e e e e e e e e e e e

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Joue Information			
Mechanism ID:	17511		
Mechanism Name:	UNODC Capacity Development for PWID		
Prime Partner Name:	United Nations Office on Drugs and Crime		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



December	IDLID	100 000		
Prevention	IDUP	100,000	0	

(No data provided.)

Implementing Mechanism Details

implementing Mechanism Details		
Mechanism ID: 17510	Mechanism Name: Technical Assistance (TA) Indicators	
Funding Agency: HHS/CDC	Procurement Type: Contract	
Prime Partner Name: Macro Atlanta		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 450,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Daagot Godo IIII oi III			
Mechanism ID:	17510		
Mechanism Name:	Technical Assistance (1	ΓA) Indicators	
Prime Partner Name:	Macro Atlanta		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17509	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17508	TBD: Yes
REDACTED	

Mechanism ID: 17507	Mechanism Name: GH001145	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Kheth'Impilo		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	



Total All Funding Sources: 2,520,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	2,520,000	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health 1,260,000	Human Resources for Health	1,260,000
--------------------------------------	----------------------------	-----------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	GH001145		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	185,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	466,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	157,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	990,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	672,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000		Redacted



				<u> </u>
C2.1.D_DSD	By Age/Sex: <15 Female	50		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	50		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	600		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	300		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,000		Redacted
C2.1.D_DSD	By Age: <15	100		Redacted
C2.1.D_DSD	By Age: 15+	900		Redacted
C2.1.D_DSD	Sum of Age disaggregates	1,000		Redacted
C2.1.D_DSD	By Sex: Female	650		Redacted
C2.1.D_DSD	By Sex: Male	350		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	1,000		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	50		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	50		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	600		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	300		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,000		Redacted
C2.1.D_NGI	By Age: <15	100		Redacted
C2.1.D_NGI	By Age: 15+	900		Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,000		Redacted
C2.1.D_NGI	By Sex: Female	650		Redacted
C2.1.D_NGI	By Sex: Male	350		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,000		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	1,000		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,000	2,000	Redacted



TV CURR DOD	Aggregated Agg/Covy, 45 Mala	FO	100	Dodostod
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	50	100	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	300	600	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	50	100	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	600	1,200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	100	200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	900	1,800	Redacted
TX_CURR_DSD	TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates		2,000	Redacted
Number of adults and children receiving		1,000		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	50		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	300		Redacted
TX_CURR_NGI				Redacted
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 600			Redacted	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,000		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	100		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	900		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	800	1,600	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,000	2,000	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	2	Redacted



	Number of PEPFAR-supported testing			
LAB_CAP_DSD	facilities with capacity to perform	1	2	Redacted
	clinical laboratory tests			

Implementing Mechanism Details

Mechanism ID: 17506	Mechanism Name: GH001145			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Institute for Youth Development SA (IYDSA)				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: Yes			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 2,520,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,520,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

5	
Human Resources for Health	1,260,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17506	Mechanism ID: 17506
---------------------	---------------------



Mechanism Name: Prime Partner Name:	GH001145 Institute for Youth Development SA (IYDSA)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	185,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	445,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	57,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	171,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	990,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	672,000	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery	1		Redacted



	(DSD)		
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	50	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	50	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	600	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	300	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,000	Redacted
C2.1.D_DSD	By Age: <15	100	Redacted
C2.1.D_DSD	By Age: 15+	900	Redacted
C2.1.D_DSD	Sum of Age disaggregates	1,000	Redacted
C2.1.D_DSD	By Sex: Female	650	Redacted
C2.1.D_DSD	By Sex: Male	350	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	1,000	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	50	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	50	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	600	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	300	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,000	Redacted
C2.1.D_NGI	By Age: <15	100	Redacted



C2.1.D_NGI	By Age: 15+	900		Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,000		Redacted
C2.1.D_NGI	By Sex: Female	650		Redacted
C2.1.D_NGI	By Sex: Male	350		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,000		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	1,000		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,000	2,000	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	50	100	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	300	600	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	50	100	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	600	1,200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	100	200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	900	1,800	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,000	2,000	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	1,000		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	50		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	300		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	50		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	600		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,000		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	100		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	900		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12	800	1,600	Redacted



	months after initiating ART			
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,000	2,000	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	2	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1	2	Redacted

Implementing Mechanism Details

Mechanism ID: 17505	Mechanism Name: UNICEF	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: United Nations Children's Fund	d .	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 100,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 689,690		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	100,000	

Sub Partner Name(s)



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Baaget Code information				
Mechanism ID:	17505			
Mechanism Name:	UNICEF			
Prime Partner Name:	United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	100,000	0	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17493	TBD: Yes
REDACTED	

Mechanism ID: 17459	Mechanism Name: HSRC	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Human Sciences Research Council		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,552,513		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17459		
Mechanism Name:	HSRC		
Prime Partner Name:	Human Sciences Research Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI		0

Implementing Mechanism Indicator Information

(No data provided.)



Mechanism ID: 17452	Mechanism Name: TBD Twinning Capacity Building	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: American International Health Alliance		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,175,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,175,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	200,000
Human Resources for Health	400,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID	: 17452
--------------	---------



Mechanism Name:	TBD Twinning Capacity Building			
Prime Partner Name:	American International Health Alliance			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	OHSS	1,175,000	0	

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	191	251	Redacted
HRH_PRE	By Graduates: Other	191	251	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	191	251	Redacted

Implementing Mechanism Details

	Mechanism Name: Nutrition Assessment,
Mechanism ID: 17047	Counseling and Support Capacity Building
	(NACSCAP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,894,466	Total Mechanism Pipeline: Redacted
--------------------------------------	------------------------------------



Applied Pipeline Amount: 805,534		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	1,894,466	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service	1,798,177
Delivery	
Water	22,109

Key Issues

Child Survival Activities Safe Motherhood Workplace Programs

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Nutrition Assessment Counseling and Support Canacity Building		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,131,470	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	303,336	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	459,660	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	86	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	86	
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	86	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	86	

Implementing Mechanism Details

Mechanism ID: 17046	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Kheth'Impilo			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 9,361,890	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 758,110			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	9,361,890		



(No data provided.)

Cross-Cutting Budget Attribution(s)

Cross-Cutting Budget Attribution(s) Human Resources for Health	4 552 024
	1,552,034
Gender: Gender Equality	350,000
Focus Area:	Equity in HIV prevention, care, treatment and
	support
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	211,400
Condom programming	50,000
Food and Nutrition: Policy, Tools, and Service	274,475
Delivery	

Key Issues

Child Survival Activities Safe Motherhood Custom



ТВ Family Planning

Budget Code Information				
Mechanism ID: 17046				
Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes Prime Partner Name: Kheth'Impilo				
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HBHC	950,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	1,169,808	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	1,485,184	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	404,486	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	532,391	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	3,894,721	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	925,300	0	



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	155	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	126	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	29	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	126	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	29	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	126	
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	29	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	126	
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	13	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	126	
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0



SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	3	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	7,684	6,147
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	7,684	6,147
PMTCT_ARV_DSD	Life-long ART (including Option B+)	4,070	3,255
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on	2,287	1,830



	treatment during the current pregnancy		
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,760	1,408
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	3,578	2,862
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	59	47
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	7,707	6,164
PMTCT_ARV_DSD	Sum of New and Current disaggregates	4,047	3,238
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,059	
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,536	
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,165	
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,416	
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	3,388	
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	90	
PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NA	Sum of Regimen disaggregates	3,478	
PMTCT_ARV_NA	Sum of New and Current disaggregates	5,581	



PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	32,579	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	33,056	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	4,070	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	8,610	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	10,192	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	13,470	
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	307	
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	17,847	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	18,802	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	15,836	15,836
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	15,836	15,836
PMTCT_ARV_TA	Life-long ART (including Option B+)	9,174	9,174
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,158	4,158
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current	5,016	5,016



	pregnancy		
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	6,504	6,504
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	158	158
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	15,836	15,836
PMTCT_ARV_TA	Sum of New and Current disaggregates	9,174	9,174
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	155	124
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	155	124
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	29	16
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	126	108
PMTCT_SITE	Sum of Numerator Support Type disaggregates	155	124
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	29	16
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	126	108
PMTCT_SITE	Sum of Denominator Support Type	155	124



	disaggregates		
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,239	12,991
PMTCT_STAT_DSD	Number of new ANC and L&D clients	16,404	13,123
PMTCT_STAT_DSD	By: Known positives at entry	3,080	2,464
PMTCT_STAT_DSD	By: Number of new positives identified	2,844	2,275
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,924	4,739
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,225	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	106,524	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	109,492	
PMTCT_STAT_NGI	By: Known positives at entry	20,316	
PMTCT_STAT_NGI	By: Number of new positives identified	10,980	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	31,296	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,060	65,060
PMTCT_STAT_TA	Number of new ANC and L&D clients	65,060	65,060
PMTCT_STAT_TA	By: Known positives at entry	10,212	10,212
PMTCT_STAT_TA	By: Number of new positives identified	5,624	5,624
PMTCT_STAT_TA	Sum of Positives Status disaggregates	15,836	15,836
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	110,964	88,773
HTC_TST_DSD	By Test Result: Negative	95,641	76,513
HTC_TST_DSD	By Test Result: Positive	15,323	12,260
HTC_TST_DSD	Sum of Test Result disaggregates	110,964	88,773
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,707	2,166



			1
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	40,444	32,355
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,760	3,808
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	63,054	50,444
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,467	5,974
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	103,498	82,799
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	110,965	88,773
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	531,508	
HTC_TST_NA	By Test Result: Negative	508,996	
HTC_TST_NA	By Test Result: Positive	22,512	
HTC_TST_NA	Sum of Test Result disaggregates	531,508	
HTC_TST_NA	Aggregated Age/sex: <15 Male	12,979	
HTC_TST_NA	Aggregated Age/sex: 15+ Male	193,734	
HTC_TST_NA	Aggregated Age/sex: <15 Female	22,813	
HTC_TST_NA	Aggregated Age/sex: 15+ Female	301,982	
HTC_TST_NA	Sum of Aggregated Age/Sex <15	35,792	
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	495,716	
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	531,508	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	950,300	
HTC_TST_NGI	By Test Result: Negative	873,052	
HTC_TST_NGI	By Test Result: Positive	77,248	
HTC_TST_NGI	Sum of Test Result disaggregates	950,300	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	23,206	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	346,383	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	40,788	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	539,923	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	63,994	



HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	886,306	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	950,300	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	307,828	307,828
HTC_TST_TA	By Test Result: Negative	271,416	271,416
HTC_TST_TA	By Test Result: Positive	36,412	36,412
HTC_TST_TA	Sum of Test Result disaggregates	307,828	307,828
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,517	7,517
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	112,203	112,203
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,212	13,212
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	174,896	174,896
HTC_TST_TA	Sum of Aggregated Age/Sex <15	20,729	20,729
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	287,099	287,099
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	307,828	307,828
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	74,101	
C2.1.D_DSD	By Age/Sex: <15 Female	3,198	
C2.1.D_DSD	By Age/Sex: <15 Male	1,799	
C2.1.D_DSD	By Age/Sex: 15+ Female	42,111	
C2.1.D_DSD	By Age/Sex: 15+ Male	26,993	
C2.1.D_DSD	Sum of Age/Sex disaggregates	74,101	
C2.1.D_DSD	By Age: <15	4,997	
C2.1.D_DSD	By Age: 15+	69,104	
C2.1.D_DSD	Sum of Age disaggregates	74,101	
C2.1.D_DSD	By Sex: Female	45,309	
C2.1.D_DSD	By Sex: Male	28,792	
C2.1.D_DSD	Sum of Sex disaggregates	74,101	
C2.1.D_NA	Number of HIV-positive individuals receiving a	86,014	



	minimum of one clinical service		
C2.1.D_NA	By Age/Sex: <15 Female	3,759	
C2.1.D_NA	By Age/Sex: <15 Male	2,075	
C2.1.D_NA	By Age/Sex: 15+ Female	48,866	
C2.1.D_NA	By Age/Sex: 15+ Male	31,314	
C2.1.D_NA	Sum of Age/Sex disaggregates	86,014	
C2.1.D_NA	By Age: <15	5,834	
C2.1.D_NA	By Age: 15+	80,180	
C2.1.D_NA	Sum of Age disaggregates	86,014	
C2.1.D_NA	By Sex: Female	52,625	
C2.1.D_NA	By Sex: Male	33,389	
C2.1.D_NA	Sum of Sex disaggregates	86,014	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	327,961	
C2.1.D_NGI	By Age/Sex: <15 Female	14,141	
C2.1.D_NGI	By Age/Sex: <15 Male	7,929	
C2.1.D_NGI	By Age/Sex: 15+ Female	186,474	
C2.1.D_NGI	By Age/Sex: 15+ Male	119,417	
C2.1.D_NGI	Sum of Age/Sex disaggregates	327,961	
C2.1.D_NGI	By Age: <15	22,070	
C2.1.D_NGI	By Age: 15+	305,891	
C2.1.D_NGI	Sum of Age disaggregates	327,961	
C2.1.D_NGI	By Sex: Female	200,615	
C2.1.D_NGI	By Sex: Male	127,346	
C2.1.D_NGI	Sum of Sex disaggregates	327,961	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	167,846	
C2.1.D_TA	By Age/Sex: <15 Female	7,237	
C2.1.D_TA	By Age/Sex: <15 Male	4,058	
C2.1.D_TA	By Age/Sex: 15+ Female	95,435	
C2.1.D_TA	By Age/Sex: 15+ Male	61,116	
C2.1.D_TA	Sum of Age/Sex disaggregates	167,846	



C2 1 D TA	Dy Ago: 445	11 205	
C2.1.D_TA	By Age: <15	11,295	
C2.1.D_TA	By Age: 15+	156,551	
C2.1.D_TA	Sum of Age disaggregates	167,846	
C2.1.D_TA	By Sex: Female	102,672	
C2.1.D_TA	By Sex: Male	65,174	
C2.1.D_TA	Sum of Sex disaggregates	167,846	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	66,691	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	74,101	
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	74,101	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	74,101	59,281
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,789	1,431
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26,983	21,586
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,198	2,559
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	42,131	33,705
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	74,101	59,281
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	167,846	195,700
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,045	3,300



	1		
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	61,187	66,571
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,247	6,047
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	95,367	119,782
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	167,846	195,700
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	77,248	90,071
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,864	1,521
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	28,138	30,614
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	3,332	2,780
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	43,914	55,156
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	77,248	90,071
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	132	105
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	155	124
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	30	24



CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	102	81
CARE_SITE	Sum of Numerator Site Support Type disaggregates	132	105
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	30	24
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	125	100
CARE_SITE	Sum of Denominator Site Support Type disaggregates	155	124
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status whoare on ART during TB treatment during the reporting period	4,560	3,763
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,800	3,840
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	124	99
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	155	124
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB	29	23



<u></u>	i I		
	basic management units at which 80% of		
	registered TB cases who are HIV-positive are		
	on ART, during the reporting period		
	By site support type: Technical		
	Assistance-only (TA): The number of		
TD ADTOITE	PEPFAR-supported TB basic management	0.5	70
TB_ARTSITE	units at which 80% of registered TB cases	95	76
	who are HIV-positive are on ART, during the		
	reporting period		
	Sum of Numerator Site Support Type		
TB_ARTSITE	disaggregates	124	99
	By site support type: Direct Service Delivery		
TB_ARTSITE	(DSD): The number of PEPFAR-supported TB	29	23
15_7(15.112	basic management units	20	20
	By site support type: Technical		
	Assistance-only (TA): The number of		
TB_ARTSITE	PEPFAR-supported TB basic management	126	101
	units		
	Sum of Denominator Site Support Type		
TB_ARTSITE	disaggregates	155	124
DMTOT FID DOD	Number of infants who had a virologic HIV test	00.005	40.000
PMTCT_EID_DSD	within 12 months of birth during the reporting	22,835	19,282
	period		
	Number of HIV- positive pregnant women		
PMTCT_EID_DSD	identified during the reporting period (include	25,372	20,297
	known HIV-positive women at entry into	ŕ	,
	PMTCT)		
PMTCT EID DSD	By infants who received a virologic test within	19,282	15,426
	2 months of birth		
PMTCT EID DSD	By infants who received their first virologic HIV	6,090	4,872
T WITCT_LID_DOD	test between 2 and 12 months of age	0,090	4,072
PMTCT_EID_DSD	Sum of Infant Age disaggregates	25,372	20,298
DMTOT FID DOD	By infants with a positive virologic test result	405	004
PMTCT_EID_DSD	within 12 months of birth	405	324
TX_CURR_DSD	Number of adults and children receiving	65,260	52,208
			•



	antiretroviral therapy (ART)		
TX_CURR_DSD	Age/Sex: <1 Male	46	37
TX_CURR_DSD	Age/Sex: 1-4 Male	335	268
TX_CURR_DSD	Age/Sex: 5-14 Male	1,069	855
TX_CURR_DSD	Age/Sex: 15+ Male	19,971	15,977
TX_CURR_DSD	Age/Sex: <1 Female	46	37
TX_CURR_DSD	Age/Sex: 1-4 Female	335	268
TX_CURR_DSD	Age/Sex: 5-14 Female	1,069	855
TX_CURR_DSD	Age/Sex: 15+ Female	42,389	33,911
TX_CURR_DSD	Sum of age/sex disaggregates	2,900	2,320
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	4	4
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	65	65
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	46	37
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	46	37
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,450	1,160
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	19,971	15,977
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,450	1,160
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	42,389	33,911
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,900	2,320
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	62,360	49,888
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	65,260	52,208
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	73,900	
TX_CURR_NA	Aggregated Age/Sex: <1 Male	52	
TX_CURR_NA	Aggregated Age/Sex: <1 Female	52	
TX_CURR_NA	Aggregated Age/Sex: <15 Male	1,622	
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	22,502	
TX_CURR_NA	Aggregated Age/Sex: <15 Female	1,889	



TX_CURR_NA	Aggregated Age/Sex: 15+ Female	47,887	
TX_CURR_NA	Sum of Aggregated Age/Sex <15	3,511	
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	70,389	
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	73,900	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	291,468	
TX_CURR_NGI	Age/Sex: <1 Male	46	
TX_CURR_NGI	Age/Sex: 1-4 Male	335	
TX_CURR_NGI	Age/Sex: 5-14 Male	1,069	
TX_CURR_NGI	Age/Sex: 15+ Male	19,971	
TX_CURR_NGI	Age/Sex: <1 Female	46	
TX_CURR_NGI	Age/Sex: 1-4 Female	335	
TX_CURR_NGI	Age/Sex: 5-14 Female	1,069	
TX_CURR_NGI	Age/Sex: 15+ Female	42,389	
TX_CURR_NGI	Sum of Age/Sex disaggregates	65,260	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	831	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	831	240
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	5,661	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	92,656	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	6,099	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	187,052	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	291,468	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	11,760	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	279,708	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	152,308	146,216
TX_CURR_TA	Age/Sex: <1 Male	107	
TX_CURR_TA	Age/Sex: 1-4 Male	782	
TX_CURR_TA	Age/Sex: 5-14 Male	2,495	
TX_CURR_TA	Age/Sex: 15+ Male	46,610	
TX_CURR_TA	Age/Sex: <1 Female	107	
TX_CURR_TA	Age/Sex: 1-4 Female	782	



	·		1
TX_CURR_TA	Age/Sex: 5-14 Female	2,495	
TX_CURR_TA	Age/Sex: 15+ Female	98,930	
TX_CURR_TA	Sum of Age/Sex disaggregations	6,768	
TX_CURR_TA	Aggregated Age/Sex: <1 Male	733	704
TX_CURR_TA	Aggregated Age/Sex: <1 Female	733	704
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,589	2,486
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	50,183	48,176
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,760	2,650
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	96,776	92,904
TX_CURR_TA	Sum of Aggregated Age/Sex <15	5,349	5,136
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	146,959	141,080
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	152,308	146,216
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4
TX_DIST	Total number of PEPFAR supported District Health Offices	4	4
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,644	8,298
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	42	40
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	148	142
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,848	2,734
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	42	40
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	157	150
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,491	5,272
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,644	8,298
TX_NEW_DSD	Pregnancy status	1,123	
TX_NEW_DSD	Breastfeeding status	842	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after	47,823	38,258



	initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	50,340	40,272
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	155	124
TX_SITE	Total number of PEPFAR-supported ART sites	155	124
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	rted ART 29 23 greater for	
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	126	101
TX_SITE	Sum of Numerator Site Support Type disaggregates	155	124
By support type: Direct Service Delivery TX_SITE (DSD): Total number of PEPFAR-supported ART sites		29	23
By support type: Technical Assistance TX_SITE (TA-only): Total number of PEPFAR-supported ART sites		126	101
TX_SITE Sum of Denominator Site Support Type disaggregates		155	124
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	45	36
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV	155	124



	service delivery points: PMTCT, Care and Treatment		
By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		29	23
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service		13
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	45	36
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	29 23	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points 126		101
FPINT_SITE_DSD Sum of Denominator Site Support Type disaggregates		155	124
FPINT_SITE_DSD	Service delivery type: Clinical	155	124
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	155	124
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	29	29
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	155	155
QI_SITE	By site support type: Direct Service Delivery	15	15



	<u> </u>		
	(DSD): Number of PEPFAR-supported clinical		
service sites with a quality improvement			
	activity completed that addresses clinical HIV		
	programs and has documented results in the		
	last 6 months		
	By site support type: Technical		
	Assistance-only (TA): Number of		
OL OITE	PEPFAR-supported clinical service sites with	4.4	4.4
QI_SITE	a quality improvement activity completed that	14	14
	addresses clinical HIV programs and has		
	documented results in the last 6 months		
QI_SITE	Sum of Numerator Site Support Type	29	29
· <u>-</u>	disaggregates		
	By site support type: Direct Service Delivery		
	(DSD): Total number of PEPFAR-supported		
QI_SITE	sites for any HIV clinical service including HIV	29	29
	Care, HIV Treatment, TB care, PMTCT,		
	VMMC, HTC		
	By site support type: Technical		
	Assistance-only (TA): Total number of		
QI_SITE	PEPFAR-supported sites for any HIV clinical	126	126
	service including HIV Care, HIV Treatment,		
	TB care, PMTCT, VMMC, and HTC		
01.6:77	Sum of Denominator Site Support Type	45-	45-
QI_SITE	disaggregates	155	155
	The number of PLHIV who were screened for		
TB_SCREEN_DSD	TB symptoms at the last clinical visit to an HIV	66,691	56,317
_	care facility during the reporting period		
	Number of HIV positive adults and children		
	who received at least one of the following		
TB_SCREEN_DSD	during the reporting period: clinical	74,101	59,281
	assessment (WHO staging) OR CD4 count		
	OR viral load		
	Aggregated Age - USE WITH HQ		
TB_SCREEN_DSD	PERMISSION ONLY: <15	5,000	5,000
L			I .



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	69,101	69,101
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	74,101	74,101
TB_SCREEN_DSD	Sex: Male	28,825	28,825
TB_SCREEN_DSD	Sex: Female	45,276	45,276
TB_SCREEN_DSD	Sum of Sex disaggregates	74,101	74,101

Mechanism ID: 17043	Mechanism Name: Ikhwezi MAMA - Monitoring & Evaluation & Vodacom Ikhwezi mHealth Program	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Reproductive Health& HIV Institute		
greement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,015,679	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Cell Life	GeoMed	Praekelt Foundation
OCH EHO	Scollica	i lackett oarlaation

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Child Survival Activities
Safe Motherhood
Family Planning

Budget Code Information

budget Code informa	Budget Code Information		
Mechanism ID: Mechanism Name:	Ikhwezi MAMA - Monitoring & Evaluation & Vodacom Ikhwezi mHealth Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label 2014		2015
SITE_SUPP	Number of unique sites supported by PEPFAR	10	30
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,500	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	12,500	
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during	3,500	



	1		1
	pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 3,500		
PMTCT_ARV_TA Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 3,500			
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,500	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	150,000	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	162,500	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	12,500	
PMTCT_STAT_NGI	By: Known positives at entry	0	
PMTCT_STAT_NGI By: Number of new positives identified 0			
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	0	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,500	
PMTCT_STAT_TA	Number of new ANC and L&D clients	12,500	

Mechanism ID: 17039	Mechanism Name: Comprehensive Clinic-Based District Services (Hybrid)	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Broadreach		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		



G2G: No	Managing Agency:
Total All Funding Sources: 3,672,622	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 827,378	-
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,672,622

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,005,251
Gender: Gender Equality	66,399
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	33,200
Food and Nutrition: Policy, Tools, and Service Delivery	146,905

Key Issues

Safe Motherhood Family Planning



Budget Code Information

Budget Code Information			
Mechanism ID:			
	: Comprehensive Clinic-Based District Services (Hybrid)		
Prime Partner Name:	Broadreach		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	296,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	473,862	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	93,462	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	259,685	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	215,659	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,899,417	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	434,373	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	15,000	



PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	20,000	
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	20,000	
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	100,000	
PMTCT_STAT_NA	Number of new ANC and L&D clients	125,000	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	100,000	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	125,000	
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,100,000	
HTC_TST_NA	Age/sex: <1 Male	8,800	
HTC_TST_NA	Age/sex: 1-4 Male	8,800	
HTC_TST_NA	Age/sex: 5-9 Male	8,800	
HTC_TST_NA	Age/sex: 10-14 Male	8,800	
HTC_TST_NA	Age/sex: 15-19 Male	8,800	
HTC_TST_NA	Age/sex: 20-24 Male	22,000	
HTC_TST_NA	Age/sex: 25-49 Male	330,000	
HTC_TST_NA	Age/sex: 50+ Male	44,000	
HTC_TST_NA	Age/sex: <1 Female	13,200	
HTC_TST_NA	Age/sex: 1-4 Female	13,200	
HTC_TST_NA	Age/sex: 5-9 Female	13,200	
HTC_TST_NA	Age/sex: 10-14 Female	13,200	
HTC_TST_NA	Age/sex: 15-19 Female	13,200	



	<u> </u>		
HTC_TST_NA	Age/sex: 20-24 Female	33,000	
HTC_TST_NA	Age/sex: 25-49 Female	495,000	
HTC_TST_NA	Age/sex: 50+ Female	66,000	
HTC_TST_NA	Sum of Age/Sex disaggregates	1,100,000	
HTC_TST_NA	Aggregated Age/sex: <15 Male	35,200	
HTC_TST_NA	Aggregated Age/sex: 15+ Male	404,800	
HTC_TST_NA	Aggregated Age/sex: <15 Female	52,800	
HTC_TST_NA	Aggregated Age/sex: 15+ Female	607,200	
HTC_TST_NA	Sum of Aggregated Age/Sex <15	88,000	
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	1,012,000	
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	1,100,000	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,100,000	
HTC_TST_NGI	Age/sex: <1 Male	8,800	
HTC_TST_NGI	Age/sex: 1-4 Male	8,800	
HTC_TST_NGI	Age/sex: 5-9 Male	8,800	
HTC_TST_NGI	Age/sex: 10-14 Male	8,800	
HTC_TST_NGI	Age/sex: 15-19 Male	8,800	
HTC_TST_NGI	Age/sex: 20-24 Male	22,000	
HTC_TST_NGI	Age/sex: 25-49 Male	330,000	
HTC_TST_NGI	Age/sex: 50+ Male	44,000	
HTC_TST_NGI	Age/sex: <1 Female	13,200	
HTC_TST_NGI	Age/sex: 1-4 Female	13,200	
HTC_TST_NGI	Age/sex: 5-9 Female	13,200	
HTC_TST_NGI	Age/sex: 10-14 Female	13,200	
HTC_TST_NGI	Age/sex: 15-19 Female	13,200	
HTC_TST_NGI	Age/sex: 20-24 Female	33,000	
HTC_TST_NGI	Age/sex: 25-49 Female	495,000	
HTC_TST_NGI	Age/sex: 50+ Female	66,000	
HTC_TST_NGI	Sum of Age/Sex disaggregates	1,100,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	35,200	



HTC_TST_NGI	Aggregated Age/sex: 15+ Male	404,800	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	52,800	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	607,200	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	88,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,012,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	1,100,000	
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	325,000	
C2.1.D_NA	By Age/Sex: <15 Female	15,600	
C2.1.D_NA	By Age/Sex: <15 Male	10,400	
C2.1.D_NA	By Age/Sex: 15+ Female	179,400	
C2.1.D_NA	By Age/Sex: 15+ Male	119,600	
C2.1.D_NA	Sum of Age/Sex disaggregates	325,000	
C2.1.D_NA	By Age: <15	26,000	
C2.1.D_NA	By Age: 15+	299,000	
C2.1.D_NA	Sum of Age disaggregates	325,000	
C2.1.D_NA	By Sex: Female	195,000	
C2.1.D_NA	By Sex: Male	130,000	
C2.1.D_NA	Sum of Sex disaggregates	325,000	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	325,000	
C2.1.D_NGI	By Age/Sex: <15 Female	15,600	
C2.1.D_NGI	By Age/Sex: <15 Male	10,400	
C2.1.D_NGI	By Age/Sex: 15+ Female	179,400	
C2.1.D_NGI	By Age/Sex: 15+ Male	119,600	
C2.1.D_NGI	Sum of Age/Sex disaggregates	325,000	
C2.1.D_NGI	By Age: <15	26,000	
C2.1.D_NGI	By Age: 15+	299,000	
C2.1.D_NGI	Sum of Age disaggregates	325,000	
C2.1.D_NGI	By Sex: Female	195,000	
C2.1.D_NGI	By Sex: Male	130,000	
C2.1.D_NGI	Sum of Sex disaggregates	325,000	



	<u> </u>	Т	
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	340,000	
TX_CURR_NA	Age/Sex: <1 Male	2,720	
TX_CURR_NA	Age/Sex: 1-4 Male	2,720	
TX_CURR_NA	Age/Sex: 5-14 Male	2,720	
TX_CURR_NA	Age/Sex: 15+ Male	127,840	
TX_CURR_NA	Age/Sex: <1 Female	4,080	
TX_CURR_NA	Age/Sex: 1-4 Female	4,080	
TX_CURR_NA	Age/Sex: 5-14 Female	4,080	
TX_CURR_NA	Age/Sex: 15+ Female	191,760	
TX_CURR_NA	Sum of Age/Sex disaggregates	340,000	
TX_CURR_NA	Aggregated Age/Sex: <1 Male	2,720	
TX_CURR_NA	Aggregated Age/Sex: <1 Female	4,080	
TX_CURR_NA	Aggregated Age/Sex: <15 Male	8,160	
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	127,840	
TX_CURR_NA	Aggregated Age/Sex: <15 Female	12,240	
TX_CURR_NA	Aggregated Age/Sex: 15+ Female	191,760	
TX_CURR_NA	Sum of Aggregated Age/Sex <15	20,400	
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	319,600	
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	340,000	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	340,000	
TX_CURR_NGI	Age/Sex: <1 Male	2,720	
TX_CURR_NGI	Age/Sex: 1-4 Male	2,720	
TX_CURR_NGI	Age/Sex: 5-14 Male	2,720	
TX_CURR_NGI	Age/Sex: 15+ Male	127,840	
TX_CURR_NGI	Age/Sex: <1 Female	4,080	
TX_CURR_NGI	Age/Sex: 1-4 Female	4,080	
TX_CURR_NGI	Age/Sex: 5-14 Female	4,080	
TX_CURR_NGI	Age/Sex: 15+ Female	191,760	
TX_CURR_NGI	Sum of Age/Sex disaggregates	340,000	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	2,720	



TX_CURR_NGI	Aggregated Age/Sex: <1 Female	4,080	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	8,160	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	127,840	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	12,240	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	191,760	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	340,000	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	20,400	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	319,600	

Mechanism ID: 17038	Mechanism Name: Strengthening District Responses for Better HIV/TB Patient Outcomes in eThekwini & Umkhanyakude Districts in KwaZulu-Natal, South Africa	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Maternal, Adolscent and Child Health (MatCH)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,013,474	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 3,106,526		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	3,013,474	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

<u> </u>	
	0.4.000
Human Resources for Health	91.689
riaman rioccarcoc for riocalar	01,000



Food and Nutrition: Policy, Tools, and Service Delivery	7,719
Motor Vehicles: Leased	192,000
Gender: Gender Equality	4,876
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: GBV	5,099
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Condom programming	16,373

Key Issues

Child Survival Activities
Safe Motherhood
TB
End-of-Program Evaluation
Family Planning

_		
	Mechanism ID:	17038



Mechanism Name: Strengthening District Responses for Better HIV/TB Patient Outcomes in Prime Partner Name: eThekwini & Umkhanyakude Districts in KwaZulu-Natal, South Africa Maternal, Adolscent and Child Health (MatCH)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	147,376	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	471,604	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	125,626	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	116,449	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	188,226	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,518,244	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	445,949	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	118	
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA)		118	



SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	116		
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	117		
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	114	114	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	114		
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	117		
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	19,363		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	24,204		
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy			
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	7,745		
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,460		
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	1,688		
PMTCT_ARV_NGI	Sum of Regimen disaggregates	4,148		
PMTCT_ARV_NGI	Sum of New and Current disaggregates	19,363		
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	19,363	16,458	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including	24,204	19,363	



	known HIV-positive at entry)		
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		9,875
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		6,583
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,460	1,968
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	1,688	1,350
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	4,148	3,318
PMTCT_ARV_TA	Sum of New and Current disaggregates	19,363	16,458
PMTCT_STAT_NGI Status (includes women who were tested for HIV and received their results)		66,192	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	82,840	
PMTCT_STAT_NGI By: Known positives at entry		13,942	
PMTCT_STAT_NGI By: Number of new positives identified		10,262	
PMTCT_STAT_NGI Sum of Positives Status disaggregates		24,204	
PMTCT_STAT_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		66,192	56,331
PMTCT_STAT_TA	Number of new ANC and L&D clients	82,840	66,272
PMTCT_STAT_TA	By: Known positives at entry	13,942	11,153
PMTCT_STAT_TA	By: Number of new positives identified	10,262	8,210
PMTCT_STAT_TA	Sum of Positives Status disaggregates	24,204	19,363
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	592,000	
HTC_TST_NGI	By Test Result: Negative	487,808	
HTC_TST_NGI	By Test Result: Positive	104,192	
HTC_TST_NGI	Sum of Test Result disaggregates	592,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	26,640	



HTC_TST_NGI	Aggregated Age/sex: 15+ Male	239,760	0
HTC_TST_NGI Aggregated Age/sex: <15 Female		32,560	
HTC_TST_NGI Aggregated Age/sex: 15+ Female		293,040	0
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	59,200	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	532,800	0
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	592,000	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	592,000	473,600
HTC_TST_TA	By Test Result: Negative	487,808	390,246
HTC_TST_TA	By Test Result: Positive	104,192	83,354
HTC_TST_TA	Sum of Test Result disaggregates	592,000	473,600
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	26,640	21,312
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	USE WITH HQ 239 760 191 808	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32,560 26,048	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	293,040 234,432	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	59,200	47,360
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	532,800	426,240
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	592,000	473,600
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service		
C2.1.D_NGI	By Age: <15	19,738	
C2.1.D_NGI	By Age: 15+	342,520	
C2.1.D_NGI Sum of Age disaggregates		362,258	
C2.1.D_NGI By Sex: Female		222,232	
C2.1.D_NGI	By Sex: Male	140,026	
C2.1.D_NGI	Sum of Sex disaggregates	362,258	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	362,258	



C2.1.D_TA	By Age: <15	19,738	
C2.1.D_TA	TA By Age: 15+		
C2.1.D_TA	Sum of Age disaggregates	362,258	
C2.1.D_TA	By Sex: Female	222,232	
C2.1.D_TA	By Sex: Male	140,026	
C2.1.D_TA	Sum of Sex disaggregates	362,258	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	266,736	247,389
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	9,869	9,154
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	93,859	87,051
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	9,869	9,153
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	153,139	142,031
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	266,736	247,389
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	19,738	18,307
TX_CURR_NGI	URR_NGI Sum of Aggregated Age/Sex 15+ 246,998 229		229,082
Number of adults and children receiving		247,389	
TX_CURR_TA	RR_TA Aggregated Age/Sex: <15 Male 9,869 9,154		9,154
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	d Age/Sex: 15+ Male 93,859 87,051	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	9,869	9,153
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	153,139	142,031
TX_CURR_TA	Sum of Aggregated Age/Sex <15	19,738	18,307
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	246,998	229,082
TX_CURR_TA Sum of Aggregated Age/Sex disaggregates 266,736 247		247,389	

Implementing Mechanism Details

implementing meenamem betane			
Mechanism ID: 17037	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes		
Funding Agency: USAID Procurement Type: Cooperative Agreement			
Prime Partner Name: Wits Reproductive Hea	alth& HIV Institute		
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No New Mechanism: No			
Global Fund / Multilateral Engagement: No			



G2G: No Managing Agency:	
Total All Funding Sources: 10,606,327 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 520,272	
FY 2013 Burn Rate: Redacted	
Funding Source Funding Amount	
GHP-State	10.606.327

Sub Partner Name(s)

Africa Health Placements	Empilweni Services and Research	
	Unit (ESRU)	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,188,800	
Gender: GBV	896,500	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	
Focus Area:	Post GBV Care	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	
Motor Vehicles: Purchased	92,500	
Condom programming	100,000	

Key Issues



Child Survival Activities Mobile Population Safe Motherhood TB Family Planning

Budget Code informa	udget Code Information			
Mechanism ID:	17037			
Mechanism Name:	Systems Strengthening	for Better HIV/TB Patient	Outcomes	
Prime Partner Name:	Wits Reproductive Heal	Wits Reproductive Health& HIV Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	1,239,945		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	1,278,311		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	177,867		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	600,725		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	666,934		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	5,239,203		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	1,403,342		0



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	126	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	1	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	124	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	5	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	120	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	108	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	107	
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	42	40
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	42	40
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	42	40
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	32	30
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	32	30
PMTCT_ARV_DSD	Sum of New and Current disaggregates	42	40
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	6,897	



mother-to-child-transmission (MTCT) during		
I		
pregnancy and delivery		
Number of HIV- positive pregnant women		
identified in the reporting period (including	8,302	
known HIV-positive at entry)		
sub-Disag of Life-long ART: Newly initiated on	4 110	
treatment during the current pregnancy	4,110	
Sub-Disag of Life-long ART: Already on		
treatment at the beginning of the current	1,206	
pregnancy		
Maternal AZT (prophylaxis component of		
WHO Option A during pregnancy and	1,613	
delivery)		
Sum of Regimen disaggregates	1,613	
Sum of New and Current disaggregates	5,316	
Number of HIV-positive pregnant women who		
received antiretrovirals to reduce risk of	0.055	0.044
mother-to-child-transmission (MTCT) during	6,855	6,044
pregnancy and delivery		
Number of HIV- positive pregnant women		
identified in the reporting period (including	8,260	6,608
known HIV-positive at entry)		
sub-Disag of Life-long ART: Newly initiated on	4.000	2.044
treatment during the current pregnancy	4,068	3,644
Sub-Disag of Life-long ART: Already on		
treatment at the beginning of the current	1,206	1,200
pregnancy		
Maternal AZT (prophylaxis component of		
WHO Option A during pregnancy and	1,581	1,200
delivery)		
Sum of Regimen Type disaggregates	1,581	1,200
Sum of New and Current disaggregates	5,274	4,844
Number of pregnant women with known HIV		
status (includes women who were tested for	/65	704
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) ub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) Sum of Regimen disaggregates Sum of New and Current disaggregates lumber of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) ub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) Sum of Regimen Type disaggregates Sum of New and Current disaggregates	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) ub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) Sum of Regimen disaggregates Sum of New and Current disaggregates lumber of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) ub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) Sum of Regimen Type disaggregates Sum of New and Current disaggregates Sum of Pregnant women with known HIV 765



	1		1
	HIV and received their results)		
PMTCT_STAT_DSD	Number of new ANC and L&D clients	800	704
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,822	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	33,815	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,057	28,000
PMTCT_STAT_TA	Number of new ANC and L&D clients	33,015	29,053
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,600	5,280
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	30	27
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,267	2,875
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	30	26
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,673	2,352
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	60	53
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,940	5,227
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,000	5,280
HTC_TST_NGI	Aggregated Age/sex: <15 Male	30	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	83,247	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	30	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	151,207	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	60	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	234,454	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	234,514	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	101,939	



C2.1.D_NGI	By Age/Sex: 15+ Female	62,947	
C2.1.D_NGI	By Age/Sex: 15+ Male	32,366	
C2.1.D_NGI	Sum of Age/Sex disaggregates	95,313	
C2.1.D_NGI	By Age: <15	6,626	
C2.1.D_NGI	By Age: 15+	95,313	
C2.1.D_NGI	Sum of Age disaggregates	101,939	
C2.1.D_NGI	By Sex: Female	66,260	
C2.1.D_NGI	By Sex: Male	35,679	
C2.1.D_NGI	Sum of Sex disaggregates	101,939	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	101,939	
C2.1.D_TA	By Age/Sex: 15+ Female	62,947	
C2.1.D_TA	By Age/Sex: 15+ Male	32,366	
C2.1.D_TA	Sum of Age/Sex disaggregates	95,313	
C2.1.D_TA	By Age: <15	6,626	
C2.1.D_TA	By Age: 15+	95,313	
C2.1.D_TA	Sum of Age disaggregates	101,939	
C2.1.D_TA	By Sex: Female	66,260	
C2.1.D_TA	By Sex: Male	35,679	
C2.1.D_TA	Sum of Sex disaggregates	101,939	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,284	6,118
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	9,582	7,665
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	101,939	
TX_CURR_NGI	Age/Sex: 15+ Male	32,366	
TX_CURR_NGI	Age/Sex: 15+ Female	62,947	
TX_CURR_NGI	Sum of Age/Sex disaggregates	95,313	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	3,313	



			1
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	32,366	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	3,313	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	62,947	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	101,939	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	6,626	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	95,313	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	101,939	85,629
TX_CURR_TA	Age/Sex: 15+ Male	32,366	27,188
TX_CURR_TA	Age/Sex: 15+ Female	62,947	52,876
TX_CURR_TA	Aggregated Age/Sex: <15 Male	3,313	2,782
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	32,366	27,188
TX_CURR_TA	Aggregated Age/Sex: <15 Female	3,313	2,782
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	62,947	52,877
TX_CURR_TA	Sum of Aggregated Age/Sex <15	6,626	5,564
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	95,313	80,065
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	101,939	85,629
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	29,283	26,570
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	316	277
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	9,933	9,541
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	316	277
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	18,718	16,475
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	29,283	26,570
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	340	272
HRH_PRE	By Graduates: Doctors	170	136
HRH_PRE	By Graduates: Nurses	170	136



HRH_PRE	Sum of Graduates disaggreagtes	340	272
---------	--------------------------------	-----	-----

Implementing Mechanism Details

Mechanism ID: 17036	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Professional Development		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 13,015,684	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	13,015,684

Sub Partner Name(s)

Africa Health Placements	University of Cape Town Call Centre	University of KwaZulu-Natal - Centre for HIV/AIDS Networking (HIVAN) - HIV 911 Programme
--------------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	7,843,672
Gender: Gender Equality	231,022
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Motor Vehicles: Purchased	624,468
Condom programming	42,417

Key Issues

Child Survival Activities
Mobile Population
Safe Motherhood
TB
Workplace Programs
Family Planning

Mechanism ID: 17036			
Mechanism Name:	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes		
Prime Partner Name:	Foundation for Professi	ional Development	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	682,274	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,447,945	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	272,910	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	676,664	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	500,016	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,091,638	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,343,569	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,000,668	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	408	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	408	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	408	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	408	
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	



SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	408	
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	408	
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	47	
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	408	
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during	17,500	



	pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	21,000	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	15,750	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	14,000	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,750	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	1,750	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	17,500	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	15,750	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	17,500	16,000
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	21,000	16,800
PMTCT_ARV_TA	Life-long ART (including Option B+)	15,750	14,400
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	14,000	12,800
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,750	1,600
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	1,750	1,600
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	17,500	16,000
PMTCT_ARV_TA	Sum of New and Current disaggregates	15,750	14,400
PMTCT_STAT_NGI	Number of pregnant women with known HIV	91,400	



	<u> </u>		1
	status (includes women who were tested for		
	HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	96,000	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	91,400	73,120
PMTCT_STAT_TA	Number of new ANC and L&D clients	96,000	76,800
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	97,000	
VMMC_CIRC_NGI	By Age: 15-19	19,400	
VMMC_CIRC_NGI	By Age: 20-24	19,400	
VMMC_CIRC_NGI	By Age: 25-49	58,200	
VMMC_CIRC_NGI	Sum of Age disaggregates	97,000	
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	97,000	78,400
VMMC_CIRC_TA	By Age: 15-19	19,400	15,680
VMMC_CIRC_TA	By Age: 20-24	19,400	15,680
VMMC_CIRC_TA	By Age: 25-49	58,200	47,040
VMMC_CIRC_TA	Sum of Age disaggregations	97,000	78,400
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	63,500	50,800
HTC_TST_DSD	Age/sex: 1-4 Male	198	158
HTC_TST_DSD	Age/sex: 5-9 Male	198	158
HTC_TST_DSD	Age/sex: 10-14 Male	264	211
HTC_TST_DSD	Age/sex: 15-19 Male	2,587	2,070
HTC_TST_DSD	Age/sex: 20-24 Male	13,094	10,475
HTC_TST_DSD	Age/sex: 25-49 Male	8,184	6,547
HTC_TST_DSD	Age/sex: 50+ Male	1,003	804



HTC_TST_DSD	Age/sex: 1-4 Female	198	158
HTC_TST_DSD	Age/sex: 5-9 Female	198	158
HTC_TST_DSD	Age/sex: 10-14 Female	264	211
HTC TST DSD	Age/sex: 15-19 Female	3,880	3,104
HTC_TST_DSD	Age/sex: 20-24 Female	19,641	15,713
HTC_TST_DSD	Age/sex: 25-49 Female	12,287	9,830
HTC_TST_DSD	Age/sex: 50+ Female	1,504	1,203
HTC_TST_DSD	Sum of Age/Sex disaggregates	63,500	50,800
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	660	528
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	24,868	19,895
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	660	528
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	37,312	29,849
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,320	1,056
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	62,180	49,744
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	63,500	50,800
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,400,000	
HTC_TST_NGI	Age/sex: <1 Male	9,960	
HTC_TST_NGI	Age/sex: 1-4 Male	4,288	
HTC_TST_NGI	Age/sex: 5-9 Male	750	
HTC_TST_NGI	Age/sex: 10-14 Male	750	
HTC_TST_NGI	Age/sex: 15-19 Male	13,685	
HTC_TST_NGI	Age/sex: 20-24 Male	54,740	
HTC_TST_NGI	Age/sex: 25-49 Male	424,237	
HTC_TST_NGI	Age/sex: 50+ Male	54,740	
HTC_TST_NGI	Age/sex: <1 Female	9,960	
HTC_TST_NGI	Age/sex: 1-4 Female	4,288	
HTC_TST_NGI	Age/sex: 5-9 Female	750	



			T
HTC_TST_NGI	Age/sex: 10-14 Female	750	
HTC_TST_NGI	Age/sex: 15-19 Female	20,528	
HTC_TST_NGI	Age/sex: 20-24 Female	82,110	
HTC_TST_NGI	Age/sex: 25-49 Female	636,354	
HTC_TST_NGI	Age/sex: 50+ Female	82,110	
HTC_TST_NGI	Sum of Age/Sex disaggregates	1,400,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	15,748	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	547,402	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	15,748	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	821,102	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	31,496	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,368,504	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	1,400,000	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,400,000	1,168,000
HTC_TST_TA	Age/sex: <1 Male	9,960	7,968
HTC_TST_TA	Age/sex: 1-4 Male	4,288	4,280
HTC_TST_TA	Age/sex: 5-9 Male	750	600
HTC_TST_TA	Age/sex: 10-14 Male	750	600
HTC_TST_TA	Age/sex: 15-19 Male	13,685	11,411
HTC_TST_TA	Age/sex: 20-24 Male	54,740	45,644
HTC_TST_TA	Age/sex: 25-49 Male	424,237	353,742
HTC_TST_TA	Age/sex: 50+ Male	54,740	45,644
HTC_TST_TA	Age/sex: <1 Female	9,960	7,968
HTC_TST_TA	Age/sex: 1-4 Female	4,288	4,280
HTC_TST_TA	Age/sex: 5-9 Female	750	600
HTC_TST_TA	Age/sex: 10-14 Female	750	600
HTC_TST_TA	Age/sex: 15-19 Female	20,528	17,117
HTC_TST_TA	Age/sex: 20-24 Female	82,110	68,466
HTC_TST_TA	Age/sex: 25-49 Female	636,354	530,614
HTC_TST_TA	Age/sex: 50+ Female	82,110	68,466



HTC_TST_TA	Sum of Age/Sex disaggregates	1,400,000	1,168,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15,748	13,448
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	547,402	456,441
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,748	13,448
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	821,102	684,663
HTC_TST_TA	Sum of Aggregated Age/Sex <15	31,496	26,896
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,368,504	1,141,104
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,400,000	1,168,000
GEND_GBV_DSD	Number of people receiving post-GBV care	5,143	4,356
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	18,260	14,608
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	19,543	15,636
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	293,744	
TX_CURR_NGI	Age/Sex: <1 Male	90	
TX_CURR_NGI	Age/Sex: 1-4 Male	4,821	
TX_CURR_NGI	Age/Sex: 5-14 Male	3,125	
TX_CURR_NGI	Age/Sex: 15+ Male	111,069	
TX_CURR_NGI	Age/Sex: <1 Female	89	
TX_CURR_NGI	Age/Sex: 1-4 Female	4,821	
TX_CURR_NGI	Age/Sex: 5-14 Female	3,125	
TX_CURR_NGI	Age/Sex: 15+ Female	166,604	
TX_CURR_NGI	Sum of Age/Sex disaggregates	293,744	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	90	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	89	



<u> </u>		
Aggregated Age/Sex: <15 Male	8,036	
Aggregated Age/Sex: 15+ Male	111,069	
Aggregated Age/Sex: <15 Female	8,035	
Aggregated Age/Sex: 15+ Female	166,604	
Sum of Aggregated Age/Sex disaggregates	293,744	
Sum of Aggregated Age/Sex <15	16,071	
Sum of Aggregated Age/Sex 15+	277,673	
Number of adults and children receiving antiretroviral therapy (ART)	293,744	282,949
Age/Sex: <1 Male	90	72
Age/Sex: 1-4 Male	4,821	4,644
Age/Sex: 5-14 Male	3,125	3,025
Age/Sex: 15+ Male	111,069	106,987
Age/Sex: <1 Female	89	71
Age/Sex: 1-4 Female	4,821	4,644
Age/Sex: 5-14 Female	3,125	3,025
Age/Sex: 15+ Female	166,604	160,481
Sum of Age/Sex disaggregations	16,071	15,481
Aggregated Age/Sex: <1 Male	90	72
Aggregated Age/Sex: <1 Female	89	71
Aggregated Age/Sex: <15 Male	8,036	7,741
Aggregated Age/Sex: 15+ Male	111,069	106,987
Aggregated Age/Sex: <15 Female	8,035	7,740
Aggregated Age/Sex: 15+ Female	166,604	160,481
Sum of Aggregated Age/Sex <15	16,071	15,481
Sum of Aggregated Age/Sex 15+	277,673	267,468
Sum of Aggregated Age/Sex disaggregates	293,744	282,949
Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4
Total number of PEPFAR supported District	4	4
	Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 15+ Female Sum of Aggregated Age/Sex disaggregates Sum of Aggregated Age/Sex disaggregates Sum of Aggregated Age/Sex 15+ Number of adults and children receiving antiretroviral therapy (ART) Age/Sex: <1 Male Age/Sex: 1-4 Male Age/Sex: 1-4 Male Age/Sex: 5-14 Male Age/Sex: 15+ Male Age/Sex: 15+ Male Age/Sex: 15+ Female Age/Sex: 15+ Female Age/Sex: 15+ Female Age/Sex: 15+ Female Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 15+ Female Sum of Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Sum of Aggregated Age/Sex: 15+ Female Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	Aggregated Age/Sex: 15+ Male 111,069 Aggregated Age/Sex: <15 Female



	Health Offices		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	68,240	59,100
TX_NEW_DSD	By Age/Sex: <1 Male	90	72
TX_NEW_DSD	By Age/Sex: 1-4 Male	1,120	800
TX_NEW_DSD	By Age/Sex: 5-9 Male	657	574
TX_NEW_DSD	By Age/Sex: 10-14 Male	120	170
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,290	1,118
TX_NEW_DSD	By Age/Sex: 25-49 Male	15,482	13,408
TX_NEW_DSD	By Age/Sex: 50+ Male	9,031	7,822
TX_NEW_DSD	By Age/Sex: <1 Female	89	71
TX_NEW_DSD	By Age/Sex: 1-4 Female	1,120	800
TX_NEW_DSD	By Age/Sex: 5-9 Female	657	574
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,161	1,006
TX_NEW_DSD	By Age/Sex: 20-24 Female	7,741	6,704
TX_NEW_DSD	By Age/Sex: 25-49 Female	23,222	20,112
TX_NEW_DSD	By Age/Sex: 50+ Female	6,580	5,699
TX_NEW_DSD	Sum of Age/Sex disaggregates	68,360	59,100
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	90	72
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,867	1,446
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	25,803	22,347
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	89	71
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,866	1,446
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	38,704	33,521
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	68,240	58,760
TX_NEW_DSD	Pregnancy status	15,750	18,000
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	50,828	4,603
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the	59,798	54,592



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	303	245
TX_SITE	Total number of PEPFAR-supported ART sites	404	327
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,026	1,226
HRH_PRE	By Graduates: Other	2,026	1,226
HRH_PRE	Sum of Graduates disaggreagtes	2,026	1,226

Implementing Mechanism Details

Mechanism ID: 17033	Mechanism Name: Medical Research Council
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 3,000,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information			
Mechanism ID:	Mechanism ID: 17033		
Mechanism Name:	: Medical Research Council		
Prime Partner Name:	Medical Research Coun	cil	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
------------	------	---	---

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism Name: Intervention with Mechanism ID: 17030 Microfinance for AIDS and Gender Ed (IMAGE)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Health Consortium (Pty) Limited		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 315,705		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

Sinamandla Self Help Group	The Small Enterprise Foundation	
----------------------------	---------------------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

- augus or an initial			
Mechanism ID:	17030		
Mechanism Name:	Intervention with Microfinance for AIDS and Gender Equity (IMAGE)		
Prime Partner Name:	Wits Health Consortium (Pty) Limited		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
	Number of people completing an intervention		
GEND_NORM_DSD	pertaining to gender norms, that meets	10,880	
	minimum criteria		
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	0	
GEND_NORM_DSD	By Age: 25+	10,880	
GEND_NORM_DSD	Sum of Age disaggregates	10,880	
GEND_NORM_DSD	By Sex: Male	0	
GEND_NORM_DSD	By Sex: Female	10,880	
GEND_NORM_DSD	Sum of Sex disaggregates	10,880	
GEND_NORM_DSD	By type of activity: Individual	0	
GEND_NORM_DSD	By type of activity: Small Group	0	
GEND_NORM_DSD	By type of activity: Community-level	0	

Implementing Mechanism Details

Mechanism ID: 17029	Mechanism Name: HIV Innovations for Improved
Mechanism ID: 17029	Patient Outcomes in South Africa (Innovation



	Clinic)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Witkoppen Health & Welfare Centre (WHWC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,761,039	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 484,908	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,761,039

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	309,667
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Operation Research
Food and Nutrition: Policy, Tools, and Service Delivery	14,121
Condom programming	30,759



Key Issues

Child Survival Activities Mobile Population Safe Motherhood TB Family Planning

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name: 17029 HIV Innovations for Improved Patient Outcomes in South Africa (Innovation Clinic) Witkoppen Health & Welfare Centre (WHWC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	336,382	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	180,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	155,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	227,592	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	695,036	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	165,811	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	13	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	1	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	10	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	1	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	1	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	1	
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	409	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women	492	



identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_NGI		1		
PMTCT_ARV_NGI		identified in the reporting period (including		
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) PMTCT_ARV_NGI Sum of Regimen disaggregates Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV-positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA PMTCT_ARV_TA Life-long ART (including Option B+) Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA PMTCT_ARV_TA PMTCT_ARV_TA Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		known HIV-positive at entry)		
PMTCT_ARV_NGI treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 PMTCT_ARV_NGI Sum of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV-positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	PMTCT_ARV_NGI	Life-long ART (including Option B+)	409	
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) PMTCT_ARV_NGI Sum of New and Current disaggregates Number of HIV-positive pregnant women identified in the reporting period (including PMTCT_ARV_TA Life-long ART (including Option B+) PMTCT_ARV_TA Life-long ART: Already on treatment at the beginning of the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 107 PMTCT_ARV_NGI Treatment at the beginning of the current pregnancy with the pregnancy of the current pregnancy and the pregnancy of the current pregnancy of the c	DMTCT ADV NO.	Sub-Disag of Life-long ART: Newly initiated on	200	
PMTCT_ARV_NGI treatment at the beginning of the current pregnancy Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 PMTCT_ARV_TA Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including 492 440 known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Life-long ART: Newly initiated on treatment during the current pregnancy 302 269 PMTCT_ARV_TA treatment at the beginning of the current 107 95 PMTCT_ARV_TA treatment at the beginning of the current 107 95	PMTCT_ARV_NGT	treatment during the current pregnancy	302	
PMTCT_ARV_NGI		Sub-Disag of Life-long ART: Already on		
Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	PMTCT_ARV_NGI	treatment at the beginning of the current	107	
PMTCT_ARV_NGI the intention to stop at the end of the breastfeeding period) Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		pregnancy		
breastfeeding period) Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		Maternal triple ARV prophylaxis (provided with		
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	PMTCT_ARV_NGI	the intention to stop at the end of the	0	
PMTCT_ARV_NGI WHO Option A during pregnancy and delivery) PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 0 PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		breastfeeding period)		
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		Maternal AZT (prophylaxis component of		
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	PMTCT_ARV_NGI	WHO Option A during pregnancy and	0	
PMTCT_ARV_NGI Sum of Regimen disaggregates 409 PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current 107 95 pregnancy		delivery)		
PMTCT_ARV_NGI Sum of New and Current disaggregates 409 Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA Number of HIV-positive pregnant women identified in the reporting period (including 492 440 440 440 440 440 440 440 440 440 44	PMTCT_ARV_NGI	Sum of Regimen disaggregates	409	
PMTCT_ARV_TA received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on pregnancy PMTCT_ARV_TA Treatment at the beginning of the current pregnancy pregnancy	PMTCT_ARV_NGI	Sum of New and Current disaggregates	409	
PMTCT_ARV_TA mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA pregnancy		Number of HIV-positive pregnant women who		
mother-to-child-transmission (MTCT) during pregnancy and delivery Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 107 95 pregnancy	DIATOT ABY TA	received antiretrovirals to reduce risk of	400	004
PMTCT_ARV_TA Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA PMTCT_ARV_TA Treatment at the beginning of the current pregnancy pregnancy	PMTCT_ARV_TA	mother-to-child-transmission (MTCT) during	409	364
PMTCT_ARV_TA identified in the reporting period (including known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA pregnancy		pregnancy and delivery		
known HIV-positive at entry) PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on PMTCT_ARV_TA treatment at the beginning of the current 107 95 pregnancy		Number of HIV- positive pregnant women		
PMTCT_ARV_TA Life-long ART (including Option B+) 409 364 PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current 107 95 PMTCT_ARV_TA pregnancy	PMTCT_ARV_TA	identified in the reporting period (including	492	440
PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current 107 95 pregnancy		known HIV-positive at entry)		
PMTCT_ARV_TA treatment during the current pregnancy Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy PMTCT_ARV_TA treatment at the beginning of the current pregnancy pregnancy 302 269 107 95	PMTCT_ARV_TA	Life-long ART (including Option B+)	409	364
Sub-Disag of Life-long ART: Already on PMTCT_ARV_TA treatment at the beginning of the current 107 95 pregnancy	DAATOT ABV TA	Sub-Disag of Life-long ART: Newly initiated on	000	000
PMTCT_ARV_TA treatment at the beginning of the current 107 95 pregnancy	PMTCT_ARV_TA	treatment during the current pregnancy	302	269
pregnancy		Sub-Disag of Life-long ART: Already on		
	PMTCT_ARV_TA	treatment at the beginning of the current	107	95
PMTCT_ARV_TA Sum of Regimen Type disaggregates 409 364		pregnancy		
	PMTCT_ARV_TA	Sum of Regimen Type disaggregates	409	364
PMTCT_ARV_TA Sum of New and Current disaggregates 409 364	PMTCT_ARV_TA	Sum of New and Current disaggregates	409	364
Number of pregnant women with known HIV	DIATOT CTAT NO	Number of pregnant women with known HIV	4.000	
PMTCT_STAT_NGI 1,999 status (includes women who were tested for	PMTCT_STAT_NGI	. •	1,999	



	HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	2,014	
PMTCT_STAT_NGI	By: Known positives at entry	134	
PMTCT_STAT_NGI	By: Number of new positives identified	358	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	492	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,999	1,799
PMTCT_STAT_TA	Number of new ANC and L&D clients	2,014	1,813
PMTCT_STAT_TA	By: Known positives at entry	134	121
PMTCT_STAT_TA	By: Number of new positives identified	358	322
PMTCT_STAT_TA	Sum of Positives Status disaggregates	492	443
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,132	10,020
HTC_TST_DSD	By Test Result: Negative	9,375	8,438
HTC_TST_DSD	By Test Result: Positive	1,757	1,582
HTC_TST_DSD	Sum of Test Result disaggregates	11,132	10,020
HTC_TST_DSD	Age/sex: <1 Male	626	565
HTC_TST_DSD	Age/sex: 1-4 Male	357	322
HTC_TST_DSD	Age/sex: 5-9 Male	195	175
HTC_TST_DSD	Age/sex: 10-14 Male	84	76
HTC_TST_DSD	Age/sex: 15-19 Male	90	80
HTC_TST_DSD	Age/sex: 20-24 Male	391	352
HTC_TST_DSD	Age/sex: 25-49 Male	2,570	2,314
HTC_TST_DSD	Age/sex: 50+ Male	451	406
HTC_TST_DSD	Age/sex: <1 Female	586	527
HTC_TST_DSD	Age/sex: 1-4 Female	360	324
HTC_TST_DSD	Age/sex: 5-9 Female	199	179
HTC_TST_DSD	Age/sex: 10-14 Female	125	113
HTC_TST_DSD	Age/sex: 15-19 Female	189	170
HTC_TST_DSD	Age/sex: 20-24 Female	704	633



HTC_TST_DSD	Age/sex: 25-49 Female	3,141	2,827
HTC_TST_DSD	Age/sex: 50+ Female	1,064	957
HTC_TST_DSD	Sum of Age/Sex disaggregates	11,132	10,020
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,262	1,136
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,502	3,152
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,270	1,143
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,098	4,589
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,532	2,279
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	8,600	7,741
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	11,132	10,020
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,648	
HTC_TST_NGI	By Test Result: Negative	12,337	
HTC_TST_NGI	By Test Result: Positive	2,311	
HTC_TST_NGI	Sum of Test Result disaggregates	14,648	
HTC_TST_NGI	Age/sex: <1 Male	824	
HTC_TST_NGI	Age/sex: 1-4 Male	470	
HTC_TST_NGI	Age/sex: 5-9 Male	256	
HTC_TST_NGI	Age/sex: 10-14 Male	110	
HTC_TST_NGI	Age/sex: 15-19 Male	118	
HTC_TST_NGI	Age/sex: 20-24 Male	515	
HTC_TST_NGI	Age/sex: 25-49 Male	3,382	
HTC_TST_NGI	Age/sex: 50+ Male	594	
HTC_TST_NGI	Age/sex: <1 Female	771	
HTC_TST_NGI	Age/sex: 1-4 Female	474	
HTC_TST_NGI	Age/sex: 5-9 Female	262	
HTC_TST_NGI	Age/sex: 10-14 Female	165	
HTC_TST_NGI	Age/sex: 15-19 Female	249	



<u> </u>	<u> </u>		
HTC_TST_NGI	Age/sex: 20-24 Female	926	
HTC_TST_NGI	Age/sex: 25-49 Female	4,132	
HTC_TST_NGI	Age/sex: 50+ Female	1,400	
HTC_TST_NGI	Sum of Age/Sex disaggregates	14,648	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,660	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	4,609	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,672	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	6,707	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3,332	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	11,316	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	14,648	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,516	3,164
HTC_TST_TA	By Test Result: Negative	2,961	2,665
HTC_TST_TA	By Test Result: Positive	555	499
HTC_TST_TA	Sum of Test Result disaggregates	3,516	3,164
HTC_TST_TA	Age/sex: <1 Male	198	177
HTC_TST_TA	Age/sex: 1-4 Male	113	102
HTC_TST_TA	Age/sex: 5-9 Male	61	55
HTC_TST_TA	Age/sex: 10-14 Male	26	24
HTC_TST_TA	Age/sex: 15-19 Male	28	25
HTC_TST_TA	Age/sex: 20-24 Male	124	111
HTC_TST_TA	Age/sex: 25-49 Male	812	731
HTC_TST_TA	Age/sex: 50+ Male	143	128
HTC_TST_TA	Age/sex: <1 Female	185	167
HTC_TST_TA	Age/sex: 1-4 Female	114	102
HTC_TST_TA	Age/sex: 5-9 Female	63	57
HTC_TST_TA	Age/sex: 10-14 Female	40	36
HTC_TST_TA	Age/sex: 15-19 Female	60	54
HTC_TST_TA	Age/sex: 20-24 Female	222	200
HTC_TST_TA	Age/sex: 25-49 Female	992	893



HTC_TST_TA	Age/sex: 50+ Female	335	302
HTC_TST_TA	Sum of Age/Sex disaggregates	3,516	3,164
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	398	359
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,107	995
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	402	361
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,609	1,449
HTC_TST_TA	Sum of Aggregated Age/Sex <15	800	720
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,716	2,444
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	3,516	3,164
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	5,860	
C2.1.D_DSD	By Age/Sex: <15 Female	128	
C2.1.D_DSD	By Age/Sex: <15 Male	71	
C2.1.D_DSD	By Age/Sex: 15+ Female	3,594	
C2.1.D_DSD	By Age/Sex: 15+ Male	2,067	
C2.1.D_DSD	Sum of Age/Sex disaggregates	5,860	
C2.1.D_DSD	By Age: <15	199	
C2.1.D_DSD	By Age: 15+	5,661	
C2.1.D_DSD	Sum of Age disaggregates	5,860	
C2.1.D_DSD	By Sex: Female	3,722	
C2.1.D_DSD	By Sex: Male	2,138	
C2.1.D_DSD	Sum of Sex disaggregates	5,860	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	7,325	
C2.1.D_NGI	By Age/Sex: <15 Female	160	
C2.1.D_NGI	By Age/Sex: <15 Male	89	
C2.1.D_NGI	By Age/Sex: 15+ Female	4,492	
C2.1.D_NGI	By Age/Sex: 15+ Male	2,584	
C2.1.D_NGI	Sum of Age/Sex disaggregates	7,325	



	<u>, </u>		
C2.1.D_NGI	By Age: <15	249	
C2.1.D_NGI	By Age: 15+	7,076	
C2.1.D_NGI	Sum of Age disaggregates	7,325	
C2.1.D_NGI	By Sex: Female	4,652	
C2.1.D_NGI	By Sex: Male	2,673	
C2.1.D_NGI	Sum of Sex disaggregates	7,325	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	1,465	
C2.1.D_TA	By Age/Sex: <15 Female	32	
C2.1.D_TA	By Age/Sex: <15 Male	18	
C2.1.D_TA	By Age/Sex: 15+ Female	898	
C2.1.D_TA	By Age/Sex: 15+ Male	517	
C2.1.D_TA	Sum of Age/Sex disaggregates	1,465	
C2.1.D_TA	By Age: <15	50	
C2.1.D_TA	By Age: 15+	1,415	
C2.1.D_TA	Sum of Age disaggregates	1,465	
C2.1.D_TA	By Sex: Female	930	
C2.1.D_TA	By Sex: Male	535	
C2.1.D_TA	Sum of Sex disaggregates	1,465	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	6,892	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	5,860	
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	5,860	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	344	310
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	984	443



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	20	18
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	324	292
PMTCT_EID_DSD	Sum of Infant Age disaggregates	344	310
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	3	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,751	3,418
TX_CURR_DSD	Age/Sex: <1 Male	2	1
TX_CURR_DSD	Age/Sex: 1-4 Male	26	23
TX_CURR_DSD	Age/Sex: 5-14 Male	62	56
TX_CURR_DSD	Age/Sex: 15+ Male	1,127	1,028
TX_CURR_DSD	Age/Sex: <1 Female	3	2
TX_CURR_DSD	Age/Sex: 1-4 Female	27	25
TX_CURR_DSD	Age/Sex: 5-14 Female	72	66
TX_CURR_DSD	Age/Sex: 15+ Female	2,432	2,217
TX_CURR_DSD	Sum of age/sex disaggregates	192	173
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	10	10
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	29	29
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	2	1
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	3	2
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	90	80
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,127	1,028
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	102	93
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,432	2,217
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	192	173
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,559	3,245
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,751	3,418



TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	5,003	
TX_CURR_NGI	Age/Sex: <1 Male	2	
TX_CURR_NGI	Age/Sex: 1-4 Male	34	
TX_CURR_NGI	Age/Sex: 5-14 Male	82	
TX_CURR_NGI	Age/Sex: 15+ Male	1,502	
TX_CURR_NGI	Age/Sex: <1 Female	4	
TX_CURR_NGI	Age/Sex: 1-4 Female	36	
TX_CURR_NGI	Age/Sex: 5-14 Female	96	
TX_CURR_NGI	Age/Sex: 15+ Female	3,247	
TX_CURR_NGI	Sum of Age/Sex disaggregates	5,003	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	2	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	4	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	118	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,502	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	136	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,247	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	5,003	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	254	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	4,749	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,252	1,080
TX_CURR_TA	Age/Sex: <1 Male	1	1
TX_CURR_TA	Age/Sex: 1-4 Male	9	7
TX_CURR_TA	Age/Sex: 5-14 Male	21	18
TX_CURR_TA	Age/Sex: 15+ Male	376	324
TX_CURR_TA	Age/Sex: <1 Female	1	1
TX_CURR_TA	Age/Sex: 1-4 Female	9	8
TX_CURR_TA	Age/Sex: 5-14 Female	24	21
TX_CURR_TA	Age/Sex: 15+ Female	811	700
TX_CURR_TA	Sum of Age/Sex disaggregations	65	56
TX_CURR_TA	Aggregated Age/Sex: <1 Male	1	1



TX_CURR_TA	Aggregated Age/Sex: <1 Female	1	1
TX_CURR_TA	Aggregated Age/Sex: <15 Male	31	26
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	376	324
TX_CURR_TA	Aggregated Age/Sex: <15 Female	34	30
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	811	700
TX_CURR_TA	Sum of Aggregated Age/Sex <15	65	56
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,187	1,024
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,252	1,080
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,592	2,333
TX_NEW_DSD	By Age/Sex: <1 Male	1	1
TX_NEW_DSD	By Age/Sex: 1-4 Male	15	14
TX_NEW_DSD	By Age/Sex: 5-9 Male	6	6
TX_NEW_DSD	By Age/Sex: 10-14 Male	9	8
TX_NEW_DSD	By Age/Sex: 15-19 Male	7	6
TX_NEW_DSD	By Age/Sex: 20-24 Male	26	23
TX_NEW_DSD	By Age/Sex: 25-49 Male	801	721
TX_NEW_DSD	By Age/Sex: 50+ Male	80	72
TX_NEW_DSD	By Age/Sex: <1 Female	4	3
TX_NEW_DSD	By Age/Sex: 1-4 Female	24	22
TX_NEW_DSD	By Age/Sex: 5-9 Female	14	13
TX_NEW_DSD	By Age/Sex: 10-14 Female	14	13
TX_NEW_DSD	By Age/Sex: 15-19 Female	23	20
TX_NEW_DSD	By Age/Sex: 20-24 Female	177	160
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,282	1,153
TX_NEW_DSD	By Age/Sex: 50+ Female	109	98
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,592	2,333
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	31	29
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	914	822
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	4	3
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	56	51



	Female		
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,591	1,431
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,592	2,333
TX_NEW_DSD	Pregnancy status	179	161
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,255	1,129
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,569	1,412
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28	25
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36	33
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,190	1,071
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35	31
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46	41
TX_RET_DSD	Age: 15+ (Denominator: Total number of	1,488	1,340



	1		
	adults and children who initiated ART in the		
	12 months prior to the beginning of the		
	reporting period, including those who have		
	died, those who have stopped ART, and those		
	lost to follow-up)		
	Aggregated Age: <15 (Numerator: Number of		
TX_RET_DSD	adults and children who are still alive and on	64	58
	treatment at 12 months after initiating ART)		
	Aggregated Age: 15+ (Numerator: Number of		
TX_RET_DSD	adults and children who are still alive and on	1,190	1,071
	treatment at 12 months after initiating ART)		
	Aggregated Age: <15 (Denominator: Total		
	number of adults and children who initiated		
TV 5=T 505	ART in the 12 months prior to the beginning of		72
TX_RET_DSD	the reporting period, including those who have	81	
	died, those who have stopped ART, and those		
	lost to follow-up)		
	Aggregated Age: 15+ (Denominator: Total		
	number of adults and children who initiated		
TV DET DOD	ART in the 12 months prior to the beginning of	4 400	4.040
TX_RET_DSD	the reporting period, including those who have	1,488	1,340
	died, those who have stopped ART, and those		
	lost to follow-up)		
	Pregnancy and breastfeeding status		
TV DET DOD	(Numerator: Number of adults and children	0.0	70
TX_RET_DSD	who are still alive and on treatment at 12	86	78
	months after initiating ART)		
	Pregnancy and breastfeeding status		
	(Denominator: Total number of adults and		
TX_RET_DSD	children who initiated ART in the 12 months		
	prior to the beginning of the reporting period,	108	97
	including those who have died, those who		
	have stopped ART, and those lost to		
	follow-up)		



	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (Adolescent Friendly Services for Prenatally & Behaviorally HIV Infected Adolescents)	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Wits Reproductive Health& HIV	/ Institute	
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 225,971	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 2,024,029	,029	
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	225,971	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	23,602
Education	18,882
Condom programming	3,571

Key Issues

Family Planning



	17028 HIV Innovations for Improved Patient Outcomes for Priority Populations (Adolescent Friendly Services for Prenatally & Behaviorally HIV Infected Adolescents) Wits Reproductive Health& HIV Institute				
Strategic Area	Budget Code Planned Amount On Hold Amount				
Treatment	HTXS	121,236			
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Treatment	PDTX	104,735	0		

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	34	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	32	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	32	
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	34	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,800	4,000
PP_PREV_DSD	Total number of people in the target	9,000	10,000



	population		
PP_PREV_DSD	Age/sex: 10-14 Male	45	100
PP_PREV_DSD	Age/sex: 15-19 Male	257	570
PP_PREV_DSD	Age/sex: 10-14 Female	45	100
PP_PREV_DSD	Age/sex: 15-19 Female	1,453	3,230
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,800	4,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,067	1,175
HTC_TST_DSD	By Test Result: Negative	1,024	1,127
HTC_TST_DSD	By Test Result: Positive	43	48
HTC_TST_DSD	Sum of Test Result disaggregates	1,067	1,175
HTC_TST_DSD	Age/sex: 10-14 Male	5	6
HTC_TST_DSD	Age/sex: 15-19 Male	262	288
HTC_TST_DSD	Age/sex: 10-14 Female	16	18
HTC_TST_DSD	Age/sex: 15-19 Female	784	863
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,067	1,175
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5	6
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	262	288
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16	18
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	784	863
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	21	24
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,046	1,151
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,067	1,175
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,875	
HTC_TST_NGI	By Test Result: Negative	13,320	
HTC_TST_NGI	By Test Result: Positive	555	



HTC_TST_NGI	Sum of Test Result disaggregates	13,875	
HTC_TST_NGI	Age/sex: 10-14 Male		
HTC_TST_NGI	Age/sex: 15-19 Male	3,400	
HTC_TST_NGI	Age/sex: 10-14 Female	208	
HTC_TST_NGI	Age/sex: 15-19 Female	10,198	
HTC_TST_NGI	Sum of Age/Sex disaggregates	13,875	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	69	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	3,400	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	208	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	10,198	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	277	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	13,598	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	13,875	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,808	14,088
HTC_TST_TA	By Test Result: Negative	12,296	13,524
HTC_TST_TA	By Test Result: Positive	512	564
HTC_TST_TA	Sum of Test Result disaggregates	12,808	14,088
HTC_TST_TA	Age/sex: 10-14 Male	64	70
HTC_TST_TA	Age/sex: 15-19 Male	3,138	3,452
HTC_TST_TA	Age/sex: 10-14 Female	192	211
HTC_TST_TA	Age/sex: 15-19 Female	9,414	10,355
HTC_TST_TA	Sum of Age/Sex disaggregates	12,808	14,088
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	64	70
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,138	3,452
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	192	211
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,414	10,355
HTC_TST_TA	Sum of Aggregated Age/Sex <15	256	281



HTC_TST_TA	Sum of Aggregated Age/Sex 15+	12,552	13,807
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	12,808	14,088
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	340	
C2.1.D_DSD	By Age/Sex: <15 Female	5	
C2.1.D_DSD	By Age/Sex: <15 Male	2	
C2.1.D_DSD	By Age/Sex: 15+ Female	250	
C2.1.D_DSD	By Age/Sex: 15+ Male	83	
C2.1.D_DSD	Sum of Age/Sex disaggregates	340	
C2.1.D_DSD	By Age: <15	7	
C2.1.D_DSD	By Age: 15+	333	
C2.1.D_DSD	Sum of Age disaggregates	340	
C2.1.D_DSD	By Sex: Female	255	
C2.1.D_DSD	By Sex: Male	85	
C2.1.D_DSD	Sum of Sex disaggregates	340	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	2,025	
C2.1.D_NGI	By Age/Sex: <15 Female	30	
C2.1.D_NGI	By Age/Sex: <15 Male	11	
C2.1.D_NGI	By Age/Sex: 15+ Female	1,489	
C2.1.D_NGI	By Age/Sex: 15+ Male	495	
C2.1.D_NGI	Sum of Age/Sex disaggregates	2,025	
C2.1.D_NGI	By Age: <15	41	
C2.1.D_NGI	By Age: 15+	1,984	
C2.1.D_NGI	Sum of Age disaggregates	2,025	
C2.1.D_NGI	By Sex: Female	1,519	
C2.1.D_NGI	By Sex: Male	506	
C2.1.D_NGI	Sum of Sex disaggregates	2,025	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	1,685	
C2.1.D_TA	By Age/Sex: <15 Female	25	
C2.1.D_TA	By Age/Sex: <15 Male	9	



00.45.74	D 4(0. 45 5 1	4.000		
C2.1.D_TA	By Age/Sex: 15+ Female	1,239		
C2.1.D_TA	By Age/Sex: 15+ Male 412			
C2.1.D_TA	Sum of Age/Sex disaggregates 1,685			
C2.1.D_TA	By Age: <15 34			
C2.1.D_TA	By Age: 15+ 1,651			
C2.1.D_TA	Sum of Age disaggregates	1,685		
C2.1.D_TA	By Sex: Female	1,264		
C2.1.D_TA	By Sex: Male	421		
C2.1.D_TA	Sum of Sex disaggregates	1,685		
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	340		
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	340		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	611		
CARE_NEW_DSD	Age/sex: 10-14 Male	3		
CARE_NEW_DSD	Age/sex: 15-19 Male	150		
CARE_NEW_DSD	Age/sex: 10-14 Female	9		
CARE_NEW_DSD	Age/sex: 15-19 Female	449		
CARE_NEW_DSD	Sum of Age/sex disaggregates	611	611	
CARE_NEW_DSD	D Aggregated Age/sex: <15 Male 3			
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	150		
CARE_NEW_DSD	Aggregated Age/sex: <15 Female 9			
CARE_NEW_DSD	D Aggregated Age/sex: 15+ Female 449			
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	611		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	319	343	
TX_CURR_DSD	Age/Sex: 5-14 Male	4	4	



TX_CURR_DSD	Age/Sex: 15+ Male	78	84
TX_CURR_DSD	Age/Sex: 5-14 Female	5	5
TX_CURR_DSD	Age/Sex: 15+ Female	234	252
TX_CURR_DSD	Sum of age/sex disaggregates	9	9
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	2	2
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	75	75
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2	2
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	78	84
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5	5
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	234	252
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7	7
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	312	336
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	319	343
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	1,950	
TX_CURR_NGI	Age/Sex: 5-14 Male	10	
TX_CURR_NGI	Age/Sex: 15+ Male	478	
TX_CURR_NGI	Age/Sex: 5-14 Female	29	
TX_CURR_NGI	Age/Sex: 15+ Female	1,433	
TX_CURR_NGI	Sum of Age/Sex disaggregates	1,950	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	10	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	478	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	29	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	1,433	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,950	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	39	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,911	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,631	1,924



	·		
TX_CURR_TA	Age/Sex: 5-14 Male	8	10
TX_CURR_TA	Age/Sex: 15+ Male	400	471
TX_CURR_TA	Age/Sex: 5-14 Female	24	29
TX_CURR_TA	Age/Sex: 15+ Female	1,199	1,414
TX_CURR_TA	Sum of Age/Sex disaggregations	32	39
TX_CURR_TA	Aggregated Age/Sex: <15 Male	8	10
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	400	471
TX_CURR_TA	Aggregated Age/Sex: <15 Female	24	29
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,199	1,414
TX_CURR_TA	Sum of Aggregated Age/Sex <15	32	39
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,599	1,885
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,631	1,924
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	289	318
TX_NEW_DSD	By Age/Sex: 10-14 Male	1	2
TX_NEW_DSD	By Age/Sex: 15-19 Male	71	78
TX_NEW_DSD	By Age/Sex: 10-14 Female	4	5
TX_NEW_DSD	By Age/Sex: 15-19 Female	213	233
TX_NEW_DSD	Sum of Age/Sex disaggregates	289	318
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	71	78
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4	5
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	213	233
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	289	318

	Mechanism Name: HIV Innovations for Improved
	Patient Outcomes for Priority Populations
Mechanism ID: 17027	(Supporting the SA Government to Develop,
	Implement and Evaluate a National Sex Worker
	and Male Client Plan)



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Reproductive Health& HIV Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 633,383 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,166,617	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	633,383

North Star Alliance Sisonke Sex Worker Movement	Sisonke Sex Worker Movement
---	-----------------------------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	77,478
Key Populations: FSW	633,383
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other



1	
	commodities essential to core HIV services for SWs
Gender: GBV	84,530
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Education	56,343
Condom programming	24,777

Key Issues

Mobile Population Safe Motherhood TB Family Planning

Mechanism ID:	17027
Mechanism Name:	HIV Innovations for Improved Patient Outcomes for Priority Populations I
Prime Partner Name:	(Supporting the SA Government to Develop, Implement and Evaluate a
Fillie Faither Name.	National Sex Worker and Male Client Plan)



	Wits Reproductive Health& HIV Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	116,056	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	116,056	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	49,554	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	351,717	0	

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	11	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	11	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	11	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	11	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery	11	



	(DSD)		
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,150	1,725
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,150	1,725
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,160	6,192
HTC_TST_DSD	By Test Result: Negative	4,592	5,511
HTC_TST_DSD	By Test Result: Positive	568	681
HTC_TST_DSD	Sum of Test Result disaggregates	5,160	6,192
HTC_TST_DSD	Age/sex: 25-49 Male	4,128	4,954
HTC_TST_DSD	Age/sex: 25-49 Female	1,032	1,238
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,160	6,192
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,128	4,954
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,032	1,238
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,160	6,192
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,160	6,192
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,160	
HTC_TST_NGI	By Test Result: Negative	4,592	



HTC_TST_NGI	By Test Result: Positive	568	
HTC_TST_NGI	Sum of Test Result disaggregates	5,160	
HTC_TST_NGI	Age/sex: 25-49 Male	4,128	
HTC_TST_NGI	Age/sex: 25-49 Female	1,032	
HTC_TST_NGI	Sum of Age/Sex disaggregates	5,160	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	4,128	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,032	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	5,160	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	5,160	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,176	
C2.1.D_DSD	By Age/Sex: 15+ Female	235	
C2.1.D_DSD	By Age/Sex: 15+ Male	941	
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,176	
C2.1.D_DSD	By Age: 15+	1,176	
C2.1.D_DSD	Sum of Age disaggregates	1,176	
C2.1.D_DSD	By Sex: Female	235	
C2.1.D_DSD	By Sex: Male	941	
C2.1.D_DSD	Sum of Sex disaggregates	1,176	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,176	
C2.1.D_NGI	By Age/Sex: 15+ Female	235	
C2.1.D_NGI	By Age/Sex: 15+ Male	941	
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,176	
C2.1.D_NGI	By Age: 15+	1,176	
C2.1.D_NGI	Sum of Age disaggregates	1,176	
C2.1.D_NGI	By Sex: Female	235	
C2.1.D_NGI	By Sex: Male	941	
C2.1.D_NGI	Sum of Sex disaggregates	1,176	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,176	
TB_ART_DSD	The number of registered new and relapse TB	0	0



	cases with documented HIV-positive status whoare on ART during TB treatment during the reporting period		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	114	148
TX_CURR_DSD	Age/Sex: 15+ Female	114	121
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	100	82
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	114	121
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	114	148
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	114	148
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	114	
TX_CURR_NGI	Age/Sex: 15+ Female	114	
TX_CURR_NGI	Sum of Age/Sex disaggregates	114	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	114	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	114	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	114	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	28	34
TX_NEW_DSD	By Age/Sex: 25-49 Male	22	27
TX_NEW_DSD	By Age/Sex: 25-49 Female	6	7
TX_NEW_DSD	Sum of Age/Sex disaggregates	28	34
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	22	27
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6	7
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	28	34

	Mechanism Name: HIV Innovations for Improved
Mechanism ID: 17026	Patient Outcomes in South Africa (Developing
	the Capacity of the South African Government to
	Achieve the eMTCT Action Framework Goals)



Funding Agency: USAID Procurement Type: Cooperative Agreement			
Prime Partner Name: Mothers to Mothers (M2M)			
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 3,452,035 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 327,965		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	3,452,035	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Free Catting Baaget Attribution(e)		
Human Resources for Health	1,139,148	
Motor Vehicles: Purchased	70,000	
Gender: GBV	5,000	
Focus Area:	GBV Prevention	
Sub Area:	Implementation	
Focus Area:	Post GBV Care	
Condom programming	60,000	

Key Issues

Malaria (PMI) Child Survival Activities Safe Motherhood TB



Family Planning

Budget Code Information					
	17026				
Mechanism ID:	HIV Innovations for Improved Patient Outcomes in South Africa				
Mechanism Name:	(Developing the Capacity of the South African Government to Achieve				
Prime Partner Name:	the eMTCT Action Frame	work Goals)			
	Mothers to Mothers (M2	PM)			
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amount			
Care	НВНС	268,895			
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Care	HVTB	188,226	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	MTCT	2,994,914	0		

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	325	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	25	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	300	
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,416	6,680
PMTCT_ARV_DSD	Number of HIV- positive pregnant women	6,090	7,004



	identified in the reporting period (including		
	known HIV-positive at entry)		
PMTCT_ARV_DSD	Life-long ART (including Option B+)	2,325	2,674
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,325	2,674
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	2,818	3,241
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	122	150
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	5,265	6,065
PMTCT_ARV_DSD	Sum of New and Current disaggregates	2,325	2,674
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,416	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,090	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,325	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,325	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	2,818	
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	122	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	5,265	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	2,325	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,574	25,450
PMTCT_STAT_DSD	Number of new ANC and L&D clients	25,500	26,775
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,574	



PMTCT_STAT_NGI	Number of new ANC and L&D clients	25,500	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	6,090	6,497
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,596	6,140
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	6,090	6,497
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	38	40
HRH_PRE	By Graduates: Other	38	40
HRH_PRE	Sum of Graduates disaggreagtes	38	40

Mechanism ID: 17025	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (INROADS: Innovations Research on HIV/AIDS)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Health Consortium, Health Economics and Epidemiology Research Office		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,686,968 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 158,032			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		



GHP-State	1,686,968

Boston University	Centre for Economic Governance	
	and AIDS in Africa	

Cross-Cutting Budget Attribution(s)

Condom programming	12,731

Key Issues

Child Survival Activities
Safe Motherhood
TB
Family Planning

Mechanism Name:	17025 HIV Innovations for Improved Patient Outcomes for Priority Populations (INROADS: Innovations Research on HIV/AIDS) Wits Health Consortium, Health Economics and Epidemiology Research Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	195,671	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	113,225	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	999,837	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	120,948	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	136,339	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	120,948	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17024	Mechanism Name: Comprehensive District-Based Support for Better HIV/TB Patient		
	Outcomes (Hybrid)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Foundation for Professional Development			
Agreement Start Date: Redacted Agreement End Date: Redacted			
BD: No New Mechanism: No			
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 3,600,000		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	0	

Sub Partner Name(s)



Distant. On the Addison	
Right To Care, South Africa	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities Safe Motherhood TB Family Planning

Mechanism ID: Mechanism Name:	Comprehensive District-Based Support for Better HIV/TB Patient Outcomes (Hybrid)		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Indicator Number	Label	2014	2015
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,025	12,600
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	17,300	17,300
PMTCT_ARV_NA	Life-long ART (including Option B+)	10,822	11,339
PMTCT_ARV_NA	_ARV_NA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 9,620		10,080
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,202	1,259
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	1,203	1,260
PMTCT_ARV_NA	ITCT_ARV_NA Single-dose nevirapine (with or without tail) 12,02		12,600
PMTCT_ARV_NA	PMTCT_ARV_NA Sum of Regimen disaggregates		25,199
PMTCT_ARV_NA	PMTCT_ARV_NA Sum of New and Current disaggregates		11,339
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	12,025	



			T
	mother-to-child-transmission (MTCT) during		
	pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	17,300	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	10,822	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	9,620	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,202	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	1,203	
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	12,025	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	24,050	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	10,822	
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,900	47,120
PMTCT_STAT_NA	Number of new ANC and L&D clients	62,000	49,600
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,900	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	62,000	
PMTCT_STAT_NGI	By: Known positives at entry	0	
PMTCT_STAT_NGI	By: Number of new positives identified	0	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	0	
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	630,000	604,800
HTC_TST_NA	Age/sex: <1 Male	8,200	7,872
HTC_TST_NA	Age/sex: 1-4 Male	3,500	3,360
HTC_TST_NA	Age/sex: 5-9 Male	6,300	6,048



HTC_TST_NA	Age/sex: 10-14 Male	7,200	6,912
HTC_TST_NA	Age/sex: 15-19 Male	17,388	16,692
HTC_TST_NA	Age/sex: 20-24 Male	17,388	16,692
HTC_TST_NA	Age/sex: 25-49 Male	104,328	100,154
HTC_TST_NA	Age/sex: 50+ Male	34,776	33,384
HTC_TST_NA	Age/sex: <1 Female	8,200	7,872
HTC_TST_NA	Age/sex: 1-4 Female	3,500	3,360
HTC_TST_NA	Age/sex: 5-9 Female	6,300	6,048
HTC_TST_NA	Age/sex: 10-14 Female	7,200	6,912
HTC_TST_NA	Age/sex: 15-19 Female	40,572	38,950
HTC_TST_NA	Age/sex: 20-24 Female	40,572	38,950
HTC_TST_NA	Age/sex: 25-49 Female	243,432	233,694
HTC_TST_NA	Age/sex: 50+ Female	81,144	77,900
HTC_TST_NA	Sum of Age/Sex disaggregates	630,000	604,800
HTC_TST_NA	Aggregated Age/sex: <15 Male	25,200	24,192
HTC_TST_NA	Aggregated Age/sex: 15+ Male	173,880	166,924
HTC_TST_NA	Aggregated Age/sex: <15 Female	25,200	24,192
HTC_TST_NA	Aggregated Age/sex: 15+ Female	405,720	389,492
HTC_TST_NA	Sum of Aggregated Age/Sex <15	50,400	48,384
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	579,600	556,416
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	630,000	604,800
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	630,000	
HTC_TST_NGI	Age/sex: <1 Male	8,200	
HTC_TST_NGI	Age/sex: 1-4 Male	3,500	
HTC_TST_NGI	Age/sex: 5-9 Male	6,300	
HTC_TST_NGI	Age/sex: 10-14 Male	7,200	
HTC_TST_NGI	Age/sex: 15-19 Male	17,388	
HTC_TST_NGI	Age/sex: 20-24 Male	17,388	
HTC_TST_NGI	Age/sex: 25-49 Male	104,328	
HTC_TST_NGI	Age/sex: 50+ Male	34,776	



			T
HTC_TST_NGI	Age/sex: <1 Female	8,200	
HTC_TST_NGI	Age/sex: 1-4 Female	3,500	
HTC_TST_NGI	Age/sex: 5-9 Female	6,300	
HTC_TST_NGI	Age/sex: 10-14 Female	7,200	
HTC_TST_NGI	Age/sex: 15-19 Female	40,572	
HTC_TST_NGI	Age/sex: 20-24 Female	40,572	
HTC_TST_NGI	Age/sex: 25-49 Female	243,432	
HTC_TST_NGI	Age/sex: 50+ Female	81,144	
HTC_TST_NGI	Sum of Age/Sex disaggregates	630,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	25,200	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	173,880	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	25,200	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	405,720	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	50,400	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	579,600	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	630,000	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status whoare on ART during TB treatment during the reporting period	8,000	7,200
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	11,000	11,000
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	193,662	
TX_CURR_NA	Age/Sex: <1 Male	59	
TX_CURR_NA	Age/Sex: 1-4 Male	3,179	
TX_CURR_NA	Age/Sex: 5-14 Male	2,060	
TX_CURR_NA	Age/Sex: 15+ Male	73,226	
TX_CURR_NA	Age/Sex: <1 Female	59	
TX_CURR_NA	Age/Sex: 1-4 Female	3,179	
TX_CURR_NA	Age/Sex: 5-14 Female	2,060	



TX_CURR_NA	Ago/Sov: 15 L Fomolo	100.940	
	Age/Sex: 15+ Female	109,840	
TX_CURR_NA	Sum of Age/Sex disaggregates	193,662	
TX_CURR_NA	Aggregated Age/Sex: <1 Male	59	
TX_CURR_NA	Aggregated Age/Sex: <1 Female	59	
TX_CURR_NA	Aggregated Age/Sex: <15 Male	5,298	
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	73,226	
TX_CURR_NA	Aggregated Age/Sex: <15 Female	5,298	
TX_CURR_NA	Aggregated Age/Sex: 15+ Female	109,840	
TX_CURR_NA	Sum of Aggregated Age/Sex <15	10,596	
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	183,066	
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	193,662	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	193,662	
TX_CURR_NGI	Age/Sex: <1 Male	59	
TX_CURR_NGI	Age/Sex: 1-4 Male	3,179	
TX_CURR_NGI	Age/Sex: 5-14 Male	2,060	
TX_CURR_NGI	Age/Sex: 15+ Male	73,226	
TX_CURR_NGI	Age/Sex: <1 Female	59	
TX_CURR_NGI	Age/Sex: 1-4 Female	3,179	
TX_CURR_NGI	Age/Sex: 5-14 Female	2,060	
TX_CURR_NGI	Age/Sex: 15+ Female	109,840	
TX_CURR_NGI	Sum of Age/Sex disaggregates	193,662	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	59	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	59	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	5,298	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	73,226	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	5,298	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	109,840	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	193,662	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	10,596	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	183,066	
TX_NEW_DSD	Number of adults and children newly enrolled	47,806	41,842



Г			
	on antiretroviral therapy (ART)		
TX_NEW_DSD	By Age/Sex: <1 Male	59	51
TX_NEW_DSD	By Age/Sex: 1-4 Male	567	496
TX_NEW_DSD	By Age/Sex: 5-9 Male	425	372
TX_NEW_DSD	By Age/Sex: 10-14 Male	366	320
TX_NEW_DSD	By Age/Sex: 15-19 Male	675	591
TX_NEW_DSD	By Age/Sex: 20-24 Male	675	591
TX_NEW_DSD	By Age/Sex: 25-49 Male	8,095	7,085
TX_NEW_DSD	By Age/Sex: 50+ Male	4,047	3,542
TX_NEW_DSD	By Age/Sex: <1 Female	59	51
TX_NEW_DSD	By Age/Sex: 1-4 Female	567	496
TX_NEW_DSD	By Age/Sex: 5-9 Female	425	372
TX_NEW_DSD	By Age/Sex: 10-14 Female	366	320
TX_NEW_DSD	By Age/Sex: 15-19 Female	2,203	1,928
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,148	2,755
TX_NEW_DSD	By Age/Sex: 25-49 Female	18,889	16,533
TX_NEW_DSD	By Age/Sex: 50+ Female	7,240	6,339
TX_NEW_DSD	Sum of Age/Sex disaggregates	47,806	41,842
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	59	51
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,417	1,239
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	13,492	11,809
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	59	51
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,417	1,239
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	31,480	27,555
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	47,806	41,842
TX_NEW_DSD	Pregnancy status	10,822	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,700	32,508
TX_RET_DSD	Total number of adults and children who	42,000	47,806



	initiated ART in the 12 months prior to the		
	beginning of the reporting period, including		
	those who have died, those who have stopped		
	ART, and those lost to follow-up		
	Number of new HCW who graduated from a		
	pre-service training institution or program as a		
HRH_PRE	result of PEPFAR-supported strengthening	122	
	efforts, within the reporting period, by select		
	cadre		
HRH_PRE	By Graduates: Other	122	
HRH_PRE	Sum of Graduates disaggreagtes	122	

Mechanism ID: 17023	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Broadreach		
greement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 13,536,898 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,873,820	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	13,536,898

Sub Partner Name(s)

		University of Kwazulu-Natal,
Daniti ya Manana Matayania	University of Kwazulu-Natal,	Nelson Mandela School of
Positive Women Network	Enhancing Care Initiative Unit	Medicine, Comprehensive
		International Program for



	Research on AIDS

Cross-Cutting Budget Attribution(s)

Human Resources for Health	6,239,586
Fluman Resources for Fleatin	0,239,300
Gender: Gender Equality	341,821
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	108,515
Food and Nutrition: Policy, Tools, and Service Delivery	217,029

Key Issues

Malaria (PMI)
Child Survival Activities
Safe Motherhood
TB
End-of-Program Evaluation
Family Planning

Mechanism ID:				
Mechanism Name:	Systems Strengthening for Better HIV/TB Patient Outcomes			
Prime Partner Name:	Broadreach			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	1,140,833	0	



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,375,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	243,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	860,479	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	642,482	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,605,430	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,668,774	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	410	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	410	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	410	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	410	
SITE_SUPP	JPP By program area/support type: PMTCT Technical Assistance-only (TA)		



	<u></u>		ı
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA) 410		
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	24,000	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	7,200	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6,336	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on V_NGI treatment at the beginning of the current 864 pregnancy		
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		10,800	
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	18,000	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	7,200	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who		16,400
PMTCT_ARV_TA	PMTCT_ARV_TA Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		24,000
PMTCT_ARV_TA	Life-long ART (including Option B+)	7,200	6,400
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6,336	5,600



	<u> </u>		
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	864	800
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	10,800	10,000
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	18,000	16,400
PMTCT_ARV_TA	Sum of New and Current disaggregates	7,200	6,400
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	120,000	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,000	84,000
PMTCT_STAT_TA	Number of new ANC and L&D clients	120,000	96,000
HTC_TST_NGI	Number of individuals who received T&C HTC_TST_NGI services for HIV and received their test results during the past 12 months		
HTC_TST_NGI	Age/sex: <1 Male	6,400	
HTC_TST_NGI	Age/sex: 1-4 Male	6,400	
HTC_TST_NGI	Age/sex: 5-9 Male	6,400	
HTC_TST_NGI	Age/sex: 10-14 Male	6,400	
HTC_TST_NGI	Age/sex: 15-19 Male	6,400	
HTC_TST_NGI	Age/sex: 20-24 Male	16,000	
HTC_TST_NGI	Age/sex: 25-49 Male	240,000	
HTC_TST_NGI	Age/sex: 50+ Male	32,000	
HTC_TST_NGI	Age/sex: <1 Female	9,600	
HTC_TST_NGI	Age/sex: 1-4 Female	9,600	



	1		T
HTC_TST_NGI	Age/sex: 5-9 Female	9,600	
HTC_TST_NGI	Age/sex: 10-14 Female	9,600	
HTC_TST_NGI	Age/sex: 15-19 Female	9,600	
HTC_TST_NGI	Age/sex: 20-24 Female	24,000	
HTC_TST_NGI	Age/sex: 25-49 Female	360,000	
HTC_TST_NGI	Age/sex: 50+ Female	48,000	
HTC_TST_NGI	Sum of Age/Sex disaggregates	800,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	25,600	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	294,400	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	38,400	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	441,600	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	64,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	736,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	800,000	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	800,000	660,000
HTC_TST_TA	Age/sex: <1 Male	6,400	5,280
HTC_TST_TA	Age/sex: 1-4 Male	6,400	5,280
HTC_TST_TA	Age/sex: 5-9 Male	6,400	5,280
HTC_TST_TA	Age/sex: 10-14 Male	6,400	5,280
HTC_TST_TA	Age/sex: 15-19 Male	6,400	5,280
HTC_TST_TA	Age/sex: 20-24 Male	16,000	13,200
HTC_TST_TA	Age/sex: 25-49 Male	240,000	198,000
HTC_TST_TA	Age/sex: 50+ Male	32,000	26,400
HTC_TST_TA	Age/sex: <1 Female	9,600	7,920
HTC_TST_TA	Age/sex: 1-4 Female	9,600	7,920
HTC_TST_TA	Age/sex: 5-9 Female	9,600	7,920
HTC_TST_TA	Age/sex: 10-14 Female	9,600	7,920
HTC_TST_TA	Age/sex: 15-19 Female	9,600	7,920
HTC_TST_TA	Age/sex: 20-24 Female	24,000	19,800
HTC_TST_TA	Age/sex: 25-49 Female	360,000	297,000



HTC_TST_TA	Age/sex: 50+ Female	48,000	39,600
HTC_TST_TA	Sum of Age/Sex disaggregates	800,000	660,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	25,600	21,120
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	294,400	242,880
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	38,400	31,680
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	441,600	364,320
HTC_TST_TA	Sum of Aggregated Age/Sex <15	64,000	52,800
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	736,000	607,200
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	800,000	660,000
C2.1.D_NGI	Number of HIV-positive individuals receiving a		
C2.1.D_NGI	By Age/Sex: <15 Female	21,000	
C2.1.D_NGI	By Age/Sex: <15 Male	14,000	
C2.1.D_NGI	By Age/Sex: 15+ Female	189,000	
C2.1.D_NGI	By Age/Sex: 15+ Male	126,000	
C2.1.D_NGI	Sum of Age/Sex disaggregates	350,000	
C2.1.D_NGI	By Age: <15 35,000		
C2.1.D_NGI	By Age: 15+	5+ 315,000	
C2.1.D_NGI	Sum of Age disaggregates	350,000	
C2.1.D_NGI	By Sex: Female	210,000	
C2.1.D_NGI	By Sex: Male	140,000	
C2.1.D_NGI	Sum of Sex disaggregates	350,000	
C2.1.D_TA	C2.1.D_TA Number of HIV-positive individuals receiving a minimum of one clinical service		
C2.1.D_TA	By Age/Sex: <15 Female	21,000	
C2.1.D_TA	By Age/Sex: <15 Male	14,000	
C2.1.D_TA	_TA By Age/Sex: 15+ Female		
C2.1.D_TA	By Age/Sex: 15+ Male	126,000	
C2.1.D_TA	Sum of Age/Sex disaggregates	350,000	



C2.1.D_TA	By Age: <15	35,000	
C2.1.D_TA	By Age: 15+	315,000	
C2.1.D_TA	Sum of Age disaggregates	350,000	
C2.1.D_TA	By Sex: Female	210,000	
C2.1.D_TA	By Sex: Male	140,000	
C2.1.D_TA	Sum of Sex disaggregates	350,000	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	325,000	
TX_CURR_NGI	Age/Sex: <1 Male	5,200	
TX_CURR_NGI	Age/Sex: 1-4 Male	3,900	
TX_CURR_NGI	Age/Sex: 5-14 Male	3,900	
TX_CURR_NGI	Age/Sex: 15+ Male	117,000	
TX_CURR_NGI	Age/Sex: <1 Female	7,800	
TX_CURR_NGI	Age/Sex: 1-4 Female		
TX_CURR_NGI	Age/Sex: 5-14 Female	5,850	
TX_CURR_NGI	Age/Sex: 15+ Female	175,500	
TX_CURR_NGI	Sum of Age/Sex disaggregates	325,000	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	5,200	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	7,800	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	13,000	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	117,000	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	19,500	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	175,500	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	325,000	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15 32,500		
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	292,500	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	325,000	280,000
TX_CURR_TA	Age/Sex: <1 Male 5,		4,480
TX_CURR_TA	Age/Sex: 1-4 Male	3,900	3,360
TX_CURR_TA	Age/Sex: 5-14 Male	3,900	3,360
TX_CURR_TA	Age/Sex: 15+ Male	117,000	100,800



TX_CURR_TA	Age/Sex: <1 Female	7,800	6,720
TX_CURR_TA	Age/Sex: 1-4 Female	5,850	5,040
TX_CURR_TA	Age/Sex: 5-14 Female	5,850	5,040
TX_CURR_TA	Age/Sex: 15+ Female	175,500	151,200
TX_CURR_TA	Sum of Age/Sex disaggregations	32,500	28,000
TX_CURR_TA	Aggregated Age/Sex: <1 Male	5,200	4,480
TX_CURR_TA	Aggregated Age/Sex: <1 Female	7,800	6,720
TX_CURR_TA	Aggregated Age/Sex: <15 Male	13,000	11,200
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	117,000	100,800
TX_CURR_TA	Aggregated Age/Sex: <15 Female	19,500	16,800
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	175,500	151,200
TX_CURR_TA	Sum of Aggregated Age/Sex <15	32,500	28,000
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	292,500	252,000
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	325,000	280,000

Implementing Mechanism Details

Mechanism ID: 17022	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Developing & Institutionalizing an Innovative Capacity Building Model to Support SA Government Priorities & to Improve HIV/TB Health Outcomes for Priority Populations - "South to South Stellenbosch")	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: The South-to-South Partners Treatment Program (S2S)	nip for Comprehensive Family HIV Care and	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
P.G: No Managing Agency:		

Total All Funding Sources: 998,790	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 711,210	
FY 2013 Burn Rate: Redacted	



Funding Source	Funding Amount
GHP-State	998,790

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service	998.790
Delivery	
Condom programming	21,260

Key Issues

(No data provided.)

Mechanism Name: Prime Partner Name:	HIV Innovations for Improved Patient Outcomes in South Africa Mechanism ID: (Developing & Institutionalizing an Innovative Capacity Building Model to chanism Name: Support SA Government Priorities & to Improve HIV/TB Health Outcomes for Priority Populations - "South to South Stellenbosch") The South-to-South Partnership for Comprehensive Family HIV Care and Treatment Program (S2S)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	27,725	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	42,392	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	369,769	0	



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	173,177	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	385,727	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	195	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	15	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	65	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	50	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	65	

Implementing Mechanism Details

Mechanism ID: 17021	Mechanism Name: Performance for Health through Focused Outputs, Results and Management	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Right To Care, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

	Total All Funding Sources: 9,055,322	Total Mechanism Pipeline: Redacted
--	--------------------------------------	------------------------------------



Applied Pipeline Amount: 3,544,678			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	9,055,322		

Sub Partner Name(s)

African Health Project	Foundation for Professional Development	Ndlovu Medical Centre
Ndlovu Medical Trust	Tshikululu Social Investments	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	6,474,804
Motor Vehicles: Purchased	351,025
Food and Nutrition: Policy, Tools, and Service	194,244
Delivery	
Condom programming	86,331

Key Issues

Child Survival Activities Safe Motherhood TB Family Planning

Mechanism ID Mechanism Name Prime Partner Name	Performance for Health through Focused Outputs, Results and Management
--	---



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	666,498	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	938,999	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	82,499	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,631	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	599,990	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,289,580	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,327,125	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	346	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	30	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	315	
SITE_SUPP	By program area/support type: Treatment	39	



	Direct Service Delivery (DSD)		
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	307	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	39	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	307	
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	20	
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	325	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	30	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	314	
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	31	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	315	
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,000	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,150	0
PMTCT_ARV_DSD	Life-long ART (including Option B+)	1,000	0
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	650	0
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	350	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	1,000	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	1,000	0



			1
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	18,500	15,600
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	23,150	23,500
PMTCT_ARV_TA	Life-long ART (including Option B+)	18,500	15,600
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	15,350	12,800
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,150	2,800
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	18,500	15,600
PMTCT_ARV_TA	Sum of New and Current disaggregates	18,500	15,600
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,250	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	5,300	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	92,500	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	93,000	
PMTCT_STAT_NGI	By: Known positives at entry	0	
PMTCT_STAT_NGI	By: Number of new positives identified	0	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	0	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,250	71,200
PMTCT_STAT_TA	Number of new ANC and L&D clients	87,700	72,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,800	1,600
HTC_TST_DSD	By Test Result: Negative	42,800	1,056



HTC_TST_DSD	By Test Result: Positive	9,000	544
HTC_TST_DSD	Sum of Test Result disaggregates	51,800	1,600
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,400	560
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	25,000	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,400	1,040
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,000	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,800	1,600
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	49,000	0
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,800	1,600
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	632,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	16,000	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	250,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	16,000	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	350,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	32,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	600,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	632,000	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	580,200	478,400
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	14,600	12,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	225,000	183,440
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14,600	12,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	326,000	270,960



	PERMISSION ONLY: 15+ Female		
HTC_TST_TA	Sum of Aggregated Age/Sex <15	29,200	24,000
HTC_TST_TA Sum of Aggregated Age/Sex 15+		551,000	454,400
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	580,200	478,400
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	26,300	
C2.1.D_DSD	By Age/Sex: <15 Female	500	
C2.1.D_DSD	By Age/Sex: <15 Male	500	
C2.1.D_DSD	By Age/Sex: 15+ Female	16,600	
C2.1.D_DSD	By Age/Sex: 15+ Male	8,700	
C2.1.D_DSD	Sum of Age/Sex disaggregates	26,300	
C2.1.D_DSD	By Age: <15	1,000	
C2.1.D_DSD	By Age: 15+	25,300	
C2.1.D_DSD	Sum of Age disaggregates	26,300	
C2.1.D_DSD	By Sex: Female	17,100	
C2.1.D_DSD	By Sex: Male	9,200	
C2.1.D_DSD	Sum of Sex disaggregates	26,300	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	a 26,300	
C2.1.D_NGI	By Age/Sex: <15 Female	500	
C2.1.D_NGI	By Age/Sex: <15 Male	500	
C2.1.D_NGI	By Age/Sex: 15+ Female	16,600	
C2.1.D_NGI	By Age/Sex: 15+ Male	8,700	
C2.1.D_NGI	Sum of Age/Sex disaggregates	26,300	
C2.1.D_NGI	By Age: <15	1,000	
C2.1.D_NGI	By Age: 15+	25,300	
C2.1.D_NGI	Sum of Age disaggregates 26,300		
C2.1.D_NGI	By Sex: Female 17,100		
C2.1.D_NGI	By Sex: Male	9,200	
C2.1.D_NGI	Sum of Sex disaggregates	26,300	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment	26,300	



	setting		
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	26,300	
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	26,300	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,300	9,600
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	500	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,700	3,360
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	500	0
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		16,600	6,240
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	26,300	9,600
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	50	40
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	50	40
FN_THER_DSD	Aggregated Age: 18+	50	40
FN_THER_DSD	Sum of Aggregated Age disaggregates	50	40
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		88
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	346	240
TB_ARTSITE By site support type: Direct Service Delivery		10	1



	(DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	70	87
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	80	88
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	31	1
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	315	239
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	346	240
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,465	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,150	0
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth		1,450	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	15	0
PMTCT_EID_DSD Sum of Infant Age disaggregates		1,465	0
PMTCT_EID_DSD By infants with a positive virologic test result within 12 months of birth		40	0



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	72,400	9,760
Percent children with advanced HIV infection TX_CURR_DSD receiving antiretroviral therapy (ART) [CURRENT]		5	0
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	65	51
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,700	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	24,000	3,520
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,700	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	45,000	6,240
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,400	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	69,000	9,760
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	72,400	9,760
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART)		256,000	
TX_CURR_NGI Age/Sex: <1 Male		0	
TX_CURR_NGI	NGI Age/Sex: 1-4 Male 0		
TX_CURR_NGI			
TX_CURR_NGI	Age/Sex: 15+ Male	0	
TX_CURR_NGI	Age/Sex: <1 Female	0	
TX_CURR_NGI	Age/Sex: 1-4 Female	0	
TX_CURR_NGI	Age/Sex: 5-14 Female	0	
TX_CURR_NGI	Age/Sex: 15+ Female	0	
TX_CURR_NGI Sum of Age/Sex disaggregates		0	
TX_CURR_NGI Aggregated Age/Sex: <1 Male		0	
TX_CURR_NGI Aggregated Age/Sex: <1 Female		0	
TX_CURR_NGI			
TX_CURR_NGI Aggregated Age/Sex: 15+ Male		82,000	
TX_CURR_NGI			
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 160,000			
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates		256,000	



TV CLIDD NCI	Sum of Aggregated Agg/Say 45	14 000	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	14,000 242,000	
TX_CURR_NGI			
TX_CURR_TA	TX_CURR_TA Number of adults and children receiving antiretroviral therapy (ART)		205,440
TX_CURR_TA	Aggregated Age/Sex: <15 Male	5,300	5,600
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	58,000	64,480
TX_CURR_TA	Aggregated Age/Sex: <15 Female	5,300	5,600
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	115,000	129,760
TX_CURR_TA	Sum of Aggregated Age/Sex <15	10,600	11,200
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	173,000	194,240
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	183,600	205,440
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV		3
TX_DIST	Total number of PEPFAR supported District Health Offices 4		4
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,200	1,120
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	20	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	100	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	100	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	20	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,000	632
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+		488
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,200	1,120
TX_NEW_DSD	Pregnancy status	550	8
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	200	200
TX_SITE	Total number of PEPFAR-supported ART	346	299



	sites		
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	20	1
By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		180	199
TX_SITE	Sum of Numerator Site Support Type disaggregates	200	200
TX_SITE	By support type: Direct Service Delivery		1
By support type: Technical Assistance TX_SITE (TA-only): Total number of PEPFAR-supported ART sites		307	298
TX_SITE	Sum of Denominator Site Support Type disaggregates	346	299
Number of PEPFAR-supported clinical service sites with a quality improvement activity QI_SITE completed that addresses clinical HIV programs and has documented process results in the last 6 months		10	21
Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		346	299
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	5	1



-			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		20
QI_SITE	Sum of Numerator Site Support Type disaggregates	10	21
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	39	1
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	307	298
QI_SITE Sum of Denominator Site Support Type disaggregates		346	299
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		9,600
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		26,300	9,600
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		1,000	0
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		25,300	9,600
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	26,300	9,600
TB_SCREEN_DSD	Sex: Male	9,200	3,360
TB_SCREEN_DSD Sex: Female		17,100	6,240



	TB_SCREEN_DSD	Sum of Sex disaggregates	26,300	9,600	
--	---------------	--------------------------	--------	-------	--

Implementing Mechanism Details

Mechanism ID: 17020	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Anova Health Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,497,291 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 4,962,709	
FY 2013 Burn Rate: Redacted	
Funding Source Funding Amount	
GHP-State	3,497,291

Sub Partner Name(s)

HIVSA	Singizi Consulting	
1111011	on gizi concatting	

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	581,064	
Focus Area:	Equity in HIV prevention, care, treatment and support	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	
Gender: GBV	3,157	
Focus Area:	GBV Prevention	



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	15,786
Food and Nutrition: Policy, Tools, and Service	69,946
Delivery	

Key Issues

Child Survival Activities
Safe Motherhood
TB
End-of-Program Evaluation
Family Planning

	17020 Systems Strengthening for Better HIV/TB Patient Outcomes Anova Health Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	390,767	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	443,575	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	56,053	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	101,822	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	210,177	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,895,076	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	399,821	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	268	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	268	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	217	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	268	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	238	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	217	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	238	



PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	11,571	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	Number of HIV- positive pregnant women identified in the reporting period (including 11,902	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	6,000	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	7,416	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	4,155	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with		
PMTCT_ARV_NGI	Sum of Regimen disaggregates	11,571	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	11,571	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	11,571	5,383
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	11,902	7,808
PMTCT_ARV_TA	Life-long ART (including Option B+)	6,000	4,896
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	7,416	6,051
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	4,155	3,390
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	5,571	4,545



PMTCT_ARV_TA	Sum of Regimen Type disaggregates	11,571	9,441
PMTCT_ARV_TA	Sum of New and Current disaggregates	11,571	9,441
PMTCT_STAT_NGI	Number of pregnant women with known HIV		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	89,073	
PMTCT_STAT_NGI	By: Known positives at entry	7,817	
PMTCT_STAT_NGI	By: Number of new positives identified	11,902	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	19,719	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,025	67,748
PMTCT_STAT_TA	Number of new ANC and L&D clients	89,073	90,854
PMTCT_STAT_TA	By: Known positives at entry	7,817	6,378
PMTCT_STAT_TA	By: Number of new positives identified	11,902	9,712
PMTCT_STAT_TA	Sum of Positives Status disaggregates 19,719		16,090
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	390,001	
HTC_TST_NGI	By Test Result: Negative	337,153	
HTC_TST_NGI	By Test Result: Positive	52,848	
HTC_TST_NGI	Sum of Test Result disaggregates	390,001	
HTC_TST_NGI	Age/sex: 10-14 Male	6,904	
HTC_TST_NGI	Age/sex: 15-19 Male	28,757	
HTC_TST_NGI	Age/sex: 20-24 Male	16,823	
HTC_TST_NGI			
HTC_TST_NGI	Age/sex: 50+ Male	3,365	
HTC_TST_NGI	Age/sex: 10-14 Female	8,159	
HTC_TST_NGI	Age/sex: 15-19 Female	70,113	
HTC_TST_NGI	Age/sex: 20-24 Female	168,693	
HTC_TST_NGI	Age/sex: 25-49 Female	Age/sex: 25-49 Female 19,237	
HTC_TST_NGI	Age/sex: 50+ Female 4,025		
HTC_TST_NGI	Sum of Age/Sex disaggregates	390,001	



			T
HTC_TST_NGI	Aggregated Age/sex: <15 Male	6,904	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male 112,870		
HTC_TST_NGI	Aggregated Age/sex: <15 Female	8,159	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	262,068	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	15,063	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	374,938	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	390,001	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	390,001	327,600
HTC_TST_TA	By Test Result: Negative	337,153	283,208
HTC_TST_TA	By Test Result: Positive	52,848	44,392
HTC_TST_TA	Sum of Test Result disaggregates	390,001	327,600
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	0	327,600
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,904	5,799
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	112,870	94,810
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,159	6,853
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	262,068	220,138
HTC_TST_TA	Sum of Aggregated Age/Sex <15	15,063	12,652
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	374,938	314,948
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	390,001	327,600
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	232,572	
C2.1.D_NGI	By Age/Sex: <15 Female	7,883	
C2.1.D_NGI	By Age/Sex: <15 Male	39,419	
C2.1.D_NGI	By Age/Sex: 15+ Female	112,345	
C2.1.D_NGI	By Age/Sex: 15+ Male	72,925	
C2.1.D_NGI	Sum of Age/Sex disaggregates	232,572	



			1
C2.1.D_NGI	By Age: <15	47,302	
C2.1.D_NGI	By Age: 15+	185,270	
C2.1.D_NGI	Sum of Age disaggregates	232,572	
C2.1.D_NGI	By Sex: Female	120,228	
C2.1.D_NGI	By Sex: Male	112,344	
C2.1.D_NGI	Sum of Sex disaggregates	232,572	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	232,572	
C2.1.D_TA	By Age/Sex: <15 Female	7,883	
C2.1.D_TA	By Age/Sex: <15 Male	39,419	
C2.1.D_TA	By Age/Sex: 15+ Female	112,345	
C2.1.D_TA	By Age/Sex: 15+ Male	72,925	
C2.1.D_TA	Sum of Age/Sex disaggregates	232,572	
C2.1.D_TA	By Age: <15	47,302	
C2.1.D_TA	By Age: 15+	185,270	
C2.1.D_TA	Sum of Age disaggregates	232,572	
C2.1.D_TA	By Sex: Female	120,228	
C2.1.D_TA	By Sex: Male	112,344	
C2.1.D_TA	Sum of Sex disaggregates	232,572	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	15,584	12,716
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	19,719	16,090
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	172,000	
TX_CURR_NGI	Age/Sex: <1 Male	354	
TX_CURR_NGI	Age/Sex: 1-4 Male	814	
TX_CURR_NGI	Age/Sex: 5-14 Male	3,052	
TX_CURR_NGI	Age/Sex: 15+ Male	52,363	
TX_CURR_NGI	Age/Sex: <1 Female	530	



TX_CURR_NGI	Age/Sex: 1-4 Female	1,221	
TX_CURR_NGI			
TX_CURR_NGI			
TX_CURR_NGI	Sum of Age/Sex disaggregates	172,000	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	4,220	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	52,363	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female		
		6,330	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	109,087	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	172,000	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	10,550	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	161,450	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	172,000	120,480
TX_CURR_TA	Age/Sex: <1 Male	354	297
TX_CURR_TA	Age/Sex: 1-4 Male	814	684
TX_CURR_TA	Age/Sex: 5-14 Male	3,052	2,565
TX_CURR_TA	Age/Sex: 15+ Male	52,363	19,985
TX_CURR_TA	Age/Sex: <1 Female	530	445
TX_CURR_TA	Age/Sex: 1-4 Female	1,221	1,025
TX_CURR_TA	Age/Sex: 5-14 Female	4,579	3,846
TX_CURR_TA	Age/Sex: 15+ Female	109,087	91,633
TX_CURR_TA	Sum of Age/Sex disaggregations	10,550	8,862
TX_CURR_TA	Aggregated Age/Sex: <15 Male	4,220	3,545
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	52,363	19,985
TX_CURR_TA	Aggregated Age/Sex: <15 Female	6,330	5,317
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	109,087	91,633
TX_CURR_TA	Sum of Aggregated Age/Sex <15	10,550	8,862
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	161,450	111,618
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	172,000	120,480
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	41,086	34,245
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	127	106



	1		
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	530	445
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	13,519	11,356
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	190	160
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	793	666
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	25,927	21,778
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	40,769	34,245
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	30,312	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	35,786	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30,312	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35,786	0
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30,312	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35,786	
FPINT_SITE_DSD	Service delivery type: Community	0	



FPINT_SITE_DSD	0	
----------------	---	--

Implementing Mechanism Details

implementing wechanism betails	
Mechanism ID: 17019	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM) - Health4Men Program
Funding Agency: USAID Procurement Type: Cooperative Agreement	
Prime Partner Name: Anova Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,673,312 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 486,688		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	1,673,312	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	241,797
Key Populations: MSM and TG	1,673,312
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Focus Area:	Conducting epidemiologic, social science, and
	operational research among MSM/TG and their sex
	partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other
	commodities essential to core HIV services for
	MSM/TG
Gender: GBV	53,733
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	26,866

Key Issues

ΤВ

Mechanism ID:	17019	



Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Population Prime Partner Name: (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM) - Health4Men Program Anova Health Institute			ort of Scale Up of		
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amount			
Care	НВНС	226,254	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Care	HVTB	226,254	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVOP	268,664	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Treatment	HTXS	952,140	0		

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	105	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	5	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	105	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	5	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	105	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	5	
SITE_SUPP	By program area/support type: Care and	105	



	Support Technical Assistance only (TA)		
SITE_SUPP	Support Technical Assistance-only (TA) By program area/support type: TB/HIV Direct Service Delivery (DSD)	5	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	105	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	5	
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	105	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,443	16,216
PP_PREV_DSD	Age/sex: 10-14 Male	90	95
PP_PREV_DSD	Age/sex: 15-19 Male	5,633	5,915
PP_PREV_DSD	Age/sex: 25-49 Male	8,446	8,868
PP_PREV_DSD	Age/sex: 15-19 Female	1,274	1,338
PP_PREV_DSD	Sum of Age/Sex disaggregates	15,443	16,216
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,809	15,567
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	105
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV	14,488	15,212



	<u> </u>		
	preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	221	250
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,267	6,060
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3	10
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,222	6,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	42	50
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3	10
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,264	6,050
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,267	6,060
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,267	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	3	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	5,222	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	42	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	5,264	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	5,267	
GEND_GBV_DSD	Number of people receiving post-GBV care	20	20
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	6,015	



C2.1.D_DSD	By Age/Sex: <15 Female	0	
C2.1.D_DSD	By Age/Sex: <15 Male	0	
C2.1.D_DSD	By Age/Sex: <15 Male By Age/Sex: 15+ Female	103	
C2.1.D_DSD	By Age/Sex: 15+ Male	5,912	
C2.1.D_DSD	Sum of Age/Sex disaggregates	6,015	
C2.1.D_DSD	By Age: <15	0	
C2.1.D_DSD	By Age: 15+	6,015	
C2.1.D_DSD	Sum of Age disaggregates	6,015	
C2.1.D_DSD	By Sex: Female	103	
C2.1.D_DSD	By Sex: Male	5,912	
C2.1.D_DSD	Sum of Sex disaggregates	6,015	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	6,015	
C2.1.D_NGI	By Age/Sex: 15+ Female	103	
C2.1.D_NGI	By Age/Sex: 15+ Male	5,912	
C2.1.D_NGI	Sum of Age/Sex disaggregates	6,015	
C2.1.D_NGI	By Age: 15+	6,015	
C2.1.D_NGI	Sum of Age disaggregates	6,015	
C2.1.D_NGI	By Sex: Female	103	
C2.1.D_NGI	By Sex: Male	5,912	
C2.1.D_NGI	Sum of Sex disaggregates	6,015	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	6,015	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	6,015	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,334	1,400
TX_CURR_DSD	Age/Sex: 15+ Male	1,291	1,350
TX_CURR_DSD	Age/Sex: 15+ Female	43	50
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,291	1,350
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	43	50



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,334	1,400
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,334	1,400
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	1,334	
TX_CURR_NGI	Age/Sex: 15+ Male	1,291	
TX_CURR_NGI	Age/Sex: 15+ Female	43	
TX_CURR_NGI	Sum of Age/Sex disaggregates	1,334	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,291	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	43	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,334	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,334	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	427	470
TX_NEW_DSD	By Age/Sex: 50+ Male	424	465
TX_NEW_DSD	By Age/Sex: 15-19 Female	3	5
TX_NEW_DSD	Sum of Age/Sex disaggregates	427	470
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	424	465
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3	5
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	427	470
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	143	150
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	165	173
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	143	150
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	165	173



reporting period, including those who have	
died, those who have stopped ART, and those	
lost to follow-up)	

Mechanism ID: 17018	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Innovation for HCTC)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: AgriAIDS			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 900,000				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	О			

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population

ΤB

Workplace Programs

End-of-Program Evaluation



Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name: Mechanism Name: AgriAIDS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	120	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	120	
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	120	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	120	
PP_PREV_DSD	Number of the target population who	13,440	16,200



	completed a standardized LIIV resuscition		
	completed a standardized HIV prevention intervention including the minimum		
	components during the reporting period.		
PP_PREV_DSD	Total number of people in the target population	21,125	23,237
PP_PREV_DSD	Age/sex: 25-49 Male	4,604	5,670
PP_PREV_DSD	Age/sex: 20-24 Female	8,736	10,530
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,340	16,200
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,752	12,960
HTC_TST_DSD	Age/sex: 25-49 Male	6,988	8,424
HTC_TST_DSD	Age/sex: 20-24 Female	3,764	4,536
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,752	12,960
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,988	8,424
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,764	4,536
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,752	12,960
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,752	12,960
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,752	
HTC_TST_NGI	Age/sex: 25-49 Male	6,988	
HTC_TST_NGI	Age/sex: 20-24 Female	3,764	
HTC_TST_NGI	Sum of Age/Sex disaggregates	10,752	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	6,988	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,764	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	10,752	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	10,752	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,688	
C2.1.D_DSD	By Age/Sex: 15+ Female	1,747	



C2.1.D_DSD	By Age/Sex: 15+ Male	941
C2.1.D_DSD	Sum of Age/Sex disaggregates	2,688
C2.1.D_DSD	By Age: 15+	2,688
C2.1.D_DSD	Sum of Age disaggregates	2,688
C2.1.D_DSD	By Sex: Female	1,747
C2.1.D_DSD	By Sex: Male	941
C2.1.D_DSD	Sum of Sex disaggregates	2,688
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	2,688
C2.1.D_NGI	By Age/Sex: 15+ Female	1,747
C2.1.D_NGI	By Age/Sex: 15+ Male	941
C2.1.D_NGI	Sum of Age/Sex disaggregates	2,688
C2.1.D_NGI	By Age: 15+	2,688
C2.1.D_NGI	Sum of Age disaggregates	2,688
C2.1.D_NGI	By Sex: Female	1,747
C2.1.D_NGI	By Sex: Male	941
C2.1.D_NGI	Sum of Sex disaggregates	2,688
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	2,688
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,688

Mechanism ID: 17017	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - National Association of Childcare Workers (Roll-out of ISIBINDI model)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: National Association of Childcare Workers			
Agreement Start Date: Redacted Agreement End Date: Redacted			
BD: No New Mechanism: No			
Global Fund / Multilateral Engagement: No			



G2G: No	Managing Agency:		
Total All Funding Sources: 459,738	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 4,040,262			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	459,738		

Bergville Wellbeing Centre	Durban Children's Home	Ikhayalethemba Community Care Centre
Impendle Drop in Centre	Khanyiselani Development Trust	Komkhulu Creche
Masakhane Creche	Owambeni masakhane	Philani Drop In Centre
Philani Drop In Centre (Nquthu AIDS Commitee)	Sicelimpilo Drop In Centre	Sinozwelo resource Centre
Sinqobile CBO	St. Anthony's Home	St. Anthony's Home/Sbonokuhle C.C.C.
St. Paul Muti Purpose Centre	Thandukuphila Drop In Centre	Thembalethu
Tholulwazi Community Day Care Centre	Ubumbano Care Centre	Zamimpilo Community Centre

Cross-Cutting Budget Attribution(s)

Human Resources for Health	337,141	
Economic Strengthening	45,974	

Key Issues

(No data provided.)



Mechanism ID: Mechanism Name:	17017 Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - National Association of Childcare Workers (Roll-out of ISIBINDI model) National Association of Childcare Workers		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	459,738	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR		
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	26	
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	128	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	19,699	16,547
OVC_SERV_TA Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS		71,322	59,910
Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		279	1,900
HRH_PRE	HRH_PRE By Graduates: Other		1,900
HRH_PRE	HRH_PRE Sum of Graduates disaggreagtes		1,900
HRH_PRE By new graduates who are licensed and registered: Other (where applicable)		279	1,900



implementing meenament betane			
Mechanism ID: 16993	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - The Networking HIV/AIDS Community of South Africa (NACOSA)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: NACOSA (Networking AIDS C	ommunity of South Africa)		
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: PR/SR			
G2G: No Managing Agency:			

Total All Funding Sources: 211,572 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 1,408,428		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	211,572	

Sub Partner Name(s)

Baphumelele Waldorf Association	Batlamedi Health and Welfare Organisation	Boitumelong Support Group	
Child Welfare South Africa	Dr M L Maile Development Centre	Dunamis Christian School	
Esiphondweni AIDS & Community Project	Ezisakwini Development Initiative	FAMSA	
Free State Care in Action	Heart to Heart Care Centre	House of Hope Hospice	
Ikhwezi Lomso Child and Family Welfare	Inkwanca HBC	Lesedi Home Based Care	
Lesedi Hospice	Lesedi Youth Empowerment	Malibongwe	
NG Welsyn Vryburg	Noncedo Home Based Care	Ophondweni Youth Development Initiative	
Orebabaletse Home Based Care	Sifisulwazi Development Organisation	Sikunye Home Community Based Care	



	Siyakhana Community Based Organization	Tshireletso Home Based Care
Unyezi Community Care Centre	Zisize Educational Trust	

Cross-Cutting Budget Attribution(s)

Key Issues

(No data provided.)

Budget Code Information

Budget Code information			
	16993		
Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and		
Mechanism Name:	Vulnerable Children (OVC) - The Networking HIV/AIDS Community of		
Prime Partner Name: South Africa (NACOSA)			
	NACOSA (Networking AIDS Community of South Africa)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	211,572	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	30	
SITE_SUPP	SITE_SUPP By program area/support type: OVC Direct Service Delivery (DSD)		
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS		60,000	48,000



Mechanism ID: 16992	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable	
	Children (OVC) - HIV SA	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: HIVSA		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 585,000		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities Mobile Population

zaagot ooao iiiioiiiid	AUG11
Mechanism ID:	16992



	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - HIV SA HIVSA		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	50	
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	50	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,000	14,000
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	20	20
HRH_PRE	By Graduates: Social service workers	20	20
HRH_PRE	Sum of Graduates disaggreagtes	20	20

Mechanism ID: 16991	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Future Families	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Future Families		
greement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 233,249 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 441,751			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	233,249		

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Future Families		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	233,249	0

Indicator Number	Label	2014	2015
Custom	Page 299 of 576	FAC	CTS Info v3.8.15.8



SITE_SUPP	Number of unique sites supported by PEPFAR	4	
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	4	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,700	8,960

Mechanism ID: 16990	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Children in Distress (CINDI)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Children in Distress			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 462,791 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 275,209			
FY 2013 Burn Rate: Redacted			
Funding Source Funding Amount			
GHP-State	462,791		

Sub Partner Name(s)

Community Care Project	Lifeline	Youth for Christ South Africa (YfC)
------------------------	----------	-------------------------------------

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	36,000
iviolor verileies. I dieriasea	30,000



Key Issues

(No data provided.)

Budget Code Information

Badget Gode Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Children in Distress (CINDI)		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HKID	462,791	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	1	
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	1	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	25,000	20,000

	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Childwelfare/Childline Bloemfontein	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Childwelfare Bloemfontein & Childline Free State		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 465,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 129,000		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	465,000	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	70.054
iviolor vernoles. I dioriasea	7 0,004

Key Issues

(No data provided.)

Budget Code Information

Baaget Gode information			
Mechanism ID: Mechanism Name: Prime Partner Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Childwelfare/Childline Bloemfontein		
Strategic Area Budget Code Planned Amount On Hold Amo		On Hold Amount	
Care	HKID	465,000	0



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	4	
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	4	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and	5,746	5,300
	families affected by HIV/AIDS		

implementing mechanism betans		
Mechanism ID: 16988	Mechanism Name: Kheth''Impilo Pharmacist Assistant PPP	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Kheth'Impilo		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 452,646		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Baagot Godo information			
Mechanism ID:	16988		
Mechanism Name:	Kheth"Impilo Pharmacist Assistant PPP		
Prime Partner Name:	Kheth'Impilo		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	123	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	123	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	435	300
HRH_PRE	By Graduates: Other	435	300
HRH_PRE	Sum of Graduates disaggreagtes	435	300
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	435	300

	Mechanism Name: Service Delivery and Support
Mechanism ID: 16987	for Families Caring for Orphans and Vulnerable
	Children (OVC) - Childline Mpumalanga &
	Limpopo



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Childline Mpumalanga	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 512,609	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,062,391	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	512,609

Childline Limpopo		
-------------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Service Delivery and Su Vulnerable Children (OV)	pport for Families Caring C) - Childline Mpumalang	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	512,609	0



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	2	
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	2	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	45,510	40,048

Implementing Mechanism Details

Mechanism ID: 16985	Mechanism Name: Demographic Health Survey Program (DHS 7)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: ICF Macro	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 257,520	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 500,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	257,520

Sub Partner Name(s)

Blue Raster	EnCompass LLC	Futures Institute
John Hopkins Bloomberg School	I/im atria a	The Program for Appropriate
of Public Health, Center for	Kimetrica	Technology in Health



Communication Programs	
(JHU-CCP)	
Vysnova Partners	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Daagot Godo IIII oriiii			
Mechanism ID:	16985		
Mechanism Name:	Demographic Health Su	rvey Program (DHS 7)	
Prime Partner Name:	ICF Macro		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	257,520	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 16984	Mechanism Name: South Africa Executive Leadership Program for Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: South Africa Partners	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	



|--|

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 513,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Harvard University	University of Fort Hare	University of Pretoria, South Africa

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	16984		
Mechanism Name:	South Africa Executive Leadership Program for Health		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Implementing Mechanism Indicator Information

(No data provided.)



Mechanism ID: 16982	Mechanism Name: A Comprehensive Community-Based HIV Prevention, Counselling and Testing Programme for Reduced HIV Incidence	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Foundation for Professional Development		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,383,398	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 791,602		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	4,383,398	

Sub Partner Name(s)

Family Health International, South	Humana People to People in	Society for Family Health - South
Africa	South Africa	Africa

Cross-Cutting Budget Attribution(s)

Gender: GBV	129,553
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	129,553
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Key Populations: MSM and TG	129,553
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	129,553
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Motor Vehicles: Purchased	351,925
Condom programming	62,620

Key Issues

Child Survival Activities
Mobile Population
Safe Motherhood
TB
Workplace Programs
End-of-Program Evaluation
Family Planning



Mechanism ID:	A Comprehensive Community-Based HIV Prevention, Counselling and Testing Programme for Reduced HIV Incidence		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	4,383,398	0

Indicator Number	Label	2014	2015
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	90,000	162,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,600	6,480
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,400	58,320
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,500	8,100
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	49,500	89,100
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,100	14,580
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	81,900	147,420
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	90,000	162,000

Mechanism ID: 16981	Mechanism Name: Africa Health Placements NPC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Africa Health Placements	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

otal All Funding Sources: 539,424 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 16,940		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	539,424	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	539 424
Turnari Nesources for Fleatin	000, 121

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16981		
Mechanism Name:	Africa Health Placements NPC		
Prime Partner Name:	Africa Health Placements		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	539,424	0

Implementing Mechanism Indicator Information

(No data provided.)



mpionioning moonamem botane		
Mechanism ID: 16980 Mechanism Name: Applying Science to Strengthen and Improve Systems (ASS		
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 3,906,328	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood Family Planning

Mechanism ID:	16980



	Applying Science to Strengthen and Improve Systems (ASSIST) University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	22	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	22	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	22	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,800	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	40	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	40	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	100	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	3,000	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	100	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,600	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	6,800	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	200	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	6,600	
TX_CURR_TA	Number of adults and children receiving	6,800	8,540



	antiretroviral therapy (ART)		
TX_CURR_TA	Aggregated Age/Sex: <1 Male	40	41
TX_CURR_TA	Aggregated Age/Sex: <1 Female	40	41
TX_CURR_TA	Aggregated Age/Sex: <15 Male	100	120
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	3,000	3,800
TX_CURR_TA	Aggregated Age/Sex: <15 Female	100	120
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,600	4,500
TX_CURR_TA	Sum of Aggregated Age/Sex <15	200	240
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	6,600	8,300
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,800	8,540

Mechanism ID: 16979	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Regional Psychosocial Support Initiative (REPSSI)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Regional Psychosocial Supp	ort Initiative, South Africa		
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

otal All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 315,000		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Information			
	16979		
Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and		
Mechanism Name:	Vulnerable Children (OVC) - Regional Psychosocial Support Initiative		
Prime Partner Name:	: (REPSSI)		
	Regional Psychosocial Support Initiative, South Africa		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	8	
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	8	

Implementing Mechanism Details

Mechanism ID: 16976	TBD: Yes	
REDACTED		

Mechanism ID: 16932	Mechanism Name: Univeristy of California San



	Francisco central funding mechanism	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 147,176	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

its Reproductive Health& HIV	
stitute	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID:	16932		
Mechanism Name:	Univeristy of California San Francisco central funding mechanism		
Prime Partner Name:	University of California at San Francisco		
Strategic Area	Budget Code Planned Amount On Hold Amount		



Prevention	HVCT	0	0	
	_	_	_	

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16929	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16835	Mechanism Name: ASLM	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: African Society for Laboratory	Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 130,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 809,276		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	130,000	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

	-,
Human Resources for Health	50,000



Key Issues

(No data provided.)

Budget Code Information

Budget Code Illionii	alion			
Mechanism ID:	16835			
Mechanism Name:	ASLM			
Prime Partner Name:	Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	130,000	0	

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 16810	Mechanism Name: Enhancing USG-SAG Financial Frameworks		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Results for Developn	nent		
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 300,000 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	300,000			



1	
Results for Development	
Incodition bevelopment	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code information				
Mechanism ID:	16810			
Mechanism Name:	Enhancing USG-SAG Financial Frameworks			
Prime Partner Name:	Results for Development			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	300,000	0	

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 16808	Mechanism Name: GH001142		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive			
International Program for Research on AIDS			
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,660,000	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	3,660,000			

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1.833.000	
	1,000,000	

Key Issues

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	GH001142 University of Kwazulu-Natal, Nelson Mandela School of Medicine.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	270,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	630,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Care	PDCS	180,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,260,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	970,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1		Redacted



	, , , , , , , , , , , , , , , , , , , ,		
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	50	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	50	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	600	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	300	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,000	Redacted
C2.1.D_DSD	By Age: <15	100	Redacted
C2.1.D_DSD	By Age: 15+	900	Redacted
C2.1.D_DSD	Sum of Age disaggregates	1,000	Redacted
C2.1.D_DSD	By Sex: Female	650	Redacted
C2.1.D_DSD	By Sex: Male	350	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	1,000	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	50	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	50	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	600	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	300	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,000	Redacted
C2.1.D_NGI	By Age: <15	100	Redacted
C2.1.D_NGI	By Age: 15+	900	Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,000	Redacted
C2.1.D_NGI	By Sex: Female	650	Redacted
C2.1.D_NGI	By Sex: Male	350	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,000	Redacted
C2.4.D_DSD	Number of HIV-positive patients who	1,000	Redacted



	I i		1	1 1
	were screened for TB in HIV care or			
	treatment setting			
C2.4.D_DSD	Number of HIV-positive individuals			
	receiving a minimum of one clinical	1,000		Redacted
	service			
TX_CURR_DSD	Number of adults and children receiving	1,000	2,000	Redacted
	antiretroviral therapy (ART)			
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	50	100	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	300	600	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	50	100	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	600	1,200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	100	200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	900	1,800	Redacted
TV 01100 000	Sum of Aggregated Age/Sex	1,000	2,000	Redacted
TX_CURR_DSD	disaggregates			
TV OUDD NO	Number of adults and children receiving	1,000		Redacted
TX_CURR_NGI	antiretroviral therapy (ART)			
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	50		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	300		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	50		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	600		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex	1,000		Redacted
	disaggregates			
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	100		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	900		Redacted
TX_RET_DSD	Number of adults and children who are			
	still alive and on treatment at 12	800	1,600	Redacted
	months after initiating ART			
TX_RET_DSD	Total number of adults and children	1,000	2,000	
	who initiated ART in the 12 months			
	prior to the beginning of the reporting			Redacted
	period, including those who have died,			Noudoleu
	those who have stopped ART, and			
	those lost to follow-up			



LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	2	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1	2	Redacted

Mechanism ID: 16807	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 16775	Mechanism Name: Correctional Services		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Aurum Health Research			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 9,200,000	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	9,200,000			

Sub Partner Name(s)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,000,000
Key Populations: MSM and TG	55,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Gender: Gender Equality	45,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and



	productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and
	support
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16775		
Mechanism Name:	Correctional Services		
Prime Partner Name:	Aurum Health Research	1	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,102,980	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,207,932	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	121,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,167,719	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	120		Redacted



I	<u>, </u>		
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	25	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	95	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	25	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	95	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	25	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	95	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	25	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	95	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	25	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	95	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	20	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	75	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	25	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical	95	Redacted



	Assistance-only (TA)			
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	25		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	95		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	25		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	95		Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	25		Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	95		Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	6		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	571	0	Redacted
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	0	0	Redacted
VMMC_CIRC_DS D	By Age: 15-19	57	0	Redacted
VMMC_CIRC_DS	By Age: 20-24	248	0	Redacted



D				
VMMC_CIRC_DS D	By Age: 25-49	209	0	Redacted
VMMC_CIRC_DS D	By Age: 50+	57	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	571	0	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	571		Redacted
VMMC_CIRC_NGI	By Age: <1	0		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0		Redacted
VMMC_CIRC_NGI	By Age: 10-14	0		Redacted
VMMC_CIRC_NGI	By Age: 15-19	57		Redacted
VMMC_CIRC_NGI	By Age: 20-24	248		Redacted
VMMC_CIRC_NGI	By Age: 25-49	209		Redacted
VMMC_CIRC_NGI	By Age: 50+	57		Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	571		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	11,970	17,955	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,970	17,955	Redacted
KP_PREV_TA	Number of key populations reached	47,880	71,820	Redacted



	T		T	1
	with individual and/or small group level HIV preventive interventions that are			
	based on evidence and/or meet the minimum standards required			
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	47,880	71,820	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	750	1,125	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	300	450	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	450	675	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	750	1,125	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	750	1,125	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,200		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,800		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	3,000		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	3,000		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,250	3,375	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	900	1,350	Redacted



	Aggregated Age/sex - USE WITH HQ			
HTC_TST_TA	PERMISSION ONLY: 15+ Female	1,350	2,025	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,250	3,375	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,250	3,375	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,500		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	125		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	2,375		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	2,500		Redacted
C2.1.D_DSD	By Age: 15+	2,500		Redacted
C2.1.D_DSD	Sum of Age disaggregates	2,500		Redacted
C2.1.D_DSD	By Sex: Female	125		Redacted
C2.1.D_DSD	By Sex: Male	2,375		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	2,500		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	10,000		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	500		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	9,500		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	10,000		Redacted
C2.1.D_NGI	By Age: 15+	10,000		Redacted
C2.1.D_NGI	Sum of Age disaggregates	10,000		Redacted
C2.1.D_NGI	By Sex: Female	500		Redacted
C2.1.D_NGI	By Sex: Male	9,500		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	10,000		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	7,500		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	375		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	7,125		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	7,500		Redacted



C2.1.D_TA	By Age: 15+	7,500		Redacted
C2.1.D_TA	Sum of Age disaggregates	7,500		Redacted
C2.1.D_TA	By Sex: Female	375		Redacted
C2.1.D_TA	By Sex: Male	7,125		Redacted
C2.1.D_TA	Sum of Sex disaggregates	7,125		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	2,500		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,500		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,500	2,250	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,375	2,063	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	125	187	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,000		Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	5,500		Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	500		Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	6,000		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,500	6,750	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	4,125	6,188	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	375	562	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	600	900	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	60	90	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	150	225	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	330	495	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	30	45	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	3	5	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	6	9	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	18	27	Redacted



TX_NEW_DSD	By Age/Sex: 50+ Female	3	4	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	600	900	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	360	480	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	600	600	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	120	180	Redacted

Mechanism ID: 16773	Mechanism Name: South African National AIDS Council new agreement		
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreemen			
Prime Partner Name: South African National AIDS Council			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: TA			
G2G: Yes	Managing Agency: HHS/CDC		

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 806,257				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

Sub Partner Name(s)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Illioilli	Budget Code Information					
Mechanism ID:	Mechanism ID: 16773					
Mechanism Name:	South African National AIDS Council new agreement					
Prime Partner Name:	South African National	South African National AIDS Council				
Strategic Area	Budget Code Planned Amount On Hold Amount					
Governance and Systems	HVSI	0	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Governance and Systems	OHSS	0	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVCT	0	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVOP	0	0			

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16772	Mechanism Name: NDOH new agreement
---------------------	------------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: National Department of Health				
Agreement Start Date: Redacted Agreement End Date: Redacted				
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: PR/SR				
G2G: Yes	Managing Agency: HHS/CDC			

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 2,497,955				
FY 2013 Burn Rate: Redacted				
Funding Source Funding Amount				
GHP-State	0			

Sub Partner Name(s)

Johns Hopkins University	University of Pretoria, South Africa	
--------------------------	--------------------------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16772			
Mechanism Name:	NDOH new agreement			
Prime Partner Name:	National Department of Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	0	0	



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16759	Mechanism Name: UTAP 2/HQ PESS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman S	School of Public Health
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 160,167	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 365,796	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	160,167

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



Budget Code Information

Mechanism ID:	16759		
Mechanism Name:	UTAP 2/HQ PESS		
Prime Partner Name:	Columbia University Ma	ailman School of Public H	lealth
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	160,167	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

V V		
Mechanism ID: 16746	Mechanism Name: Central Mechanism Emory University	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Emory University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	o

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



Key Issues

(No data provided.)

Budget Code Information

Budget Code Illionii	alion		
Mechanism ID:	16746		
Mechanism Name:	Central Mechanism Em	ory University	
Prime Partner Name: Emory University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

mpromorming moonamen 2 came		
Mechanism ID: 16584	Mechanism Name: Comprehensive Facility Based Service	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Institute for Youth Developm	ent SA (IYDSA)	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 13,992,884	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,500,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	13,992,884



Sub Partner Name(s)

Africare	Sophumelela	Strategic Evaluation, Advisory & Development Consulting (Pty) Ltd
----------	-------------	---

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	358,458	
INDIDI VEHICIES. FUICHASEU	330,430	

Key Issues

(No data provided.)

Budget Code Information

Budget Code information						
Mechanism ID:	16584					
Mechanism Name:	Comprehensive Facility	Based Service				
Prime Partner Name:	Institute for Youth Deve	stitute for Youth Development SA (IYDSA)				
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	НВНС	488,509	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	HVTB	1,829,839	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	PDCS	141,942	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Governance and Systems	HLAB	331,193	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			



Governance and Systems	OHSS	331,193	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	929,604	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,119,045	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,821,559	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	91	65	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	339	279	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	91	65	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	339	279	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	91	65	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	339	279	Redacted



	B			
SITE_SUPP	By program area/support type: Food	91	65	Redacted
SITE_SUPP	and Nutrition Direct Service Delivery (DSD)	91	65	Redacted
	By program area/support type: Food			
SITE_SUPP	and Nutrition Technical Assistance-only	339	279	Redacted
3112_3011	(TA)	339	213	Redacted
	By program area/support type: PMTCT			
SITE_SUPP	Direct Service Delivery (DSD)	87	62	Redacted
	By program area/support type: PMTCT			
SITE_SUPP	Technical Assistance-only (TA)	334	275	Redacted
	By program area/support type: TB/HIV			
SITE_SUPP	Direct Service Delivery (DSD)	91	65	Redacted
	By program area/support type: TB/HIV			
SITE_SUPP	Technical Assistance-only (TA)	339	279	Redacted
	By program area/support type: General			
SITE_SUPP	Population Prevention Direct Service	91	65	Redacted
	Delivery (DSD)			
	By program area/support type: General			
SITE_SUPP	Population Prevention Technical	339	279	Redacted
	Assistance-only (TA)			
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	91	65	Redacted
	Direct Service Delivery (DSD)			
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	339	279	Redacted
	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Lab	430	368	Redacted
	Technical Assistance-only (TA)			
	Number of HIV-positive pregnant			
PMTCT_ARV_DS	women who received antiretrovirals to	7.055	7.004	D. L. C.
D	reduce risk of	7,655	7,091	Redacted
	mother-to-child-transmission (MTCT)			
DMTCT ADV DC	during pregnancy and delivery			
PMTCT_ARV_DS	Number of HIV- positive pregnant women identified in the reporting period	8,058	7,091	Redacted
D	women identified in the reporting period			



	(including known HIV-positive at entry)			
PMTCT_ARV_DS D	Life-long ART (including Option B+)	3,410	3,000	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,273	2,000	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,137	1,000	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	4,056	3,924	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	139	122	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	50	45	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	7,655	7,091	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	3,410	3,000	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	21,336	19,764	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	22,459	19,764	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	8,616	7,582	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5,744	5,054	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the	2,872	2,527	Redacted



	aumant programme			
	current pregnancy			
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	12,239	11,759	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	354	311	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	127	112	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	21,336	19,764	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	8,616	7,581	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	13,681	12,673	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	14,401	12,673	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	5,178	4,557	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,452	3,038	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,726	1,519	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	8,212	7,860	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	214	188	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	77	68	Redacted



PMTCT_ARV_TA	Sum of Regimen Type disaggregates	13,681	12,673	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	5,178	4,557	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	337	297	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	421	337	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	70	62	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	267	294	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	337	356	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	87	62	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	334	275	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	421	337	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	22,900	22,671	Redacted



	results)			
PMTCT_STAT_DS D	,	28,625	25,190	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	4,294	3,778	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	3,764	3,312	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	8,058	7,090	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,878	63,240	Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	79,848	87,832	Redacted
PMTCT_STAT_NG	By: Known positives at entry	11,977	9,582	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	10,482	9,224	Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	22,459	18,806	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,979	40,569	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	51,223	45,076	Redacted
PMTCT_STAT_TA	By: Known positives at entry	7,683	6,761	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	6,718	5,912	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	14,401	12,673	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	113,296	99,700	Redacted
HTC_TST_DSD	By Test Result: Negative	96,316		Redacted
HTC_TST_DSD	By Test Result: Positive	16,980		Redacted



	<u> </u>			
HTC_TST_DSD	Sum of Test Result disaggregates	113,296		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	355,830	313,130	Redacted
HTC_TST_NGI	By Test Result: Negative	317,438		Redacted
HTC_TST_NGI	By Test Result: Positive	38,392		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	355,830		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	242,534	213,427	Redacted
HTC_TST_TA	By Test Result: Negative	221,121		Redacted
HTC_TST_TA	By Test Result: Positive	21,413		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	242,534		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	64,463	61,885	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	306,967		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	242,504		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	64,463	61,885	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	64,463	61,885	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	12,157	11,670	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic	8,058	7,091	Redacted



	I			
	HIV test within 12 months of birth			
	during the reporting period			
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	8,058	7,091	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	8,058	7,091	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,058	7,091	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	91,912	80,882	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	15,571	18,685	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	291,252	256,302	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	199,340	175,419	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	41,180	36,238	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	430	344	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	430	344	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	430	344	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	412	330	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	412	330	Redacted



FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	87	62	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	325	268	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	412	330	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	87	62	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	325	268	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	412	330	Redacted
FPINT_SITE_DSD	Service delivery type: Community	0		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	412	330	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	412	330	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	12,157	11,670	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting	12,157	11,670	Redacted



period: clinical assessment (WHO		
staging) OR CD4 count OR viral load		

implementing Mechanism Betalis				
Mechanism ID: 16583	Mechanism Name: Comprehensive facility-based services			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Aurum Health Research				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 7,168,830	Sources: 7,168,830 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 7,032,126			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	7,168,830		

Sub Partner Name(s)

Foundat	ion for Professional	Strategic Evaluation, Advisory &
Develop	ment	Development Consulting (Pty) Ltd

Cross-Cutting Budget Attribution(s)

<u> </u>	· · · · · · · · · · · · · · · · · · ·
11 B b (1116	4 000 000
Human Resources for Health	1.000.000

Key Issues

Mobile Population

TB

End-of-Program Evaluation



Budget Code Information

Budget Code Inform	ation					
Mechanism ID:	16583					
Mechanism Name:	Comprehensive facility-based services					
Prime Partner Name:	Aurum Health Research	Aurum Health Research				
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	НВНС	249,753	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	HVTB	925,010	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	PDCS	96,484	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Governance and Systems	HLAB	185,002	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Governance and Systems	OHSS	231,253	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	MTCT	468,484	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Treatment	HTXS	4,064,708	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Treatment	PDTX	948,136	0			

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	475		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	475		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	475		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	475		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	475		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0		Redacted



	<u>, </u>		
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	475	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	22,573	Redacted



	T i			1
	mother-to-child-transmission (MTCT)			
	during pregnancy and delivery			
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	25,081		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	22,573		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	17,573		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	5,000		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	22,573		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	22,573		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	22,573	12,672	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	25,081	247,808	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	22,573	14,080	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	17,573	9,440	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	5,000	3,168	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	22,573	14,080	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	22,573	12,608	Redacted
PMTCT_STAT_NG	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	84,052		Redacted



	results)			
PMTCT_STAT_NG I	Number of new ANC and L&D clients	88,475		Redacted
PMTCT_STAT_NG	By: Known positives at entry	17,650		Redacted
PMTCT_STAT_NG	By: Number of new positives identified	11,768		Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	29,418		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	84,052	70,400	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	93,000	76,000	Redacted
PMTCT_STAT_TA	By: Known positives at entry	5,832	8,000	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	19,249	10,800	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	25,081	18,800	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	887,588		Redacted
HTC_TST_NGI	By Test Result: Negative	110,000		Redacted
HTC_TST_NGI	By Test Result: Positive	777,588		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	887,588		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	13,119		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	333,701		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	12,916		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	527,852		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	26,035		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	861,553		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	887,588		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their	887,588	497,048	Redacted



			<u> </u>	
	test results during the past 12 months			
HTC_TST_TA	By Test Result: Negative	110,000	61,600	Redacted
HTC_TST_TA	By Test Result: Positive	777,588	435,448	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	887,588	497,048	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,119	9,183	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,916	233,590	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	527,852	9,041	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	333,701	369,497	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	540,971	18,224	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	346,617	603,087	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	887,588	621,311	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	337,512		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	5,827		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	5,827		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	234,577		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	91,281		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	337,512		Redacted
C2.1.D_NGI	By Age: <15	11,654		Redacted
C2.1.D_NGI	By Age: 15+	325,858		Redacted
C2.1.D_NGI	Sum of Age disaggregates	337,512		Redacted
C2.1.D_NGI	By Sex: Female	240,405		Redacted
C2.1.D_NGI	By Sex: Male	97,107		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	337,512		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	337,512		Redacted



				T.
C2.1.D_TA	By Age/Sex: <15 Female	5,827		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	5,827		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	234,577		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	91,281		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	337,512		Redacted
C2.1.D_TA	By Age: <15	11,654		Redacted
C2.1.D_TA	By Age: 15+	325,858		Redacted
C2.1.D_TA	Sum of Age disaggregates	337,512		Redacted
C2.1.D_TA	By Sex: Female	240,405		Redacted
C2.1.D_TA	By Sex: Male	97,107		Redacted
C2.1.D_TA	Sum of Sex disaggregates	337,512		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	338,766		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	150		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	136		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	6,306		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	91,290		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	6,592		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	234,578		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	338,766		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	12,898		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	325,868		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	338,766	298,114	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	150	165	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	136	150	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	6,306	6,937	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	91,290	100,419	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	6,592	7,251	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	234,578	258,036	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	12,898	14,188	Redacted



TX_CURR_TA	Sum of Aggregated Age/Sex 15+	325,868	358,455	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex	338,766 372,643	272 642	Redacted
	disaggregates		372,643	

Mechanism ID: 16372	Mechanism Name: Voluntary Medical Male Circumcision Service Delivery II Project (VMMC II)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Right To Care, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 13,427,788	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 8,838,400			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	13,427,788		

Sub Partner Name(s)

Anova Health Institute	ICHAPS	Maternal, Adolscent and Child Health (MatCH)
Right to Care Health Services (Pty) Ltd		

Cross-Cutting Budget Attribution(s)

Gender: GBV	3,050	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic	
	Information	



Sub Area:	Implementation
Gender: Gender Equality	3,450
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Human Resources for Health	60,000
Condom programming	400,000

Key Issues

Military Population
Mobile Population
Workplace Programs
End-of-Program Evaluation
Family Planning

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Voluntary Medical Male Circumcision Service Delivery II Project (VMMC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	13,427,788	0



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	170	
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	170	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	175,000	192,403
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	40,041	44,023
VMMC_CIRC_DSD	By Age: 15-19	60,616	66,644
VMMC_CIRC_DSD	By Age: 20-24	34,048	37,434
VMMC_CIRC_DSD	By Age: 25-49	39,027	42,908
VMMC_CIRC_DSD	By Age: 50+	1,268	1,394
VMMC_CIRC_DSD	Sum of age disaggregates	175,000	192,403
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	175,000	
VMMC_CIRC_NGI	By Age: <1	0	
VMMC_CIRC_NGI	By Age: 1-9	0	
VMMC_CIRC_NGI	By Age: 10-14	40,041	
VMMC_CIRC_NGI	By Age: 15-19	60,616	
VMMC_CIRC_NGI	By Age: 20-24	34,048	
VMMC_CIRC_NGI	By Age: 25-49	39,027	
VMMC_CIRC_NGI	By Age: 50+	1,268	
VMMC_CIRC_NGI	Sum of Age disaggregates	175,000	
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients	3,650	



	(tested HIV positive at VMMC site)		
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program	118,025	
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	22,139	
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	175,000	
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	122,500	
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	52,500	

Mechanism ID: 14847	Mechanism Name: Partnership Information Management System (PIMS) Database Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,723,621	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation

Budget Code Information

Budget Code Illionia	ation			
Mechanism ID:	14847			
Mechanism Name:	Partnership Information Management System (PIMS) Database Project			
Prime Partner Name:	me: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	

Implementing Mechanism Indicator Information

(No data provided.)

	Mechanism Name: Strategic Information for	
Mechanism ID: 14846	Evidence-Based Management of HIV and	
	Related Health Program in South Africa	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of North Carolina at	Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,227,976	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 496,779		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	2,227,976	

ICF Macro	John Snow Inc (JSI)	Management Science for Health
The Futures Group International	Tulane University	

Cross-Cutting Budget Attribution(s)

Condom programming	49,511	

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Strategic Information for Evidence-Based Management of HIV and Related Health Program in South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	2,227,976	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

implementing wechanism betails	
	Mechanism Name: Tulane University - Compiling
Mechanism ID: 14667	Evidence Base for Orphans and Vulnerable
	Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Tulane University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 900,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Impact Research International	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation



Budget Code Information

Baagot ocac inform			
Mechanism ID:	Tulane University - Compiling Evidence Base for Orphans and		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

mpionionally moonament became			
Mechanism ID: 14631	Mechanism Name: Government Capacity Building and Support Mechanism		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: Pact, Inc.			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 8,960,939 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 4,539,061	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	8,960,939

Sub Partner Name(s)

Development & Training Services	Health and Development Africa	Isibani Development Partners
---------------------------------	-------------------------------	------------------------------



Cross-Cutting Budget Attribution(s)

Human Resources for Health	6,816,658
Gender: Gender Equality	100,566
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Motor Vehicles: Purchased	127,543

Key Issues

(No data provided.)

Budget Code Information

Baaget Gode Illioning	ation		
Mechanism ID:	14631		
Mechanism Name:	Government Capacity Building and Support Mechanism		
Prime Partner Name:	Pact, Inc.		
Strategic Area	Budget Code Planned Amount On Hold Amount		On Hold Amount
Care	HKID	8,960,939	0

Indicator Number	Label	2014	2015
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	300,000	
OVC_SERV_TA	Sex: Male	150,000	
OVC_SERV_TA	Sex: Female	150,000	
OVC_SERV_TA	Sum of Sex disaggregates	300,000	
OVC_SERV_TA	Age: <1	10,000	
OVC_SERV_TA	Age: 1-4	20,000	
OVC_SERV_TA	Age: 5-9	40,000	
OVC_SERV_TA	Age: 10-14	100,000	
OVC_SERV_TA	Age: 15-17	100,000	



OVC_SERV_TA	Age: 18+	30,000	
OVC_SERV_TA	Sum of Age disaggregates	300,000	

mpromorming moontainem zettane		
Mechanism ID: 14623	Mechanism Name: Increasing Services to Survivors of Sexual Assault	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Professional Development		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,315,989	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	o

Sub Partner Name(s)

|--|

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



	14623 Increasing Services to Survivors of Sexual Assault Foundation for Professional Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Indicator Number	Label	2014	2015
GEND_GBV_DSD	Number of people receiving post-GBV care	2,800	2,100
GEND_GBV_DSD	Age: 0-9	600	450
GEND_GBV_DSD	Age: 10-14	500	375
GEND_GBV_DSD	Age: 15-17	500	375
GEND_GBV_DSD	Age: 18-24	600	450
GEND_GBV_DSD	Age: 25+	600	450
GEND_GBV_DSD	Sum of Age disaggregates	2,800	2,100
GEND_GBV_DSD	Sex: Male	500	375
GEND_GBV_DSD	Sex: Female	2,300	1,725
GEND_GBV_DSD	Sum of Sex disaggregates	2,800	2,100
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,000	750
GEND_GBV_DSD			450



	(Post-Rape Care)		
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	600	450
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	70,000	52,500
GEND_NORM_DSD	By Age: 0-9	10,000	7,500
GEND_NORM_DSD	By Age: 10-14	15,000	11,250
GEND_NORM_DSD	By Age: 15-19	15,000	11,250
GEND_NORM_DSD	By Age: 20-24	20,000	15,000
GEND_NORM_DSD	By Age: 25+	10,000	7,500
GEND_NORM_DSD	Sum of Age disaggregates	70,000	52,500
GEND_NORM_DSD	By Sex: Male	28,000	21,000
GEND_NORM_DSD	By Sex: Female	42,000	31,500
GEND_NORM_DSD	Sum of Sex disaggregates	70,000	52,500
GEND_NORM_DSD	By type of activity: Individual	12,000	9,000
GEND_NORM_DSD	By type of activity: Small Group	18,000	13,500
GEND_NORM_DSD	By type of activity: Community-level	30,000	22,500

p.:			
Mechanism Name: Systems for Improve			
Mechanism ID: 14617	Access to Pharmaceuticals and Services		
	Program (SIAPS)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Management Sciences for Health			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No Managing Agency:			

Total All Funding Sources: 1,423,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 4,269,814	
FY 2013 Burn Rate: Redacted	



Funding Source	Funding Amount
GHP-State	1,423,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

	\ /	_
Human Resources for Health	223,576	

Key Issues

ТВ

Budget Code Information

Mechanism ID: Mechanism Name:	Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	227,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	295,092	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	900,278	0



Implementing Mechanism Indicator Information

Indicator Number	cator Number Label		2015
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	125	230
HRH_PRE	By Graduates: Other	125	230
HRH_PRE	Sum of Graduates disaggreagtes	125	230
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	51	116

Implementing Mechanism Details

mpionioning moonament betane			
Mechanism ID: 14616	Mechanism Name: Sexual HIV Prevention Program (SHIPP)		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: Futures Group			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 4,250,000 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 4,608,822			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	4,250,000		

Sub Partner Name(s)

CADRE Engender Health Futures Institute	
---	--



Cross-Cutting Budget Attribution(s)

<u> </u>	
Education	644,828
Gender: GBV	175,862
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	263,793
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	146,552

Key Issues

(No data provided.)

Budget Code Information

budget Code information				
Mechanism ID:	4616			
Mechanism Name:	Sexual HIV Prevention Program (SHIPP)			
Prime Partner Name:	Futures Group	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVAB	1,900,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	2,350,000	0	



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	70	
By program area/support type: General SITE_SUPP Population Prevention Technical Assistance-only (TA)		70	

Mechanism ID: 14450	Mechanism Name: Society for Family Health / Population Services Interantional			
Funding Agency: DOD Procurement Type: Grant				
Prime Partner Name: Society for Family Health - South Africa				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
BD: No New Mechanism: No				
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
applied Pipeline Amount: 600,000		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	o	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Military Population



Workplace Programs

Budget Code Information

Budget Code Information				
Mechanism ID:	ism ID: 14450			
Mechanism Name:	Society for Family Health / Population Services Interantional			
Prime Partner Name:	Society for Family Healt	th - South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	CIRC	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	3	5
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	128	256
VMMC_AE_DSD	By AE type: Number of VMMC clients with	64	128



<u> </u>	<u> </u>		
	one or more moderate or severe surgical		
	intra-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	32	64
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	32	64
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	64	128
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	32	64
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	64	96
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,200	6,400
VMMC_CIRC_DSD	By Age: 15-19	1,000	2,000
VMMC_CIRC_DSD	By Age: 20-24	1,500	3,000
VMMC_CIRC_DSD	By Age: 25-49	650	1,300
VMMC_CIRC_DSD	By Age: 50+	50	100
VMMC_CIRC_DSD	Sum of age disaggregates	3,200	6,400
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	3,200	6,400



Mechanism ID: 14295	Mechanism Name: Capacity Development and Support Program	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,850,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 5,150,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,850,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	193,327
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	193,327
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	161,106

Key Issues

Safe Motherhood

Budget Code Information

Budget Code Information			
Mechanism ID:	Mechanism ID: 14295		
Mechanism Name:	Name: Capacity Development and Support Program		
Prime Partner Name:			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	950,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,000	6,298
PP_PREV_DSD	Age/sex: 10-14 Male	1,250	1,312
PP_PREV_DSD	Age/sex: 15-19 Male	1,250	1,312
PP_PREV_DSD	Age/sex: 20-24 Male	500	525
PP_PREV_DSD	Age/sex: 10-14 Female	1,250	1,312
PP_PREV_DSD	Age/sex: 15-19 Female	1,250	1,312
PP_PREV_DSD	Age/sex: 20-24 Female	500	525
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,000	6,298
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,000	6,298
PP_PREV_TA	Age/sex: 15-19 Male	1,250	1,312
PP_PREV_TA	Age/sex: 20-24 Male	1,250	1,312
PP_PREV_TA	Age/sex: 25-49 Male	500	525
PP_PREV_TA	Age/sex: 15-19 Female	1,250	1,312
PP_PREV_TA	Age/sex: 20-24 Female	1,250	1,312
PP_PREV_TA	Age/sex: 25-49 Female	500	525
PP_PREV_TA	Sum of Age/Sex disaggregates	6,000	6,298

Mechanism ID: 14294	Mechanism Name: DSD - Children"s Services Directory
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: University Research South Africa		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
pplied Pipeline Amount: 1,285,387		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Daagot Godo IIII oi III			
Mechanism ID:	14294		
Mechanism Name:	DSD - Children"s Services Directory		
Prime Partner Name:	University Research So	uth Africa	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14291	Mechanism Name: Care and Support to Improve Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Hospice and Palliative Care Assn. Of South Africa		
Agreement Start Date: Redacted	dacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,488,023	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,461,977	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,488,023

Sub Partner Name(s)

Family Health International (FHI)	Foundation for Professional	
anny riealth international (1111)	Development	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	971,587
Education	615,672
Water	22,548
Gender: Gender Equality	117,894
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Capacity building
Condom programming	11,064

Key Issues

End-of-Program Evaluation Family Planning

Budget Code Information

Budget Code Inform				
Mechanism ID:				
Mechanism Name:	Care and Support to Im	Care and Support to Improve Patient Outcomes		
Prime Partner Name:	Hospice and Palliative (Care Assn. Of South Afric	a	
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amount		
Care	НВНС	1,890,870	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	252,550	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	344,603	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	0	0	

Indicator Number	Label	2014	2015
SITE SUPP	Number of unique sites supported by	40	
SITE_SUFF	PEPFAR	40	



	· ·		
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	40	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	20	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	450	
C2.1.D_DSD	By Age/Sex: <15 Female	100	
C2.1.D_DSD	By Age/Sex: <15 Male	50	
C2.1.D_DSD	By Age/Sex: 15+ Female	200	
C2.1.D_DSD	By Age/Sex: 15+ Male	100	
C2.1.D_DSD	Sum of Age/Sex disaggregates	450	
C2.1.D_DSD	By Age: <15	150	
C2.1.D_DSD	By Age: 15+	300	
C2.1.D_DSD	Sum of Age disaggregates	450	
C2.1.D_DSD	By Sex: Female	300	
C2.1.D_DSD	By Sex: Male	150	
C2.1.D_DSD	Sum of Sex disaggregates	450	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	5,450	
C2.1.D_NGI	By Age/Sex: <15 Female	1,100	
C2.1.D_NGI	By Age/Sex: <15 Male	750	
C2.1.D_NGI	By Age/Sex: 15+ Female	2,200	
C2.1.D_NGI	By Age/Sex: 15+ Male	1,400	
C2.1.D_NGI	Sum of Age/Sex disaggregates	5,450	
C2.1.D_NGI	By Age: <15	1,850	
C2.1.D_NGI	By Age: 15+	3,600	
C2.1.D_NGI	Sum of Age disaggregates	5,450	
C2.1.D_NGI	By Sex: Female	3,300	
C2.1.D_NGI	By Sex: Male	2,150	
C2.1.D_NGI	Sum of Sex disaggregates	5,450	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	5,000	



C2.1.D_TA	By Age/Sex: <15 Female	1,000
C2.1.D_TA	By Age/Sex: <15 Male	700
C2.1.D_TA	By Age/Sex: 15+ Female	2,000
C2.1.D_TA	By Age/Sex: 15+ Male	1,300
C2.1.D_TA	Sum of Age/Sex disaggregates	5,000
C2.1.D_TA	By Age: <15	1,700
C2.1.D_TA	By Age: 15+	3,300
C2.1.D_TA	Sum of Age disaggregates	5,000
C2.1.D_TA	By Sex: Female	3,000
C2.1.D_TA	By Sex: Male	2,000
C2.1.D_TA	Sum of Sex disaggregates	5,000
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	15,000
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	450

Mechanism ID: 14126	Mechanism Name: GH11-1151 MARPs	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: South Africa Partners		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 324,412	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 200,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	324,412

Sub Partner Name(s)



Health Information Systems	
Program	

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	17,000
Condom programming	30,000

Key Issues

ТВ

Budget Code Information

Budget Code Illionia	ation		
Mechanism ID:	14126		
Mechanism Name:	GH11-1151 MARPs		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	274,412	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	2		Redacted



SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	2		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,950	2,600	Redacted
PP_PREV_DSD	Total number of people in the target population	3,690	3,690	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	350	300	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	800	900	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,700	1,200	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	100	200	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,950	2,600	Redacted

Mechanism ID: 13938	Mechanism Name: Catholic Medical Mission Board			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Catholic Medical Mission Board				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No New Mechanism: No				
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	



FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

ΤB

Workplace Programs

Budget Code Information

Duaget Code Illioning	20011		
Mechanism ID:	13938		
Mechanism Name:	Catholic Medical Missio	n Board	
Prime Partner Name:	Catholic Medical Missio	n Board	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	22	28	Redacted



T				
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	22	22	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	6	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	22	22	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	6	Redacted



	T i			1
SITE_SUPP	By program area/support type: General Population Prevention Direct Service	0	0	Redacted
	Delivery (DSD)			
	By program area/support type: General			
SITE_SUPP	Population Prevention Technical	0	0	Redacted
	Assistance-only (TA)			
	By program area/support type: Key			
SITE_SUPP	Populations Prevention Direct Service	0	0	Redacted
	Delivery (DSD)			
	By program area/support type: Key			
SITE_SUPP	Populations Prevention Technical	0	0	Redacted
	Assistance-only (TA)			
	By program area/support type: OVC			
SITE_SUPP	Direct Service Delivery (DSD)	0	0	Redacted
	By program area/support type: OVC			
SITE_SUPP	Technical Assistance-only (TA)	0	0	Redacted
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	0	0	Redacted
	Direct Service Delivery (DSD)	ŭ		
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	0	0	Redacted
0.1.2_0011	Technical Assistance-only (TA)	-		Neuduleu
	By program area/support type: Lab			
SITE_SUPP	Direct Service Delivery (DSD)	0	0	Redacted
	By program area/support type: Lab			
SITE_SUPP	Technical Assistance-only (TA)	0	0	Redacted
	Number of males circumcised surgically or by medical device that experienced			
VMMC_AE_DSD	at least one moderate or severe	110		Redacted
	adverse event(s) (AEs)			
VMMAC AT DOD	By AE type: Number of VMMC clients	20		Dodostad
VMMC_AE_DSD	with one or more moderate or severe	30		Redacted
	surgical intra-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative	20		Redacted
·	AE(s) by maximum severity category:			



	Number of clients with one or more			
	moderate surgical intra-operative			
	AE(s), but no severe surgical			
	intra-operative AE(s)			
	Sub-Disag: Surgical intra-operative			
VMMC AE DSD	AE(s) by maximum severity category:	10		Redacted
VIVIIVIC_AE_DSD	Number of clients with one or more	10		Redacted
	severe surgical intra-operative AE(s)			
	By AE Type: Number of VMMC clients			
VMMC_AE_DSD	with one or more moderate or severe	80		Redacted
	surgical post-operative AE(s)			
	Sub-Disag: By Surgical post-operative			
	AE(s) by maximum severity category:			
\/A440 AE DOD	Number of clients with one or more	0.5		5
VMMC_AE_DSD	moderate surgical post-operative AE(s),	65		Redacted
	but no severe surgical post-operative			
	AE(s)			
	Sub-Disag: By Surgical post-operative			
\/A440 AE DOD	AE(s) by maximum severity category:	4-5		5
VMMC_AE_DSD	Number of clients with one or more	15		Redacted
	severe surgical intra-operative AE(s)			
	By AE Type: Number of VMMC clients			
VMMC_AE_DSD	with one or more moderate or severe	0		Redacted
	medical device-related AE(s)			
	Sub-Disag: By Medical device-based			
	AE(s) by maximum severity category:			
\/AB40_4E_B0B	Number of clients with one or more	•		5
VMMC_AE_DSD	moderate medical device-related AE(s),	0		Redacted
	but no severe medical device-related			
	AE(s)			
	Sub-Disag: By Medical device-based			
VMMC_AE_DSD	AE(s) by maximum severity category:	0		Dodestad
	Number of clients with one or more	0		Redacted
	severe medical device-related AE(s)			
VMMC_CIRC_DS	Number of males circumcised as part of	3,000	4,020	Redacted



D	the voluntary medical male circumcision (VMMC) for HIV			
	prevention program within the reporting period			
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	300	400	Redacted
VMMC_CIRC_DS D	By Age: 15-19	900	1,300	Redacted
VMMC_CIRC_DS D	By Age: 20-24	900	1,300	Redacted
VMMC_CIRC_DS D	By Age: 25-49	880	1,000	Redacted
VMMC_CIRC_DS D	By Age: 50+	20	20	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	3,000	4,020	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	100	120	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	2,800	3,800	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	100	100	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	3,000	4,020	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_DS	By follow-up status: Number of	2,500	3,417	Redacted



		T		
D	surgically circumcised clients who			
	returned at least once for follow-up care			
	within 14 days of circumcision surgery			
	By follow-up status: Number of			
VMMC_CIRC_DS	surgically circumcised clients who did	500	603	Redacted
D	NOT return for follow-up care within 14			
	days of circumcision surgery			
	Number of males circumcised as part of			
	the voluntary medical male			
VMMC_CIRC_NGI	, ,	3,000		Redacted
	prevention program within the reporting			
	period			
VMMC_CIRC_NGI	By Age: <1	0		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0		Redacted
VMMC_CIRC_NGI	By Age: 10-14	300		Redacted
VMMC_CIRC_NGI	By Age: 15-19	900		Redacted
VMMC_CIRC_NGI	By Age: 20-24	900		Redacted
VMMC_CIRC_NGI	By Age: 25-49	880		Redacted
VMMC_CIRC_NGI	By Age: 50+	20		Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	3,000		Redacted
	By HIV status: Number of HIV-positive			
VMMC_CIRC_NGI	clients (tested HIV positive at VMMC	100		Redacted
	site)			
	By HIV status: Number of HIV-negative			
VMMC_CIRC_NGI	clients (tested HIV negative at VMMC	2,800		Redacted
	program			
	By HIV status: Number of clients with			
VMMC_CIRC_NGI	undocumented/indeterminate HIV	100		Redacted
	status or not tested for HIV at site			
VMMC_CIRC_NGI	By circumcision technique: Surgical	0.055		Destant
	VMMC	3,000		Redacted
VMMC_CIRC_NGI	By circumcision technique:			Dodostod
	Device-based VMMC	0		Redacted
VMMC_CIRC_NGI	By follow-up status: Number of	2,500		Redacted



	T i	1		<u> </u>
	surgically circumcised clients who			
	returned at least once for follow-up care			
	within 14 days of circumcision surgery			
VMMC_CIRC_NGI	By follow-up status: Number of			
	surgically circumcised clients who did	500		Redacted
	NOT return for follow-up care within 14			11000000
	days of circumcision surgery			
	Number of males circumcised as part of			
	the voluntary medical male			
VMMC_CIRC_TA	circumcision (VMMC) for HIV	0	1,600	Redacted
	prevention program within the reporting			
	period			
VMMC_CIRC_TA	By Age: <1	0	0	Redacted
VMMC_CIRC_TA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_TA	By Age: 10-14	0	400	Redacted
VMMC_CIRC_TA	By Age: 15-19	0	300	Redacted
VMMC_CIRC_TA	By Age: 20-24	0	300	Redacted
VMMC_CIRC_TA	By Age: 25-49	0	600	Redacted
VMMC_CIRC_TA	By Age: 50+	0	0	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0	1,600	Redacted
	By HIV status: Number of HIV-positive			
VMMC_CIRC_TA	clients (tested HIV positive at VMMC	0	80	Redacted
	site)			
	By HIV status: Number of HIV-negative			
VMMC_CIRC_TA	clients (tested HIV negative at VMMC	0	1,400	Redacted
	program			
	By HIV status: Number of clients with			
VMMC_CIRC_TA	undocumented/indeterminate HIV	0	120	Redacted
	status or not tested for HIV at site			
VAANAO OIDO TA	By circumcision technique: Surgical		1.000	Dodestad
VMMC_CIRC_TA	VMMC	0	1,600	Redacted
VMMC_CIRC_TA	By circumcision technique:	0	0 0	Redacted
	Device-based VMMC	U		
VMMC_CIRC_TA	By follow-up status: Number of	0	1,360	Redacted



	l i			1
	surgically circumcised clients who			
	returned at least once for follow-up care			
	within 14 days of circumcision surgery			
	By follow-up status: Number of			
VMMC_CIRC_TA	surgically circumcised clients who did	0	240	Redacted
	NOT return for follow-up care within 14			
	days of circumcision surgery Number of individuals who received			
HTC_TST_DSD	T&C services for HIV and received their	3,400	5,120	Redacted
1110_131_030	test results during the past 12 months	3,400	3,120	Nedacied
HTC_TST_DSD	By Test Result: Negative	3,100	4,700	Redacted
HTC_TST_DSD	By Test Result: Positive	300	420	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	3,400	5,120	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	300	400	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	600	1,500	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,000	1,800	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,250	1,200	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	50	20	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	100	100	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	100	100	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,400	5,120	Redacted
	Number of individuals who received			
HTC_TST_NGI	T&C services for HIV and received their	3,400		Redacted
	test results during the past 12 months			



	-		
HTC_TST_NGI	By Test Result: Negative	3,100	Redacted
HTC_TST_NGI	By Test Result: Positive	300	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	3,400	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	300	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	600	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	1,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,250	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	50	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	100	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	100	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	3,400	Redacted

Mechanism ID: 13923	Mechanism Name: NEPI	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 600,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	



Funding Source	Funding Amount
GHP-State	600,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	210,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	13923 NEPI International Center for AIDS Care and Treatment Programs. Columbia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	600,000	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or	150	150	Redacted



	program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre			
HRH_PRE	By Graduates: Nurses	50	50	Redacted
HRH_PRE	By Graduates: Midwives	100	100	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	150	150	Redacted

Mechanism ID: 13904	Mechanism Name: Tuberculosis Care Association - 1151		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: TB/HIV Care			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No New Mechanism: No			
Global Fund / Multilateral Engagement: PR/SR			
G2G: No	Managing Agency:		

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 1,810,000			
FY 2013 Burn Rate: Redacted			
Funding Source Funding Amount			
GHP-State	0		

Sub Partner Name(s)

		i I
Lifeline - Durban		SWEAT
Lifeline - Durban	OUT LGBT	OVVLAI

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mobile Population
Safe Motherhood
TB
Workplace Programs
Family Planning

Budget Code Information

budget code illiornation				
Mechanism ID:	13904			
Mechanism Name:	Tuberculosis Care Association - 1151			
Prime Partner Name:	TB/HIV Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	20		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	20		Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	120	240	Redacted
KP_PREV_DSD	Number of key populations reached	6,200	9,750	Redacted



	with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,200	5,750	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,550	3,100	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	450	900	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset	0	0	Redacted



T	1		
SM/TG) (Numerator: Number of key			
populations reached with individual			
d/or small group level HIV preventive			
interventions that are based on			
evidence and/or meet the minimum			
standards required)			
Number of individuals who received			
C services for HIV and received their	5,000	6,500	Redacted
est results during the past 12 months			
ggregated Age/sex - USE WITH HQ	705	050	Dadaatad
PERMISSION ONLY: 15+ Male	725	950	Redacted
ggregated Age/sex - USE WITH HQ	4.075	5 550	Redacted
PERMISSION ONLY: 15+ Female	4,275	5,550	
Sum of Aggregated Age/Sex 15+	5,000	6,500	Redacted
Sum of Aggregated Age/Sex	5.000	6,500	Redacted
disaggregates	5,000		
Number of individuals who received			
C services for HIV and received their	6,000		Redacted
est results during the past 12 months			
Aggregated Age/sex: <15 Male	725		Redacted
Aggregated Age/sex: <15 Female	5,275		Redacted
Sum of Aggregated Age/Sex <15	6,000		Redacted
Sum of Aggregated Age/Sex	0.000		Dadastad
disaggregates	6,000		Redacted
umber of PEPFAR-supported testing			
facilities with capacity to perform	6	6	Redacted
clinical laboratory tests			
By Point-of-care testing sites	6	6	Redacted
Number of HIV positive adults and			
hildren who received at least one of			
the following during the reporting	0	0	Redacted
period: clinical assessment (WHO			
taging) OR CD4 count OR viral load			
	copulations reached with individual d/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) Jumber of individuals who received C services for HIV and received their st results during the past 12 months ggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male ggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates Jumber of individuals who received C services for HIV and received their st results during the past 12 months Aggregated Age/sex: <15 Male Aggregated Age/sex: <15 Female Sum of Aggregated Age/sex: <15 Female Sum of Aggregated Age/sex <15 Sum of Aggregated Age/Sex disaggregates Jumber of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests By Point-of-care testing sites Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO)	populations reached with individual d/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) Jumber of individuals who received C services for HIV and received their st results during the past 12 months aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female Sum of Aggregated Age/Sex disaggregates Jumber of individuals who received C services for HIV and received their st results during the past 12 months Aggregated Age/sex: <15 Male 725 Aggregated Age/sex: <15 Male 725 Aggregated Age/sex: <15 Male 725 Sum of Aggregated Age/Sex <15 6,000 Sum of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests By Point-of-care testing sites 6 Number of HIV positive adults and hildren who received at least one of the following during the reporting period: clinical assessment (WHO)	populations reached with individual d/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) Jumber of individuals who received C services for HIV and received their st results during the past 12 months gargegated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male gargegated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female Sum of Aggregated Age/Sex 15+ 5,000 6,500 Sum of Aggregated Age/Sex disaggregates Jumber of individuals who received C services for HIV and received their st results during the past 12 months Aggregated Age/sex: <15 Male 725 Aggregated Age/sex: <15 Male 725 Sum of Aggregated Age/Sex 415 Sum of Aggregated Age/Sex <15 6,000 Sum of Aggregated Age/Sex <15 6,000 Sum of Aggregated Age/Sex <15 6,000 Sum of Aggregated Age/Sex <16 6,000 Sum of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests By Point-of-care testing sites 6 6 Number of HIV positive adults and mildren who received at least one of the following during the reporting period: clinical assessment (WHO)



Mechanism ID: 13903	Mechanism Name: Community Media Trust	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Community Media Trust		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 676,554		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood

ТВ

Family Planning

Budget Code Information

Daugot Godo information		
Mechanism ID:	13903	
Mechanism Name:	Community Media Trust	
Prime Partner Name:	Community Media Trust	



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

<u> </u>		
Mechanism ID: 13902	Mechanism Name: HSRC	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Human Sciences Research Council		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,490,289		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



(No data provided.)

Budget Code Information

Duaget Code Illionii	ation			
Mechanism ID:	13902			
Mechanism Name:	HSRC			
Prime Partner Name: Human Sciences Research Council				
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

mplementing meenament became		
Mechanism ID: 13888	Mechanism Name: Population Services International	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 3,004,752		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	



Sub Partner Name(s)

	Training Institute for Primary	
Mosamaria AIDS Ministry	Health Care	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Information					
Mechanism ID:					
Mechanism Name:	Population Services Interest	ernational			
Prime Partner Name:	Population Services Interest	ernational			
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and					
Systems	HLAB	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVAB	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVCT	0	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVOP	0	0		



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	47	40	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	37	30	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	10	10	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	7	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	75,000	65,000	Redacted
HTC_TST_DSD	By Test Result: Negative	69,000	61,750	Redacted
HTC_TST_DSD	By Test Result: Positive	6,000	3,250	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	75,000	65,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,200	1,000	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,350	1,200	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	975	800	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,675	3,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	6,450	6,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	16,050	15,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,150	3,000	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,350	1,000	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,500	1,200	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,350	1,200	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,375	6,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,450	8,000	Redacted



	T		I	1
HTC_TST_DSD	Age/sex: 25-49 Female	17,775	15,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,350	2,600	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	75,000	65,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,000	9,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	27,000	20,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	10,000	10,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	30,000	26,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18,000	19,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	57,000	46,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	75,000	65,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	100,000	92,000	Redacted
HTC_TST_NGI	By Test Result: Negative	91,500	87,400	Redacted
HTC_TST_NGI	By Test Result: Positive	8,500	4,600	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	100,000	92,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	0		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	0		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	0		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted



				1
HTC_TST_NGI	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	0	0	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,000	27,500	Redacted
HTC_TST_TA	By Test Result: Negative	22,500	24,750	Redacted
	By Test Result: Positive	2,500	2,750	Redacted
HTC_TST_TA		·	·	
HTC_TST_TA	Sum of Test Result disaggregates	25,000	27,500	Redacted
HTC_TST_TA	Age/sex: <1 Male	1,000	1,100	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	500	550	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	500	550	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	500	550	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,000	1,100	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	1,000	1,100	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	750	825	Redacted
HTC_TST_TA	Age/sex: 50+ Male	1,000	1,100	Redacted
HTC_TST_TA	Age/sex: <1 Female	1,000	1,100	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	500	550	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	500	550	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	500	550	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	4,000	4,400	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	5,000	5,500	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	6,250	6,875	Redacted
HTC_TST_TA	Age/sex: 50+ Female	1,000	1,100	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	25,000	27,500	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,500	2,750	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,750	4,125	Redacted



HTC_TST_TA					ì
HIC_TST_TA	HTC_TST_TA		2,500	2,750	Redacted
HTC_TST_TA Sum of Aggregated Age/Sex 15+ 20,000 22,000 Redacted HTC_TST_TA Sum of Aggregated Age/Sex disaggregates 25,000 27,500 Redacted GEND_GBV_DSD Number of people receiving post-GBV care 200 200 Redacted GEND_GBV_DSD Age: 0-9 10 10 Redacted GEND_GBV_DSD Age: 10-14 10 10 Redacted GEND_GBV_DSD Age: 15-17 20 20 Redacted GEND_GBV_DSD Age: 18-24 60 60 Redacted GEND_GBV_DSD Age: 25+ 100 100 Redacted GEND_GBV_DSD Sum of Age disaggregates 200 200 Redacted GEND_GBV_DSD Sex: Male 0 0 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV 190 200	HTC_TST_TA		16,250	17,875	Redacted
HTC_TST_TA	HTC_TST_TA	Sum of Aggregated Age/Sex <15	5,000	5,500	Redacted
HTC_ISI_IA disaggregates 25,000 27,500 Redacted Description of people receiving post-GBV care Description of people receiving post-GBV care Description of people receiving post-GBV care 200 200 Redacted Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Description of people receiving post-GBV care 200 200 Redacted Care Care By type of service: Sexual Violence (Post-Rape Care) Description of people received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS Description of people received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS Description of people received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS Description of people received at least one of the foll	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	20,000	22,000	Redacted
GEND_GBV_DSD Care 200 200 Redacted GEND_GBV_DSD Age: 0-9 10 10 Redacted GEND_GBV_DSD Age: 10-14 10 10 Redacted GEND_GBV_DSD Age: 15-17 20 20 Redacted GEND_GBV_DSD Age: 18-24 60 60 Redacted GEND_GBV_DSD Age: 25+ 100 100 Redacted GEND_GBV_DSD Sum of Age disaggregates 200 200 Redacted GEND_GBV_DSD Sex: Male 0 0 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD Emotional Violence (Other Post-GBV Care) 190 200 Redacted GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 10 10 Redacted GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 0 0 Redacted	HTC_TST_TA		25,000	27,500	Redacted
GEND_GBV_DSD Age: 10-14 10 10 Redacted GEND_GBV_DSD Age: 15-17 20 20 Redacted GEND_GBV_DSD Age: 18-24 60 60 Redacted GEND_GBV_DSD Age: 25+ 100 100 Redacted GEND_GBV_DSD Sum of Age disaggregates 200 200 Redacted GEND_GBV_DSD Sex: Male 0 0 Redacted GEND_GBV_DSD Sex: Female 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV 190 200 Redacted GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 10 10 Redacted GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 0 0 Redacted CARE_CURR_DS Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 6,000	GEND_GBV_DSD		200	200	Redacted
GEND_GBV_DSD Age: 15-17 20 20 Redacted GEND_GBV_DSD Age: 18-24 60 60 Redacted GEND_GBV_DSD Age: 25+ 100 100 Redacted GEND_GBV_DSD Sum of Age disaggregates 200 200 Redacted GEND_GBV_DSD Sex: Male 0 0 Redacted GEND_GBV_DSD Sex: Female 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted By type of service: Physical and/or GEND_GBV_DSD Redacted 190 200 Redacted GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 10 10 Redacted GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 0 0 Redacted CARE_CURR_DS Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 6,000 6,000 Redacted CARE_CURR_DS Age/sex: <1 Male	GEND_GBV_DSD	Age: 0-9	10	10	Redacted
GEND_GBV_DSD Age: 18-24 60 60 Redacted GEND_GBV_DSD Age: 25+ 100 100 Redacted GEND_GBV_DSD Sum of Age disaggregates 200 200 Redacted GEND_GBV_DSD Sex: Male 0 0 Redacted GEND_GBV_DSD Sex: Female 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 190 200 Redacted GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 10 10 Redacted GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 0 0 Redacted CARE_CURR_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 6,000 6,000 Redacted CARE_CURR_DSD Age/sex: <1 Male	GEND_GBV_DSD	Age: 10-14	10	10	Redacted
GEND_GBV_DSD	GEND_GBV_DSD	Age: 15-17	20	20	Redacted
GEND_GBV_DSD Sum of Age disaggregates 200 200 Redacted GEND_GBV_DSD Sex: Male 0 0 0 Redacted GEND_GBV_DSD Sex: Female 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted By type of service: Physical and/or Emotional Violence (Other Post-GBV 190 200 Redacted Care) GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 10 10 Redacted Post-Rape Care) GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 0 0 Redacted CARE_CURR_DS D Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS D Age/sex: <1 Male 0 0 Redacted	GEND_GBV_DSD	Age: 18-24	60	60	Redacted
GEND_GBV_DSD Sex: Male 0 0 0 Redacted GEND_GBV_DSD Sex: Female 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted By type of service: Physical and/or GEND_GBV_DSD Emotional Violence (Other Post-GBV Care) GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) CARE_CURR_DS D Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS D Age/sex: <1 Male 0 0 0 Redacted	GEND_GBV_DSD	Age: 25+	100	100	Redacted
GEND_GBV_DSD Sex: Female 200 200 Redacted GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted By type of service: Physical and/or GEND_GBV_DSD Emotional Violence (Other Post-GBV Care) GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) CARE_CURR_DS D Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS D Age/sex: <1 Male 0 0 0 Redacted	GEND_GBV_DSD	Sum of Age disaggregates	200	200	Redacted
GEND_GBV_DSD Sum of Sex disaggregates 200 200 Redacted By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 190 200 Redacted GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 10 10 Redacted GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 0 0 Redacted CARE_CURR_DS D Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 6,000 6,000 Redacted CARE_CURR_DS D Age/sex: <1 Male	GEND_GBV_DSD	Sex: Male	0	0	Redacted
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) By type of service: Sexual Violence (Post-GBV Care) By type of service: Sexual Violence (Post-Rape Care) By PEP service provision (related to sexual violence services provided) Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS D By type of service: Physical and/or 190 200 Redacted 0 Redacted 6,000 6,000 Redacted	GEND_GBV_DSD	Sex: Female	200	200	Redacted
GEND_GBV_DSD Emotional Violence (Other Post-GBV Care) GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) CARE_CURR_DS D Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS D Age/sex: <1 Male 0 0 Redacted	GEND_GBV_DSD	Sum of Sex disaggregates	200	200	Redacted
GEND_GBV_DSD GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load CARE_CURR_DS D Age/sex: <1 Male 10 10 Redacted 6,000 6,000 Redacted 7 Redacted 0 Redacted	GEND_GBV_DSD	Emotional Violence (Other Post-GBV	190	200	Redacted
CARE_CURR_DS D CARE_CURR_DS D CARE_CURR_DS D Age/sex: <1 Male O O Redacted	GEND_GBV_DSD	• • •	10	10	Redacted
CARE_CURR_DS D	GEND_GBV_DSD	BV DSDI i i i i i i i i i i i i i i i i i i i		0	Redacted
CARE_CURR_DS D Age/sex: <1 Male 0 0 Redacted		children who received at least one of the following during the reporting period: clinical assessment (WHO	6,000	6,000	Redacted
CARE_CURR_DS	_	<u> </u>	0	0	Redacted
	CARE_CURR_DS	Age/sex: 1-4 Male	10	10	Redacted



D				
CARE_CURR_DS D	Age/sex: 5-9 Male	10	10	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	20	20	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	100	100	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	600	600	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,500	1,500	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	160	160	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	10	10	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	10	10	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	10	10	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	670	670	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,200	1,200	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	1,200	1,200	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	500	500	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	6,000	6,000	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40	40	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	2,360	2,360	Redacted



D	PERMISSION ONLY: 15+ Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	30	30	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,570	3,570	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	6,000	6,000	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	47	47	Redacted
LAB_CAP_DSD	By clinical laboratories	0		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	47		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	37		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	10		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	47		Redacted
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		0		Redacted
HRH_PRE	By Graduates: Midwives	0	0	Redacted
HRH_PRE	By Graduates: Social service workers	0	0	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	0	0	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	0	0	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,000	6,000	Redacted



Mechanism ID: 13800	Mechanism Name: TB Capacity Building
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman	School of Public Health
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	600,000		

Sub Partner Name(s)

	University of Cape Town	UNIVERSITY OF PRETORIA	
--	-------------------------	------------------------	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	70,000	
	-,	

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13800
Mechanism Name:	TB Capacity Building
Prime Partner Name:	Columbia University Mailman School of Public Health



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	600,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

in plantaling incontainon batana		
Mechanism ID: 13798	Mechanism Name: GH1152	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Soul City		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 3,011,225		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood



TB Family Planning

Budget Code Information

Budget Code Illioning	ation		
Mechanism ID:	13798		
Mechanism Name:	GH1152		
Prime Partner Name:	Soul City		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	11,850	12,600	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	11,850	12,600	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	1,875	2,625	Redacted
GEND_NORM_DS D	By Age: 15-19	700	1,000	Redacted
GEND_NORM_DS D	By Age: 20-24	1,175	1,625	Redacted
GEND_NORM_DS	Sum of Age disaggregates	1,875	2,625	Redacted



D				
GEND_NORM_DS D	By Sex: Female	1,875	2,625	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	1,875	2,625	Redacted
GEND_NORM_DS D	By type of activity: Small Group	1,875	2,625	Redacted

mereniening meenanen zetane		
Mechanism ID: 13797	Mechanism Name: Track 1 Follow-On	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreeme		
Prime Partner Name: Health Systems Trust		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 5,109,118	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 19,792,295		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	5,109,118	

Sub Partner Name(s)

Management Sciences for Health	Philanjalo Hospice, Tugela Ferry	University of Cape Town, Infectious Disease Unit
Wits Health Consortium (Pty)		
Limited		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Food and Nutrition: Policy, Tools, and Service	50,000



Delivery	
Delivery	

TB End-of-Program Evaluation Family Planning

Budget Code Information

Budget Code Inform	ation		
Mechanism ID:	13797		
Mechanism Name:	Track 1 Follow-On		
Prime Partner Name:	Health Systems Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	154,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	117,182	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	609,344	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	58,591	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	46,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	468,726	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	311,972	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,724,203	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	617,547	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	630	504	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	630	504	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	630	504	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	630	504	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	630	504	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	630	504	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	630	504	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant	46,000	38,640	Redacted



	1			1
	women who received antiretrovirals to			
	reduce risk of			
	mother-to-child-transmission (MTCT)			
	during pregnancy and delivery			
	Number of HIV- positive pregnant			
PMTCT_ARV_NGI	women identified in the reporting period	48,643	40,860	Redacted
	(including known HIV-positive at entry)			
PMTCT_ARV_NGI	Life-long ART (including Option B+)	8,280	6,955	Redacted
	Sub-Disag of Life-long ART: Newly			
PMTCT_ARV_NGI	initiated on treatment during the current	3,395	2,852	Redacted
	pregnancy			
	Sub-Disag of Life-long ART: Already on			
PMTCT_ARV_NGI	treatment at the beginning of the	4,885	4,103	Redacted
	current pregnancy			
	Maternal triple ARV prophylaxis			
PMTCT_ARV_NGI	(provided with the intention to stop at	3,680	3,092	Redacted
	the end of the breastfeeding period)			
	Maternal AZT (prophylaxis component			
PMTCT_ARV_NGI	of WHO Option A during pregnancy	15,640	13,137	Redacted
	and delivery)			
DMTOT ADV NO	Single-dose nevirapine (with or without	40.400	45 450	Dadadal
PMTCT_ARV_NGI	tail)	18,400	15,456	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	46,000	38,640	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	8,280	6,955	Redacted
	Number of HIV-positive pregnant			
	women who received antiretrovirals to			
PMTCT_ARV_TA	reduce risk of	39,100	32,844	Redacted
	mother-to-child-transmission (MTCT)			
	during pregnancy and delivery			
	Number of HIV- positive pregnant			
PMTCT_ARV_TA	women identified in the reporting period	41,347	34,731	Redacted
	(including known HIV-positive at entry)			
PMTCT_ARV_TA	Life-long ART (including Option B+)	7,038	5,912	Redacted
DNATOT ADV TA	Sub-Disag of Life-long ART: Newly	0.000	0.404	Dodostad
PMTCT_ARV_TA	initiated on treatment during the current	2,886	2,424	Redacted
			-	-



	pregnancy			
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	4,152	3,488	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	3,128	2,627	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	13,294	11,167	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	15,640	13,137	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	39,100	32,843	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	7,038	5,912	Redacted
PMTCT_STAT_NG	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	160,076	133,813	Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	170,583	142,265	Redacted
PMTCT_STAT_NG	By: Known positives at entry	94,444	78,950	Redacted
PMTCT_STAT_NG	By: Number of new positives identified	65,632	54,863	Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	160,076	133,813	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	136,065	114,148	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	144,996	121,796	Redacted
PMTCT_STAT_TA	By: Known positives at entry	80,278	67,434	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	55,787	46,861	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	136,065	114,295	Redacted



	T		Т	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,129,022	948,378	Redacted
HTC_TST_NGI	By Test Result: Negative	1,043,216	876,301	Redacted
HTC_TST_NGI	By Test Result: Positive	85,806	72,077	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	1,129,022	948,378	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	45,161	47,419	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	406,448	426,770	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	67,741	71,128	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	609,672	640,156	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	112,902	118,547	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,016,120	1,066,926	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	1,129,022	1,185,473	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	880,637	739,735	Redacted
HTC_TST_TA	By Test Result: Negative	813,709	683,515	Redacted
HTC_TST_TA	By Test Result: Positive	66,928	56,220	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	880,637	739,735	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	35,226	28,590	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	317,029	266,304	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	52,838	44,384	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	475,544	399,458	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	88,064	72,974	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	792,573	665,762	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	880,637	738,736	Redacted
OVC_SERV_TA	Number of active beneficiaries served	200,000	168,000	Redacted



	<u> </u>		<u> </u>	
	by PEPFAR OVC programs for children			
	and families affected by HIV/AIDS			
	Number of HIV-positive individuals			
C2.1.D_NGI	receiving a minimum of one clinical	700,000		Redacted
00 1 5 1101	service	40.000		5
C2.1.D_NGI	By Age/Sex: <15 Female	42,000		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	28,000		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	378,000		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	252,000		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	700,000		Redacted
C2.1.D_NGI	By Age: <15	70,000		Redacted
C2.1.D_NGI	By Age: 15+	630,000		Redacted
C2.1.D_NGI	Sum of Age disaggregates	700,000		Redacted
C2.1.D_NGI	By Sex: Female	420,000		Redacted
C2.1.D_NGI	By Sex: Male	280,000		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	700,000		Redacted
	Number of HIV-positive individuals			
C2.1.D_TA	receiving a minimum of one clinical	546,000		Redacted
	service			
C2.1.D_TA	By Age/Sex: <15 Female	32,760		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	21,840		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	294,840		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	196,560		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	546,000		Redacted
C2.1.D_TA	By Age: <15	54,600		Redacted
C2.1.D_TA	By Age: 15+	491,400		Redacted
C2.1.D_TA	Sum of Age disaggregates	546,000		Redacted
C2.1.D_TA	By Sex: Female	327,600		Redacted
C2.1.D_TA	By Sex: Male	218,400		Redacted
C2.1.D_TA	Sum of Sex disaggregates	546,000		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	525,000	441,000	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	29,578	24,845	Redacted



			T	
TX_CURR_NGI	Age/Sex: 1-4 Male	88,735	74,537	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	59,157	49,691	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	1,030	865	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	57,417	48,229	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	172,251	144,690	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	114,833	96,459	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	1,999	1,684	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	525,000	441,000	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	29,578	24,844	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	57,417	48,230	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	147,892	124,288	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,030	865	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	287,084	241,150	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	1,999	1,678	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	438,005	367,981	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	434,976	365,438	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	3,029	2,543	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	409,500	429,936	Redacted
TX_CURR_TA	Age/Sex: <1 Male	23,071	24,225	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	69,213	72,634	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	46,142	48,449	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	803	843	Redacted
TX_CURR_TA	Age/Sex: <1 Female	44,785	47,024	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	134,355	141,073	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	89,471	93,945	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	1,660	1,743	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	407,037	427,350	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	23,071	24,225	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	44,785	47,024	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	115,355	120,931	Redacted



TX_CURR_TA	Aggregated Age/Sex: 15+ Male	803	843	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	223,826	235,170	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,660	1,743	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	339,181	356,101	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,463	2,586	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	341,644	358,687	Redacted

Mechanism ID: 13793	Mechanism Name: THCA - GH1152	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: TB/HIV Care		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,338,141	s: 3,338,141 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 1,882,999				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	3,338,141			

Sub Partner Name(s)

Edzimkulu	Sonke Gender Justice	
-----------	----------------------	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	175,000
Motor Vehicles: Purchased	754,000



Mobile Population
Safe Motherhood
TB
Workplace Programs
Family Planning

Budget Code Information

Budget Code Informa	alion		
Mechanism ID:	13793		
Mechanism Name:	THCA - GH1152		
Prime Partner Name:	TB/HIV Care		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,246,902	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,045,619	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,045,620	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	260	260	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	260	260	Redacted
SITE_SUPP	By program area/support type: VMMC	60	60	Redacted



	Division 1 D. II. (202)			
	Direct Service Delivery (DSD)			
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	260	260	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	37	37	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	320	320	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	120	120	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	100	100	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	20	20	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	185	185	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	145	145	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more	40	40	Redacted



	severe surgical intra-operative AE(s)			
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	15	15	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	10	10	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	5	5	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	16,000	16,000	Redacted
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	4,320	4,320	Redacted
VMMC_CIRC_DS D	By Age: 15-19	4,800	4,800	Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,600	1,600	Redacted
VMMC_CIRC_DS D	By Age: 25-49	3,680	3,680	Redacted
VMMC_CIRC_DS D	By Age: 50+	1,600	1,600	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	16,000	16,000	Redacted



				TI.
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	160	160	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	14,080	14,080	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,760	1,760	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	15,500	12,500	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	500	3,500	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	13,800	14,500	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	2,200	1,500	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	16,000	16,000	Redacted
VMMC_CIRC_NGI	By Age: <1	0		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0		Redacted
VMMC_CIRC_NGI	By Age: 10-14	4,320	4,320	Redacted
VMMC_CIRC_NGI	By Age: 15-19	4,800	4,800	Redacted
VMMC_CIRC_NGI	By Age: 20-24	1,600	1,600	Redacted
VMMC_CIRC_NGI	By Age: 25-49	3,680	3,680	Redacted
VMMC_CIRC_NGI	By Age: 50+	1,600	1,600	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	16,000	16,000	Redacted



VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	160	160	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program	14,080	14,080	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,760	1,760	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	15,500	12,500	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	500	3,500	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	12,000	14,500	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	4,000	1,500	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	60,000	72,000	Redacted
PP_PREV_DSD	Total number of people in the target population	100,000	120,000	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	12,000	14,400	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	12,000	14,400	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	6,000	7,200	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted



	1			Y
PP_PREV_DSD	Age/sex: 15-19 Female	12,000	14,400	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	12,000	14,400	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	6,000	7,200	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	60,000	72,000	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	500,000	500,000	Redacted
HTC_TST_DSD	By Test Result: Negative	450,000	450,000	Redacted
HTC_TST_DSD	By Test Result: Positive	50,000	50,000	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	500,000	500,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	12,500	12,500	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	20,000	20,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	55,000	55,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	90,000	90,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	12,500	12,500	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	15,000	15,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	120,000	120,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	175,000	175,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	500,000	500,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,500	12,500	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	165,000	165,000	Redacted



	T			1
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,500	12,500	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	310,000	310,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	25,000	25,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	475,000	475,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	500,000	500,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	500,000	500,000	Redacted
HTC_TST_NGI	By Test Result: Negative	450,000	450,000	Redacted
HTC_TST_NGI	By Test Result: Positive	50,000	50,000	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	500,000	500,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	20,000	20,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	55,000	55,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	90,000	90,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	0		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	15,000	15,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	120,000	120,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	200,000	200,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	500,000	500,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0		Redacted



			1	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	165,000	165,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	335,000	335,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	500,000	500,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	500,000	500,000	Redacted
GEND_NORM_DS D	By Age: 0-9	0		Redacted
GEND_NORM_DS D	By Age: 10-14	0	1,500	Redacted
GEND_NORM_DS D	By Age: 15-19	0	2,500	Redacted
GEND_NORM_DS D	By Age: 20-24	0	2,500	Redacted
GEND_NORM_DS D	By Age: 25+	0	1,500	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	0	8,000	Redacted
GEND_NORM_DS D	By Sex: Male	0	4,000	Redacted
GEND_NORM_DS D	By Sex: Female	0	4,000	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	0	8,000	Redacted
GEND_NORM_DS D	By type of activity: Individual	0	4,000	Redacted
GEND_NORM_DS D	By type of activity: Small Group	0	4,000	Redacted
GEND_NORM_DS D	By type of activity: Community-level	0	2,000	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	50,000	50,000	Redacted



-			ı	1
C2.1.D_DSD	By Age/Sex: <15 Female	500	500	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	500	500	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	32,500	32,500	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	16,500	16,500	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	50,000	50,000	Redacted
C2.1.D_DSD	By Age: <15	1,000	1,000	Redacted
C2.1.D_DSD	By Age: 15+	49,000	49,000	Redacted
C2.1.D_DSD	Sum of Age disaggregates	50,000	50,000	Redacted
C2.1.D_DSD	By Sex: Female	33,000	33,000	Redacted
C2.1.D_DSD	By Sex: Male	17,000	17,000	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	50,000	50,000	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	50,000	50,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	500	500	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	500	500	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	32,500	32,500	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	16,500	16,500	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	50,000	50,000	Redacted
C2.1.D_NGI	By Age: <15	1,000	1,000	Redacted
C2.1.D_NGI	By Age: 15+	49,000	49,000	Redacted
C2.1.D_NGI	Sum of Age disaggregates	50,000	50,000	Redacted
C2.1.D_NGI	By Sex: Female	33,000	33,000	Redacted
C2.1.D_NGI	By Sex: Male	17,000	17,000	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	50,000	50,000	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	50,000	50,000	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	50,000	50,000	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care	50,000	60,000	Redacted



	I I			i I
	during the reporting period and			
	received at least one of the following at			
	enrollment: clinical assessment (WHO			
	staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Age/sex: <1 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	500	600	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	2,000	2,400	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	5,500	6,600	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	9,000	10,800	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	500	600	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,500	1,800	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	12,000	14,400	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	19,000	22,800	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	0	0	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	50,000	60,000	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	500	600	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	16,500	19,800	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	500	600	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	32,500	39,000	Redacted
CARE NEW DOD	Sum of Aggregated Age/sex	E0 000	60,000	Dodostod
CARE_NEW_DSD	disaggregates	50,000	60,000	Redacted
	Number of PEPFAR-supported HIV			
CARE_SITE	clinical care sites at which at least 80%			
	of PLHIV received all of the following	260	260	Redacted
3,2_3, 12	during the reporting period: 1) clinical	_55	250	
	assessment (WHO staging) OR CD4			
	count OR viral load, AND 2) TB			



	screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	260	260	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	260	260	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	260	260	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	260	260	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	260	260	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	37	37	Redacted



	facilities with capacity to perform			
	clinical laboratory tests			
LAB_CAP_DSD	By Point-of-care testing sites	37		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	37	37	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	37	37	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	259	259	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	259	259	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	259	259	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	259	259	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	259	259	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service	0	0	Redacted



	delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	259	259	Redacted
FPINT_SITE_DSD	Service delivery type: Community	259	259	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	0	0	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	259	259	Redacted

Mechanism ID: 13789	Mechanism Name: SACTWU
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South African Clothing & Textil	e Workers' Union
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 5,600,000 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 3,000,000				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	5,600,000			

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

l	
Human Resources for Health	21.250
pridman resources for ricalin	Z 1,Z00

Key Issues

ТВ



Budget Code Information

Mechanism ID:	13789		
Mechanism Name:	SACTWU		
Prime Partner Name:	South African Clothing	& Textile Workers' Union	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	5,600,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	160	160	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	160	112	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	1,930	1,351	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	90	63	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	80	56	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative	10	7	Redacted



	1			,
	AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)			
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	1,440	1,008	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	1,080	756	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	360	252	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	400	280	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	300	210	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	100	70	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	55,000	90,000	Redacted
VMMC_CIRC_DS	By Age: <1	0	0	Redacted



D				
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	5,500	17,800	Redacted
VMMC_CIRC_DS D	By Age: 15-19	24,750	20,000	Redacted
VMMC_CIRC_DS D	By Age: 20-24	13,750	28,000	Redacted
VMMC_CIRC_DS D	By Age: 25-49	8,250	23,000	Redacted
VMMC_CIRC_DS D	By Age: 50+	2,750	1,200	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	55,000	90,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	75	1,200	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,425	87,100	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	50	1,700	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	45,000	82,000	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	10,000	8,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	36,000	84,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did	9,000	6,000	Redacted



		1		1
	NOT return for follow-up care within 14			
	days of circumcision surgery			
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	55,000	90,000	Redacted
VMMC_CIRC_NGI	By Age: <1	0	0	Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	5,500	17,800	Redacted
VMMC_CIRC_NGI	By Age: 15-19	24,750	20,000	Redacted
VMMC_CIRC_NGI	By Age: 20-24	13,750	28,000	Redacted
VMMC_CIRC_NGI	By Age: 25-49	8,250	23,000	Redacted
VMMC_CIRC_NGI	By Age: 50+	2,750	1,200	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	55,000	90,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	75	1,200	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program	5,425	87,100	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	50	1,700	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	45,000	82,000	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	10,000	8,000	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	36,000	84,000	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did	9,000	6,000	Redacted



	NOT return for follow-up care within 14			
	days of circumcision surgery			
VMMC_CIRC_TA	By Age: <1	0	0	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,500	9,000	Redacted
HTC_TST_DSD	By Test Result: Negative	5,425	8,700	Redacted
HTC_TST_DSD	By Test Result: Positive	75	300	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	5,500	9,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	550	550	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,475	2,500	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,375	4,550	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	825	800	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	275	500	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,500	8,900	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	550	550	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,950	8,450	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	550	550	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,950	8,450	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,500	9,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,500	9,000	Redacted
HTC_TST_NGI	By Test Result: Negative	5,425	89,700	Redacted
HTC_TST_NGI	By Test Result: Positive	75	300	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	5,500	90,000	Redacted



HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	550	550	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,475	2,500	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	1,375	4,550	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	825	900	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	275	500	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	5,500	9,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	550	550	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	4,950	8,450	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	550	550	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	4,950	8,450	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	5,500	9,000	Redacted

Mechanism ID: 13771	Mechanism Name: Howard University		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Howard University			
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 500,000 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 76,486			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	500,000		

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Illionia	ation		
Mechanism ID:	13771		
Mechanism Name:	Howard University		
Prime Partner Name:	Howard University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13767	Mechanism Name: Re-Action!
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Re-Action!	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,308,968	
FY 2013 Burn Rate: Redacted	



Funding Source	Funding Amount		
GHP-State	0		

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name:			
Prime Partner Name:			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	3	6	Redacted



-	T .		I	l .
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	3	6	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,000	2,500	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,000	2,500	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	3,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	150	100	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	750	500	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	90	60	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	350	240	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	750	520	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	2,200	1,440	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	210	140	Redacted



HTC_TST_DSD	Sum of Age/Sex disaggregates	4,500	3,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10	10	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	990	660	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	100	70	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,400	2,260	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	110	80	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,390	2,920	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,500	3,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	3,000	Redacted
HTC_TST_NGI	By Test Result: Negative	3,870	2,660	Redacted
HTC_TST_NGI	By Test Result: Positive	630	340	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	4,500	3,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	10	10	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	990	660	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	100	70	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,400	2,260	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	110	80	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	4,390	2,920	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,500	3,000	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	630	340	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has	2	2	Redacted



	documented process results in the last 6 months			
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	2	2	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	2	2	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted

Mechanism ID: 13761	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13760	Mechanism Name: Education and HIV Prevention	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of the Western Cape		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 279,717	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-USAID	0

Sub Partner Name(s)

University of the Western Cape		
--------------------------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

ТВ

Workplace Programs

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	13760		
Mechanism Name:	Education and HIV Prevention		
Prime Partner Name:	University of the Western Cape		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	2,600	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2,600	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,245	
PP_PREV_DSD	Age/sex: 15-19 Male	127	
PP_PREV_DSD	Age/sex: 20-24 Male	1,512	
PP_PREV_DSD	Age/sex: 25-49 Male	1,059	
PP_PREV_DSD	Age/sex: 15-19 Female	5	
PP_PREV_DSD	Age/sex: 20-24 Female	3,016	
PP_PREV_DSD	Age/sex: 25-49 Female	1,526	
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,245	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,600	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	600	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,600	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,600	



HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,600	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	600	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	2,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	2,600	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	2,600	

Mechanism ID: 13750	Mechanism Name: GH1152		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Stellenbosch, South Africa			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 249,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 942,400		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	249,000	

Sub Partner Name(s)

Etafeni Day Care Center	Living Hope	Sizakuyenza

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	50,000	
Focus Area:	Promoting gender-related policies and laws that	
	increase legal protection	
Sub Area:	Collection and Use of Gender-related Strategic	
	Information	



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

Family Planning

Budget Code Information

Budget Code Illioini			
Mechanism ID:	13750		
Mechanism Name:	GH1152		
Prime Partner Name:	University of Stellenbos	sch, South Africa	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	24,844	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	106,741	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	117,415	0



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	5	5	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	5	5	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,464	17,640	Redacted
HTC_TST_DSD	By Test Result: Negative	15,476	16,582	Redacted
HTC_TST_DSD	By Test Result: Positive	988	1,058	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	16,464	17,640	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,399	1,499	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,399	1,499	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	4,775	5,116	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	659	706	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,235	1,323	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	2,223	2,381	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	4,281	4,586	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	493	530	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	16,464	17,640	Redacted



		, -		1
LITO TOT NO.	Number of individuals who received	40.404		D. lastad
HTC_TST_NGI	T&C services for HIV and received their test results during the past 12 months	16,464		Redacted
HTC_TST_NGI	By Test Result: Negative	15,476		Redacted
HTC_TST_NGI	By Test Result: Positive	988		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	16,464		Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,399		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	1,399		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	4,775		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	659	Redacted	
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0 Redacted		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,235		Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	2,223		Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	4,281		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	493		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	16,464		Redacted
	Number of service delivery points			
FPINT_SITE_DSD	supported by PEPFAR for HIV services	2	5	Redacted
	that are directly providing integrated	_		
	voluntary family planning services			
EDINT CITE DOD	Total number of PEPFAR-supported	Г	F	Dodostod
FPINT_SITE_DSD	HIV service delivery points: PMTCT, Care and Treatment	5	5	Redacted
	By site support type: Direct Service			
FPINT_SITE_DSD	Delivery (DSD): Number of service	2		Redacted
_== 32	delivery points supported by PEPFAR			



		1		
	for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points		5	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	5	5	Redacted
FPINT_SITE_DSD	Service delivery type: Community	5	5	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	0		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	5	5	Redacted

Mechanism ID: 13709	Mechanism Name: University of Washington	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 6,515,207	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	6,515,207	

Sub Partner Name(s)

li e e e e e e e e e e e e e e e e e e e	1
	1
LICCE	1
IUUSE	1
1000.	1



Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	70,000
Economic Strengthening	500,000
Human Resources for Health	3,800,000

Key Issues

(No data provided.)

Budget Code Information

Budget Code Inform				
Mechanism ID:	13709			
Mechanism Name:	University of Washingto	University of Washington		
Prime Partner Name:	University of Washingto	on		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	750,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	5,062,707	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	702,500	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated	1,000		Redacted



	from a pre-service training institution or		
	program as a result of		
	PEPFAR-supported strengthening		
	efforts, within the reporting period, by		
	select cadre		
HRH_PRE	By Graduates: Other	1,000	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	1,000	Redacted

Mechanism ID: 13695	Mechanism Name: Epicentre AIDS Risk Management	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Epicentre AIDS Risk Managen	nent	
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

otal All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 1,792,290				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Budget Code Information				
Mechanism ID: 13695				
Mechanism Name:	Epicentre AIDS Risk Ma	Epicentre AIDS Risk Management		
Prime Partner Name:	Epicentre AIDS Risk Ma	nagement		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	CIRC	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	17	17	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	17	17	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	17	17	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	2,000	3,100	Redacted



	test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	1,400	2,381	Redacted
HTC_TST_DSD	By Test Result: Positive	600	719	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	2,000	3,100	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	179	277	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	210	327	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	610	946	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	180	277	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	210	327	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	611	946	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,000	3,100	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,000	1,550	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,000	1,550	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,000	3,100	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex	2,000	3,100	Redacted



	T T		
	disaggregates		
	Number of individuals who received		
HTC_TST_NGI	T&C services for HIV and received their	2,000	Redacted
	test results during the past 12 months		
HTC_TST_NGI	By Test Result: Negative	1,400	Redacted
HTC_TST_NGI	By Test Result: Positive	600	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	2,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	179	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	210	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	610	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	0	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	180	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	210	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	611	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	2,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	2,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	0	Redacted
HTC TOT NO	Sum of Aggregated Age/Sex	2 000	Podostod
HTC_TST_NGI	disaggregates	2,000	Redacted



Mechanism ID: 13688	Mechanism Name: GH1151	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Health and Development Africa		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

otal All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 728,805				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

Sub Partner Name(s)

Project Support Association	Sonke Gender Justice	
-----------------------------	----------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13688		
Mechanism Name:	GH1151		
Prime Partner Name:	Health and Development Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	8		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	8		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	8		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,200	1,500	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,200	1,500	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	550	800	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	50	100	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	50	100	Redacted



	T			Υ
HTC_TST_DSD	Age/sex: 15-19 Female	150	200	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	150	200	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	150	200	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	550	800	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	100	200	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	450	600	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	550	800	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	550	800	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	550	800	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	50	100	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	50	100	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	150	200	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	150	200	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	150	200	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	550	800	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	100	200	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	450	600	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	550	800	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	550	800	Redacted

Mechanism ID: 13682	Mechanism Name: Health Information Systems Program	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Health Information Systems Program		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,995,582	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Health Partners Southern Africa	Jembi Health Systems of Cape Town	Management Sciences for Health
UNIVERSITY OF PRETORIA		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

- augus or as in a			
Mechanism ID:	13682		
Mechanism Name:	Health Information Systems Program		
Prime Partner Name:	Health Information Syst	ems Program	
Strategic Area	Budget Code Planned Amount On Hold Amount		
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and	OHSS	0	0
Systems	OHSS	0	J

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13644	Mechanism Name: University of Cape Town
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Cape Tow	n
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 507,080			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	0		

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Badget Gode Information			
Mechanism ID:	13644		
Mechanism Name:	University of Cape Town		
Prime Partner Name:	University of Cape Town		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13619	Mechanism Name: JHPIEGO SA			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: JHPIEGO				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 1,200,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	1,200,000	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



Motor Vehicles: Purchased	121,266
Motor verticles. Furchased	121,200

Key Issues

Mobile Population TB Workplace Programs End-of-Program Evaluation Family Planning

Budget Code Information

Daagot Godo IIII office			
Mechanism ID:	13619		
Mechanism Name:	JHPIEGO SA		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,200,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	23	23	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	23	23	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	360	360	Redacted



VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,000	15,286	Redacted
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	900	2,500	Redacted
VMMC_CIRC_DS D	By Age: 15-19	6,750	6,750	Redacted
VMMC_CIRC_DS D	By Age: 20-24	3,000	4,686	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,050	1,050	Redacted
VMMC_CIRC_DS D	By Age: 50+	300	300	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	12,000	15,286	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	9,000	13,000	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	3,000	2,286	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,000	15,286	Redacted
VMMC_CIRC_NGI	By Age: <1	0	0	Redacted



VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	900	2,500	Redacted
VMMC_CIRC_NGI	By Age: 15-19	6,750	6,750	Redacted
VMMC_CIRC_NGI	By Age: 20-24	3,000	4,686	Redacted
VMMC_CIRC_NGI	By Age: 25-49	1,050	1,050	Redacted
VMMC_CIRC_NGI	By Age: 50+	300	300	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	12,000	15,286	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	9,000	13,000	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	3,000	2,286	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,000	12,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	900	900	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	6,750	6,750	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,000	3,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,050	1,050	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	300	300	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	12,000	12,000	Redacted
HTC_TST_NGI	Number of individuals who received	12,000	12,000	Redacted



	T&C services for HIV and received their			
	test results during the past 12 months			
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	900	900	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	6,750	6,750	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	3,000	3,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,050	1,050	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	300	300	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	0		Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	0		Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	0		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	12,000	12,000	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	23	23	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	23	23	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV	23	18	Redacted



	programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	23	23	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	23	18	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	23	23	Redacted

Mechanism ID: 13618	Mechanism Name: GH1151			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Columbia University Mailman School of Public Health				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 1,655,112 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	1,655,112			

Sub Partner Name(s)

ľ		
OUTLGBI		
0012001	I .	

Cross-Cutting Budget Attribution(s)



Human Resources for Health	25,000
Motor Vehicles: Purchased	123,546
Key Populations: FSW	75,000
Focus Area:	Training of health workers and community outreach
	workers
Key Populations: MSM and TG	900,000

Key Issues

(No data provided.)

Budget Code Information

Duaget Code illionità	ation					
Mechanism ID:	13618					
Mechanism Name:	GH1151	GH1151				
Prime Partner Name:	Columbia University Ma	nilman School of Public H	lealth			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVCT	455,112	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVOP	1,200,000	0			

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	28	28	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	13	10	Redacted



SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	15	18	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0		Redacted



	T			i
	By program area/support type: General			
SITE_SUPP	Population Prevention Technical	0		Redacted
	Assistance-only (TA)			
	By program area/support type: Key			
SITE_SUPP	Populations Prevention Direct Service	13	10	Redacted
	Delivery (DSD)			
	By program area/support type: Key			
SITE_SUPP	Populations Prevention Technical	15	18	Redacted
	Assistance-only (TA)			
	By program area/support type: OVC			
SITE_SUPP	Direct Service Delivery (DSD)	0		Redacted
	By program area/support type: OVC			
SITE_SUPP	Technical Assistance-only (TA)	0		Redacted
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	0	0	Redacted
_	Direct Service Delivery (DSD)	Ŭ		
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	0		Redacted
	Technical Assistance-only (TA)			
	By program area/support type: Lab	0		
SITE_SUPP	Direct Service Delivery (DSD)			Redacted
	By program area/support type: Lab			
SITE_SUPP	Technical Assistance-only (TA)	0		Redacted
	Number of key populations reached			
	with individual and/or small group level			
KP PREV DSD	HIV preventive interventions that are	12,000	18,000	Redacted
	based on evidence and/or meet the	ŕ	,	
	minimum standards required			
	By key population type: Female sex			
	workers (FSW) (Numerator: Number of			
	key populations reached with individual			
KP_PREV_DSD	and/or small group level HIV preventive	0		Redacted
_ _	interventions that are based on			
	evidence and/or meet the minimum			
	standards required)			



				<u> </u>
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,000	18,000	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,000	2,000	Redacted
HTC_TST_DSD	By Test Result: Negative	1,750	1,750	Redacted
HTC_TST_DSD	By Test Result: Positive	250	250	Redacted



	T		I	1
HTC_TST_DSD	Sum of Test Result disaggregates	2,000	2,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	100	100	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	500	500	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	750	750	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	650	650	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,000	2,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	100	100	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,900	1,900	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USF WITH HO		0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	100	100	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,900	1,900	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,000	2,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,000	3,000	Redacted



	I I			ı
HTC_TST_NGI	By Test Result: Negative	2,500	2,500	Redacted
HTC_TST_NGI	By Test Result: Positive	500	500	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	3,000	3,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	150	150	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,000	1,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	1,400	1,400	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	350	350	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	100	100	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	3,000	3,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	700	700	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	2,300	2,300	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	0		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	700	700	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	2,300	2,300	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	3,000	3,000	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,000	1,000	Redacted
HTC_TST_TA	By Test Result: Negative	750	750	Redacted



HTC_TST_TA	By Test Result: Positive	250	250	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	1,000	1,000	Redacted
HTC_TST_TA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	20	20	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	280	280	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	500	500	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	200	200	Redacted
HTC_TST_TA	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_TA	Age/sex: <1 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	1,000	1,000	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	20	20	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	980	980	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	20	20	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	980	980	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,000	1,000	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender	200	200	Redacted



	norms, that meets minimum criteria			
GEND_NORM_DS D	By Age: 0-9	0	0	Redacted
GEND_NORM_DS D	By Age: 10-14	0	0	Redacted
GEND_NORM_DS D	By Age: 15-19	0	0	Redacted
GEND_NORM_DS D	By Age: 20-24	50	50	Redacted
GEND_NORM_DS D	By Age: 25+	150	150	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	200	200	Redacted
GEND_NORM_DS D	By Sex: Male	50	50	Redacted
GEND_NORM_DS D	By Sex: Female	150	150	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	200	200	Redacted
GEND_NORM_DS D	By type of activity: Individual	0	0	Redacted
GEND_NORM_DS D	By type of activity: Small Group	200	200	Redacted
GEND_NORM_DS D	By type of activity: Community-level	0	0	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	100	100	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	0	0	Redacted



CARE_CURR_DS D	Age/sex: 5-9 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	20	20	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	30	30	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	50	50	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	0	0	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	100	100	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	100	100	Redacted



				Į.
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	0	0	Redacted
D	PERMISSION ONLY: 15+ Female	ŭ		reducted
CARE_CURR_DS	Sum of Aggregated Age/Sex	100	100	Redacted
D	disaggregates	100	100	reddoled
	Number of HIV positive adults and			
	children who received at least one of			
CARE_CURR_TA	the following during the reporting	400	400	Redacted
	period: clinical assessment (WHO			
	staging) OR CD4 count OR viral load			
CARE_CURR_TA	Age/sex: <1 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	80	80	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	150	150	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	170	170	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	0	0	Redacted
CARE_CURR_TA	Age/sex: <1 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	0	0	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	400	400	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	400	400	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ	0	0	Redacted



	PERMISSION ONLY: <15 Female			
CARE_CURR_TA	CURR_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		0	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	400	400	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	100	100	Redacted
TB_SCREEN_DSD	Age: 15-19	20	20	Redacted
TB_SCREEN_DSD	Age: 20-24	30	30	Redacted
TB_SCREEN_DSD	Age: 25-49	50	50	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	20	20	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	100		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	100		Redacted
TB_SCREEN_DSD	Sex: Male	100	100	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	100	100	Redacted

mpromorning moontainem zotame			
Mechanism ID: 13608	Mechanism Name: University of Washington		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Washington			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 1,120,000 Total Mechanism Pipeline: Redacted					
Applied Pipeline Amount: 435,457					
FY 2013 Burn Rate: Redacted					
Funding Source	Funding Amount				
GHP-State	1,120,000				



Sub Partner Name(s)

Lifeline Mafikeng	LifeLine North West - Rustenburg	University of California at San
	Centre	Francisco

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Leased	24,000
Human Resources for Health	100,000

Key Issues

(No data provided.)

Budget Code Information

Baaget Gode Illioning				
Mechanism ID:	3608			
Mechanism Name:	University of Washington			
Prime Partner Name:	University of Washingto	on		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	380,377	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	739,623	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by	20		Redacted



	PEPFAR			
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	20		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	20		Redacted
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	192	192	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	192	192	Redacted
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	192		Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	192		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,500	9,600	Redacted
PP_PREV_DSD	Total number of people in the target population	7,500	9,600	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	117	152	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	409	532	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,240	1,613	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	828	1,078	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	320	406	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	958	1,217	Redacted



DD DDE:// DOE		0.450	0 =0 /	
PP_PREV_DSD	Age/sex: 25-49 Female	2,156	2,734	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	1,472	1,868	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,500	9,600	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,500	9,600	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	108	138	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	540	691	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,658	2,122	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	394	504	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	418	535	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,488	1,905	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	2,304	2,949	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	590	756	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	7,500	9,600	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,700	3,456	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,800	6,144	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,500	9,600	Redacted



	,			
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,500	9,600	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,500		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	2,700		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	4,800		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	7,500		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	7,500		Redacted

Mechanism ID: 13585	Mechanism Name: GH1152
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Shout It Now	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 728,911	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Buuget Code IIIIoiiii	ation		
Mechanism ID:	13585		
Mechanism Name:	GH1152		
Prime Partner Name:	Shout It Now		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	8	8	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	8	8	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	45,000	27,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	750	375	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	750	375	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,875	3,000	Redacted



	T T			
HTC_TST_DSD	Age/sex: 20-24 Male	5,875	3,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,500	6,100	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	750	412	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	750	412	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	750	412	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,875	3,231	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,875	3,231	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,500	6,050	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	750	402	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	45,000	27,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	27,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	750	375	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	750	375	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,875	3,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	5,875	3,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	11,000	6,100	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	750	412	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	750	412	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	750	412	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,875	3,231	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	5,875	3,231	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	11,000	6,050	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	750	402	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	50,000	27,000	Redacted



Mechanism ID: 13577	Mechanism Name: GH1152
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: HIV Managed Care Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 800,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 602,452	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	800,000

Sub Partner Name(s)

|--|

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Gender: Gender Equality	500,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	50,000

Key Issues

(No data provided.)

Budget Code Information

Budget Code Informa	ation		
Mechanism ID:	13577		
Mechanism Name:	GH1152		
Prime Partner Name:	HIV Managed Care Solu	tions	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Indicator Number	Label	2014	2015	Planning Budget
				Targets



	1			1
SITE_SUPP	Number of unique sites supported by PEPFAR	44	31	Redacted
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD)		44	31	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	44		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	44	31	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	27,000	13,500	Redacted
PP_PREV_DSD	Total number of people in the target population	54,000	27,000	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	878	438	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	7,897	3,717	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	7,897	4,000	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	878	438	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,418	707	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,780	2,000	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	3,780	2,000	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	472	200	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	27,000	13,500	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	500	500	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual	500	500	Redacted



	I			1
	and/or small group level HIV preventive			
	interventions that are based on			
	evidence and/or meet the minimum			
	standards required)			
	Number of individuals who received			
HTC_TST_DSD	T&C services for HIV and received their	27,000	13,500	Redacted
	test results during the past 12 months			
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	878	438	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	7,897	3,717	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	7,897	4,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	878	438	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,418	707	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	3,780	2,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	3,780	2,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	472	200	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	27,000	13,500	Redacted
	Number of individuals who received			
HTC_TST_NGI	T&C services for HIV and received their	27,000	13,500	Redacted
	test results during the past 12 months			
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	878	438	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	7,897	3,717	Redacted



HTC_TST_NGI	Age/sex: 25-49 Male	7,897	4,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	878	438	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,418	707	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	3,780	2,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	3,780	2,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	472	200	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	27,000	13,500	Redacted

Mechanism ID: 13570	Mechanism Name: GH1151		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Population Services International			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

otal All Funding Sources: 500,000 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 2,500,000	
FY 2013 Burn Rate: Redacted	-
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

Wits Health Consortium (Pty)	
Limited	



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Illionia	ation		
Mechanism ID:	13570		
Mechanism Name:	GH1151		
Prime Partner Name:	Population Services Intervices	ernational	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	500,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	7	7	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	7	7	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	703	346	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	5	2	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative	3	2	Redacted



	T T			1
	AE(s) by maximum severity category:			
	Number of clients with one or more			
	moderate surgical intra-operative			
	AE(s), but no severe surgical			
	intra-operative AE(s)			
	Sub-Disag: Surgical intra-operative			
VAMAC AE DOD	AE(s) by maximum severity category:	0	0	Dadastad
VMMC_AE_DSD	Number of clients with one or more	2	0	Redacted
	severe surgical intra-operative AE(s)			
	By AE Type: Number of VMMC clients			
VMMC_AE_DSD	with one or more moderate or severe	350	150	Redacted
	surgical post-operative AE(s)			
	Sub-Disag: By Surgical post-operative			
	AE(s) by maximum severity category:			
	Number of clients with one or more	340	189	Redacted
VMMC_AE_DSD	moderate surgical post-operative AE(s),			
	but no severe surgical post-operative			
	AE(s)			
	Sub-Disag: By Surgical post-operative			
	AE(s) by maximum severity category:			
VMMC_AE_DSD	Number of clients with one or more	10	3	Redacted
	severe surgical intra-operative AE(s)			
	By AE Type: Number of VMMC clients			
VMMC_AE_DSD	with one or more moderate or severe	0		Redacted
VIVIIVIO_AL_BOD	medical device-related AE(s)	O		Redacted
	Sub-Disag: By Medical device-based			
	AE(s) by maximum severity category:			
VMMC_AE_DSD	Number of clients with one or more	0		Redacted
	moderate medical device-related AE(s),			
	but no severe medical device-related			
	AE(s)			
	Sub-Disag: By Medical device-based			
VMMC_AE_DSD	AE(s) by maximum severity category:	0		Redacted
	Number of clients with one or more			
	severe medical device-related AE(s)			



	1			Ti Ti
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	49,334	42,286	Redacted
VMMC_CIRC_DS D	By Age: <1	0		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	11,347	9,500	Redacted
VMMC_CIRC_DS D	By Age: 15-19	14,800	12,000	Redacted
VMMC_CIRC_DS D	By Age: 20-24	10,360	9,800	Redacted
VMMC_CIRC_DS D	By Age: 25-49	12,334	10,436	Redacted
VMMC_CIRC_DS D	By Age: 50+	493	550	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	49,334	42,286	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	1,727	1,743	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	45,567	40,523	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	50	20	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	44,334	42,286	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	5,000		Redacted



	,		T	
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	32,067	32,377	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	17,267	9,909	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	46,867	42,286	Redacted
HTC_TST_DSD	By Test Result: Negative	45,930	41,000	Redacted
HTC_TST_DSD	By Test Result: Positive	937	1,286	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	46,867	42,286	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	10,779	9,500	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	14,060	12,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	9,842	9,800	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	11,717	10,436	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	469	550	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	46,867	42,286	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,779	9,500	Redacted



Г	T		ı	i .
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	36,088	32,786	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,779	9,500	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	36,088	32,786	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	46,867	42,286	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	46,867	42,286	Redacted
HTC_TST_NGI	By Test Result: Negative	45,930	41,000	Redacted
HTC_TST_NGI	By Test Result: Positive	937	1,286	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	46,867	42,286	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	10,779	9,500	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	14,060	12,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	9,842	9,800	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	11,717	10,436	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	469	550	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	46,867	42,286	Redacted



	<u> </u>		ı	,
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	7	Redacted
LAB_CAP_DSD	By clinical laboratories	0	0	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	7	7	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	7	7	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	7	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	12	5	Redacted
HRH_PRE	By Graduates: Doctors	2	0	Redacted
HRH_PRE	By Graduates: Nurses	10	5	Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	By Graduates: Other	0		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	12	5	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	7	7	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	7	7	Redacted



Mechanism ID: 13567	Mechanism Name: GH1151			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: University of California at San Francisco				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 1,377,427				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

Sub Partner Name(s)

Anova Health Institute	Desmond Tutu HIV Foundation	San Francisco Department of Public Health
University of the Free State, Center for Health Systems		
Research and Development		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Custom

(No data provided.)

Budget Code Information

Budget Oode information				
Mechanism ID: 1	13567			



Mechanism Name: Prime Partner Name:	GH1151 University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	9		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	8		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	9		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	424		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations	424		Redacted



	reached with individual and/or small		
	group level HIV preventive		
	interventions that are based on		
	evidence and/or meet the minimum		
	standards required)		
	Number of individuals who received		
HTC_TST_NGI	T&C services for HIV and received their	2,475	Redacted
	test results during the past 12 months		
HTC_TST_NGI	By Test Result: Negative	902	Redacted
HTC_TST_NGI	By Test Result: Positive	1,573	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	2,475	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,832	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	643	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	2,475	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	2,475	Redacted

Mechanism ID: 13558	Mechanism Name: GH1151			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Human Science Research Council of South Africa				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 502,614				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Information				
Mechanism ID:	13558			
Mechanism Name:	GH1151			
Prime Partner Name:	Human Science Research Council of South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	4	4	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery	4	4	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	4	4	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	200	200	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200	200	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	260	260	Redacted
HTC_TST_DSD	By Test Result: Negative	200	200	Redacted
HTC_TST_DSD	By Test Result: Positive	60	60	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	260	260	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	20	20	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	125	125	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	95	95	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	20	20	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	260	260	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	260	260	Redacted



	PERMISSION ONLY: 15+ Male			
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	260	260	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex	260	260	Redacted
	disaggregates Number of individuals who received			
HTC TST NGI	T&C services for HIV and received their	260	260	Redacted
1110_131_101	test results during the past 12 months	200	200	Neuacieu
HTC_TST_NGI	By Test Result: Negative	200	200	Redacted
HTC_TST_NGI	By Test Result: Positive	60	60	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	260	260	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	20	20	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	125	125	Redacted
HTC TST NGI	Age/sex: 25-49 Male	95	95	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	20	20	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	260	260	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	260	260	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	260	260	Redacted
1110_101_1(0)	Sum of Aggregated Age/Sex	200	200	rtoddotod
HTC_TST_NGI	disaggregates	260	260	Redacted
	Number of HIV-positive individuals			
C2.1.D_DSD	receiving a minimum of one clinical	50 50	50	Redacted
	service			
C2.1.D_DSD	By Age/Sex: 15+ Male	50	50	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	50	50	Redacted
C2.1.D_DSD	By Age: 15+	50	50	Redacted
C2.1.D_DSD	Sum of Age disaggregates	50	50	Redacted
C2.1.D_DSD	By Sex: Male	50	50	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	50	50	Redacted
	Number of HIV-positive individuals			
C2.4.D_DSD	receiving a minimum of one clinical	50	50	Redacted
	service			
CARE_CURR_TA	Number of HIV positive adults and	50	50	Redacted
	children who received at least one of			



	the following during the reporting			
	period: clinical assessment (WHO			
	staging) OR CD4 count OR viral load			
CARE_CURR_TA	Age/sex: 15-19 Male	4	4	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	30	30	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	14	14	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	2	2	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	50	50	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50	50	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	50	50	Redacted

Mechanism ID: 13000	Mechanism Name: Council of Scientific and Industrial Research		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 555,313	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 404,687			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	555,313		

Sub Partner Name(s)

University of Cape Town	University of Pretoria, South Africa	University of Venda, South Africa
University of Cape Town	University of Fredoria, South Africa	Offiversity of Verida, South Africa



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

ㅁ	budget Code information				
	Mechanism ID:	13000			
	Mechanism Name:	Council of Scientific and Industrial Research			
	Prime Partner Name:	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH			
	Strategic Area	Budget Code Planned Amount On Hold Amount			
	Care	HVTB	555,313	0	

Implementing Mechanism Indicator Information

(No data provided.)

,			
Mechanism ID: 12887	Mechanism Name: GH11-1152 Comp Prev		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: AIDS Foundation			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 880,000			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		



GHP-State	0
orn otato	

LifeLine PMB	Thandanani	Umvoti Aids Centre

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population

ТВ

End-of-Program Evaluation

Budget Code Information

Budget Gode Inform			
Mechanism ID:	12887		
Mechanism Name:	GH11-1152 Comp Prev		
Prime Partner Name:	AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	7	6	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	7	6	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	7	6	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	7	6	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	110,000	35,280	Redacted
PP_PREV_DSD	Total number of people in the target population	1,060,995	800,000	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	5,000	2,000	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	15,000	4,000	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	15,000	4,280	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	15,000	4,000	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	5,000	2,000	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	5,000	2,000	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	15,000	5,000	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	15,000	5,000	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	15,000	5,000	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	5,000	2,000	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	110,000	35,280	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	72,000	26,460	Redacted



			<u> </u>	1
	test results during the past 12 months			
HTC_TST_DSD	Age/sex: 10-14 Male	1,500	400	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	7,000	3,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	12,000	4,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	10,500	4,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,000	2,000	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,500	400	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	7,000	2,000	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	12,000	3,500	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	10,500	4,160	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,000	3,000	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	72,000	26,460	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	72,000	26,460	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,500	400	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	7,000	3,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	12,000	4,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	10,500	4,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,000	2,000	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,500	400	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	7,000	2,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	12,000	3,500	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	10,500	4,160	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,000	3,000	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	72,000	26,460	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	7,560	2,400	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	7	6	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported	7	6	Redacted



	HIV service delivery points: PMTCT,			
	Care and Treatment			
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	7	6	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	7	6	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	7	6	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	7	6	Redacted
FPINT_SITE_DSD	Service delivery type: Community	7	6	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	7	6	Redacted

, ,	T T		
Mechanism ID: 12840	Mechanism Name: Pathfinder		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Pathfinder International			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 433,352 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 490,237				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	433,352			



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Pathfinder		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	26,553	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	17,702	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	17,702	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	53,105	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	26,553	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	291,737	0



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	19	19	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	7		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	12	19	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	7		Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	8	15	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	7		Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	8	15	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	7		Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	8	15	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	7		Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	8	15	Redacted
SITE_SUPP	By program area/support type:	7		Redacted



	I			i 1
	PHDP/Family Planning & Integration			
	Direct Service Delivery (DSD)			
	By program area/support type:			
SITE_SUPP	PHDP/Family Planning & Integration	8	15	Redacted
	Technical Assistance-only (TA)			
	Number of HIV-positive pregnant			
DMTCT ADV DC	women who received antiretrovirals to			
PMTCT_ARV_DS	reduce risk of	414		Redacted
D	mother-to-child-transmission (MTCT)			
	during pregnancy and delivery			
D14T0T ADV D0	Number of HIV- positive pregnant			
PMTCT_ARV_DS	women identified in the reporting period	427		Redacted
D	(including known HIV-positive at entry)			
PMTCT_ARV_DS				
D	Life-long ART (including Option B+)	414		Redacted
	Sub-Disag of Life-long ART: Newly			
PMTCT_ARV_DS	initiated on treatment during the current	412		Redacted
D	pregnancy			
	Sub-Disag of Life-long ART: Already on			
PMTCT_ARV_DS	treatment at the beginning of the	2		Redacted
D	current pregnancy	_		
PMTCT_ARV_DS	. 5			
D	Sum of Regimen Type disaggregates	414		Redacted
PMTCT_ARV_DS				
D D	Sum of New and Current disaggregates	414		Redacted
	Number of HIV-positive pregnant			
	women who received antiretrovirals to			
PMTCT_ARV_NGI		886		Redacted
WITCI_ARV_NOI	mother-to-child-transmission (MTCT)	000		Nedacted
	during pregnancy and delivery			
PMTCT ARV NGI	Number of HIV- positive pregnant women identified in the reporting period	914		Redacted
FINITCT_ARV_NGI	(including known HIV-positive at entry)	914		Redacted
DMTOT ADV NO	, , , , , , , , , , , , , , , , , , , ,	000		Dodestad
PMTCT_ARV_NGI		886		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly	882		Redacted



	I			1
	initiated on treatment during the current			
	pregnancy			
	Sub-Disag of Life-long ART: Already on			
PMTCT_ARV_NGI	treatment at the beginning of the	4		Redacted
	current pregnancy			
	Maternal AZT (prophylaxis component			
PMTCT_ARV_NGI	of WHO Option A during pregnancy	0		Redacted
	and delivery)			
PMTCT_ARV_NGI	Sum of Regimen disaggregates	886		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	886		Redacted
	Number of HIV-positive pregnant			
	women who received antiretrovirals to			
PMTCT_ARV_TA	reduce risk of	472	990	Redacted
	mother-to-child-transmission (MTCT)			
	during pregnancy and delivery			
	Number of HIV- positive pregnant			
PMTCT_ARV_TA	women identified in the reporting period	487	1,018	Redacted
	(including known HIV-positive at entry)			
PMTCT_ARV_TA	Life-long ART (including Option B+)	472	990	Redacted
	Sub-Disag of Life-long ART: Newly			
PMTCT_ARV_TA	initiated on treatment during the current	470	985	Redacted
	pregnancy			1
	Sub-Disag of Life-long ART: Already on			
PMTCT_ARV_TA	treatment at the beginning of the	2	5	Redacted
	current pregnancy			
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	472	990	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	472	990	Redacted
	Number of pregnant women with known			
PMTCT_STAT_DS	HIV status (includes women who were	1 410		Redacted
D	tested for HIV and received their	1,410		Redacted
	results)			
PMTCT_STAT_DS	Number of new ANC and L&D clients	1,484		Redacted
D	Trainber of New Airo and Lab clients	1,704		Neuduleu
PMTCT_STAT_DS	By: Known positives at entry	17		Redacted



D				
PMTCT_STAT_DS D	By: Number of new positives identified	410		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	427		Redacted
PMTCT_STAT_NG	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,000		Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	3,157		Redacted
PMTCT_STAT_NG	By: Known positives at entry	36		Redacted
PMTCT_STAT_NG	By: Number of new positives identified	878		Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	914		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,590	3,395	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,673	3,500	Redacted
PMTCT_STAT_TA	By: Known positives at entry	19	41	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	468	977	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	487	1,018	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,960		Redacted
HTC_TST_DSD	By Test Result: Negative	0		Redacted
HTC_TST_DSD	By Test Result: Positive	2,960		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	2,960		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	298		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	486		Redacted



	1		T	1
	PERMISSION ONLY: 15+ Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	530		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,646		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	828		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,132		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,960		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,000		Redacted
HTC_TST_NGI	By Test Result: Negative	6,340		Redacted
HTC_TST_NGI	By Test Result: Positive	1,660		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	8,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	810		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,310		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,427		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	4,453		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	2,237		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	5,763		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	8,000		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,040	10,260	Redacted
HTC_TST_TA	By Test Result: Negative	3,995	8,143	Redacted
HTC_TST_TA	By Test Result: Positive	1,045	2,117	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	5,040	10,260	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	511	1,086	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	825	1,590	Redacted



			1	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	897	1,842	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,807	5,742	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,408	2,928	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	3,632	7,332	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	5,040	10,260	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	624		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	98		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	63		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	117		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	346		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	624		Redacted
C2.1.D_DSD	By Age: <15	161		Redacted
C2.1.D_DSD	By Age: 15+	463		Redacted
C2.1.D_DSD	Sum of Age disaggregates	624		Redacted
C2.1.D_DSD	By Sex: Female	444		Redacted
C2.1.D_DSD	By Sex: Male	180		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	624		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,328		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	218		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	134		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	237		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	739		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,328		Redacted
C2.1.D_NGI	By Age: <15	352		Redacted
C2.1.D_NGI	By Age: 15+	976		Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,328		Redacted



C2.1.D_NGI	By Sex: Female	957	Redacted
C2.1.D_NGI	By Sex: Male	371	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,328	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	704	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	115	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	72	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	125	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	392	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	704	Redacted
C2.1.D_TA	By Age: <15	187	Redacted
C2.1.D_TA	By Age: 15+	517	Redacted
C2.1.D_TA	Sum of Age disaggregates	704	Redacted
C2.1.D_TA	By Sex: Female	507	Redacted
C2.1.D_TA	By Sex: Male	197	Redacted
C2.1.D_TA	Sum of Sex disaggregates	704	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	443	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	624	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	415	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	427	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	415	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	415	Redacted



	1		I	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	141		Redacted
TX_CURR_DSD			Redacted	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	51		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	7		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	76		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	14		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	127		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	141		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	661		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	33		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	238		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	33		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	357		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	661		Redacted
TX_CURR_NGI	_CURR_NGI Sum of Aggregated Age/Sex <15 66		Redacted	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	595		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	520	1,050	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	26	53	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	187	378	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	26	53	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	281	566	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	52	106	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	468	944	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	520	1,050	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	165		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	8		Redacted



	Male		
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	59	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	8	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	90	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	165	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	141	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	141	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART	127	Redacted



in the 12 months prior to the beginning		
of the reporting period, including those		
who have died, those who have		
stopped ART, and those lost to		
follow-up)		

Mechanism ID: 12510	Mechanism Name: South Africa Partners			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: South Africa Partners				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 953,485	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

lMasibambane lZoe-Life l	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

ΤB



Budget Code Information

Baaget Goad Inform			
Mechanism ID:	12510		
Mechanism Name:	South Africa Partners		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	pported by 171		Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	171		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	2		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	ion 171		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,950	2,600	Redacted
PP_PREV_DSD	Total number of people in the target	3,690	3,690	Redacted



	population			
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD			Redacted	
PP_PREV_DSD	Age/sex: 20-24 Male	800	900	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,700	1,200	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	100	200	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,950	2,600	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	73,550		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	1,608		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	5,780		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	3,622		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	6,543		Redacted
PP_PREV_TA	Age/sex: 50+ Male	3,711		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	2,189		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	11,653		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	13,227		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	16,927		Redacted
PP_PREV_TA	Age/sex: 50+ Female	8,290		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	73,550		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	65,260		Redacted
GEND_NORM_DS D	By Age: 0-9	0		Redacted



GEND_NORM_DS D	By Age: 10-14	497	Redacted
GEND_NORM_DS D	By Age: 15-19	12,443	Redacted
GEND_NORM_DS D	By Age: 20-24	16,849	Redacted
GEND_NORM_DS D	By Age: 25+	35,471	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	65,260	Redacted
GEND_NORM_DS D	By Sex: Male	43,996	Redacted
GEND_NORM_DS D	By Sex: Female	21,264	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	65,260	Redacted
GEND_NORM_DS D	By type of activity: Small Group	65,260	Redacted
GEND_NORM_DS D	By type of activity: Community-level	33,892	Redacted

Mechanism ID: 12509	Mechanism Name: WAMTechnology		
Funding Agency: HHS/CDC	Procurement Type: Contract		
Prime Partner Name: WamTechnology			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 863,940			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		



GHP-State	0

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code illioilli	ation		
Mechanism ID:	12509		
Mechanism Name:	WAMTechnology		
Prime Partner Name:	WamTechnology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 11500	Mechanism Name: Community Grants	
Funding Agency: State/AF	Procurement Type: Cooperative Agreement	
Prime Partner Name: U.S. Department of Sta	ate	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		



G2G: No	Managing Agency:	
Total All Funding Sources: 1,490,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0	,	
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	1,490,000	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	20,000	
Focus Area:	Changing harmful gender norms and promoting positive gender norms	
Sub Area:	Implementation	
Focus Area:	Increase gender-equitable access to income and productive resources, including education	
Water	65,000	
Economic Strengthening	300,000	

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	11500		
Mechanism Name:	Community Grants		
Prime Partner Name:	U.S. Department of Stat	е	
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	НВНС	345,000	0
Strategic Area	Budget Code	Planned Amount On Hold	
Care	HKID	1,145,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
OVC_SERV_DSD	Sex: Male	10,000	5,000
OVC_SERV_DSD	Sex: Female	10,000	5,000
OVC_SERV_DSD	Sum of Sex disaggregates	20,000	10,000

Implementing Mechanism Details

Mechanism ID: 11498 Mechanism Name: U.S. Peace Corps		
Funding Agency: PC	Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 425,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	425,000	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Malaria (PMI) Child Survival Activities

Budget Code Information				
Mechanism ID:	11498			
Mechanism Name:	U.S. Peace Corps			
Prime Partner Name:	U.S. Peace Corps	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	52,200	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HKID	172,800	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVAB	100,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	100,000	0	

Indicator Number	Label	2014	2015
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	36,000	
PP_PREV_DSD	Total number of people in the target	35,000	35,000



	population		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	10,000	10,000
OVC_ACC_DSD Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		18,000	18,000

Mechanism ID: 9821	Mechanism Name: CAPRISA	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

ZIMNANDI ZONKE		
----------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Pudget Code Information

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	CAPRISA : University of Kwazulu-Natal, Nelson Mandela School of Medicine.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 9816	Mechanism Name: The Thogomleo Project
mediamoni ib. 3010	(AIDSTAR)



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Program for Appropriate Technology in Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,125,000	
FY 2013 Burn Rate: Redacted	
Funding Source Funding Amount	
GHP-State	0

Health and Development Africa	International HIV/AIDS Alliance	
-------------------------------	---------------------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9816		
Mechanism Name:	The Thogomleo Project	(AIDSTAR)	
Prime Partner Name:	Program for Appropriat	e Technology in Health	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	8	9
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	8	9
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	360	192
HRH_PRE	By Graduates: Social service workers	90	48
HRH_PRE	By Graduates: Other	270	144
HRH_PRE	Sum of Graduates disaggreagtes	360	192

Mechanism ID: 9610	Mechanism Name: Migrants and Mobile Populations HIV Prevention Program	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: International Organization for Migration		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 901,762		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	



Center for Positive Care	CHoiCe Trust	Hoedspruit Training Trust
Nkomazi Municipality		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population
TB
Workplace Programs
End-of-Program Evaluation

Budget Code Information

Budget oode inform				
Mechanism ID:	D: 9610			
Mechanism Name:	Migrants and Mobile Populations HIV Prevention Program			
Prime Partner Name:	International Organization for Migration			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Care	НВНС	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	4	4
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	4	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	4	4
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	2	2
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)		4
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	4	4
SITE_SUPP	By program area/support type: General SITE_SUPP Population Prevention Technical Assistance-only (TA)		2
SITE_SUPP	By program area/support type: Key		2
PP_PREV_DSD	PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.		50,000
PP_PREV_DSD	Total number of people in the target population	500,000	500,000
PP_PREV_DSD	Age/sex: 20-24 Male	10,000 10,000	



PP_PREV_DSD	Age/sex: 25-49 Male	10,000	10,000
PP_PREV_DSD	Age/sex: 50+ Male	5,000	5,000
PP_PREV_DSD	Age/sex: 20-24 Female 10,		10,000
PP_PREV_DSD	Age/sex: 25-49 Female	10,000	10,000
PP_PREV_DSD	Age/sex: 50+ Female	5,000	5,000
PP_PREV_DSD	Sum of Age/Sex disaggregates	50,000	50,000
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	80	90
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	80	90
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,000	
HTC_TST_DSD	By Test Result: Negative	4,500	
HTC_TST_DSD	By Test Result: Positive	5,500	
HTC_TST_DSD	Sum of Test Result disaggregates	10,000	
HTC_TST_DSD	Age/sex: 20-24 Male	1,000	
HTC_TST_DSD	Age/sex: 25-49 Male	3,000	
HTC_TST_DSD	Age/sex: 50+ Male	1,000	
HTC_TST_DSD	Age/sex: 20-24 Female	1,000	
HTC_TST_DSD	Age/sex: 25-49 Female	3,000	
HTC_TST_DSD	Age/sex: 50+ Female	1,000	
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,000	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,000	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,000	



	1		
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,000	
	Number of individuals who received T&C		
HTC_TST_NGI	services for HIV and received their test results	10,000	
	during the past 12 months		
HTC_TST_NGI	By Test Result: Negative	4,500	
HTC_TST_NGI	By Test Result: Positive	5,500	
HTC_TST_NGI	Sum of Test Result disaggregates	10,000	
HTC_TST_NGI	Age/sex: 20-24 Male	1,000	
HTC_TST_NGI	Age/sex: 25-49 Male	3,000	
HTC_TST_NGI	Age/sex: 50+ Male	1,000	
HTC_TST_NGI	Age/sex: 20-24 Female	1,000	
HTC_TST_NGI	Age/sex: 25-49 Female	3,000	
HTC_TST_NGI	Age/sex: 50+ Female	1,000	
HTC_TST_NGI	Sum of Age/Sex disaggregates	10,000	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	5,000	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	5,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	10,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	10,000	
GEND_GBV_DSD	Number of people receiving post-GBV care	100	100
GEND_GBV_DSD	Age: 15-17	20	20
GEND_GBV_DSD	Age: 18-24	50	50
GEND_GBV_DSD	Age: 25+	30	30
GEND_GBV_DSD	Sum of Age disaggregates	100	100
GEND_GBV_DSD	Sex: Male	20	20
GEND_GBV_DSD	Sex: Female	80	80
GEND_GBV_DSD	Sum of Sex disaggregates	100	100
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	50	50
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	50	50
GEND_GBV_DSD	By PEP service provision (related to sexual	0	0



	violence services provided)		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	20,000	20,000
GEND_NORM_DSD	By Age: 20-24	5,000	5,000
GEND_NORM_DSD	By Age: 25+	15,000	15,000
GEND_NORM_DSD	Sum of Age disaggregates	20,000	20,000
GEND_NORM_DSD	By Sex: Male	15,000	15,000
GEND_NORM_DSD	By Sex: Female	5,000	5,000
GEND_NORM_DSD	Sum of Sex disaggregates	20,000	20,000
GEND_NORM_DSD	By type of activity: Individual	1,000	1,000
GEND_NORM_DSD	By type of activity: Small Group	2,000	2,000
GEND_NORM_DSD	By type of activity: Community-level	17,000	17,000
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service		
C2.1.D_DSD	By Age/Sex: 15+ Female	200	
C2.1.D_DSD	By Age/Sex: 15+ Male	200	
C2.1.D_DSD	Sum of Age/Sex disaggregates	400	
C2.1.D_DSD	By Age: 15+	400	
C2.1.D_DSD	Sum of Age disaggregates	400	
C2.1.D_DSD	By Sex: Female	200	
C2.1.D_DSD	By Sex: Male	200	
C2.1.D_DSD	Sum of Sex disaggregates	400	
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service		400	
C2.1.D_NGI	By Age/Sex: 15+ Female	200	
C2.1.D_NGI	By Age/Sex: 15+ Male	200	
C2.1.D_NGI	Sum of Age/Sex disaggregates	400	
C2.1.D_NGI	By Age: 15+	400	
C2.1.D_NGI	Sum of Age disaggregates	400	
C2.1.D_NGI	By Sex: Female	200	
C2.1.D_NGI	By Sex: Male	200	



C2.1.D_NGI	Sum of Sex disaggregates	400	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	200	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	400	

Mechanism ID: 9590 Mechanism Name: Lifeline Mafikeng			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Lifeline Mafikeng			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

otal All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

Gelduldspan HBC	Kraaipan Community Project	LifeLine Mafikeng Centre PTC
Tlamelo TB & HIV&AIDS HBC	Tshwaraganang Barolong Project	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



ТВ

Budget Code Information

Zuuget eeue mierin	a		
Mechanism ID:	9590		
Mechanism Name:	Lifeline Mafikeng		
Prime Partner Name:	Lifeline Mafikeng		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9569	TBD: Yes
REDACTED	

Mechanism ID: 9562	Mechanism Name: National Alliance of State and Territorial AIDS Directors	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Alliance of State and Territorial AIDS Directors		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 639,000	
FY 2013 Burn Rate: Redacted	



Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Dauget Gode Internit	411011		
Mechanism ID:	9562		
Mechanism Name:	National Alliance of Sta	te and Territorial AIDS Di	irectors
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	125		Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	125		Redacted



SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	125		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,912	11,137	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	159	111	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	3,023	2,116	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	1,273	891	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	11,457	8,019	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	15,912	11,137	Redacted

Implementing Mechanism Details

Mechanism ID: 9529	Mechanism Name: South Africa National Blood Service	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: South Africa National Blood Se	ervice	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,388,000		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Į	Budget Code Informa	ation		
	Mechanism ID:	9529		
ı	Mechanism Name:	South Africa National Blood Service		
	Prime Partner Name:	South Africa National B	lood Service	
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Governance and Systems	HLAB	0	0
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 9526	Mechanism Name: Supply Chain Management System (SCMS)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Partnership for Supply Chain N	Management (
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	



Total All Funding Sources: 4,562,674	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 3,159,089		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	4,562,674	

l .	1	
E 15115	1	
	1	
II UCI I IID	1	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

	Judgot Godo III of III de la companya de la company			
Mechanism ID:	Mechanism ID: 9526			
Mechanism Name:	Supply Chain Management System (SCMS)			
Prime Partner Name:	Partnership for Supply	Partnership for Supply Chain Management		
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	OHSS	3,562,674	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	CIRC	1,000,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXD	0	0	



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

implementing Meenamen Details		
Mechanism ID: 9521	Mechanism Name: Southern African Catholic Bishops" Conference (SACBC)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: SOUTHERN AFRICAN CATHO	OLIC BISHOP'S CONFERENCE (SACBC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Sub Partner Name(s)

Catholic Relief Services	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Budget Code Illioilli	sudget Code Information		
Mechanism ID:	9521		
Mechanism Name:	Mechanism Name: Southern African Catholic Bishops" Conference (SACBC)		
Prime Partner Name:	SOUTHERN AFRICAN CATHOLIC BISHOP'S CONFERENCE (SACBC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	O	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	O	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	O	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	o	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	О	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 9509	Mechanism Name: St. Mary"s Hospital (St Mary"s)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	



Prime Partner Name: St. Mary's Hospital		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	All Funding Sources: 0 Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

_ uugu			
Mechanism ID: 9509			
Mechanism Name:	Mechanism Name: St. Mary"s Hospital (St Mary"s)		
Prime Partner Name:	ame: St. Mary's Hospital		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 9497	Mechanism Name: University of KwaZulu-Natal Innovations	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: UNIVERSITY OF KWAZULU-N	NATAL INNOVATIONS	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	



GHP-State	0

Institute for Healthcare	
Improvement (IHI)	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities Workplace Programs Family Planning

Budget Code Information

Budget Code Illionia	ation		
Mechanism ID:	9497		
Mechanism Name:	University of KwaZulu-Natal Innovations		
Prime Partner Name:	UNIVERSITY OF KWAZULU-NATAL INNOVATIONS		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 9496	Mechanism Name: Re-Action!		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Xstrata Coal SA & Re-Action!			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source Funding Amount				
GHP-State	0			

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

baaget boat information			
Mechanism ID:	9496		
Mechanism Name:	Re-Action!		
Prime Partner Name:	Xstrata Coal SA & Re-Action!		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 9464	Mechanism Name: Africare	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	



Prime Partner Name: Africare				
Agreement Start Date: Redacted Agreement End Date: Redacted				
TBD: No New Mechanism: No				
Global Fund / Multilateral Engagement: No				
G2G: No Managing Agency:				

Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 515,666				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

Adelaide Advice Centre	Adelaide Child Welfare	Akhanani
Bolotwa Domestic Violence	CSOS-IT	Ebenezer
Empilweni HCBC	Good Samaritan HBC	Health Information Systems Program
House of Hope Hospice	Ikwezi Lomzo	Ilingelethu HCBC
Ilitha Psychological Centre	Ilitha Soup Kitchen	Imbumba HCBC
Inkwanca HBC	Isolomzi Community Health Organization	Jabez AIDS Health Centre
Malibongwe	Masibambane HBC	Masibambane HCBC
Meropa Communications	Middleburg HCBC	Mnqediqiqa
Mother Soul Home Based Care	Mthombowempilo HBC	Mzamomhle
Ndonga HCBC	Noncedo Home Based Care	Ntllontle
Othwadweni HCBC	Rise and Shine Home Based Caregivers Project	Sakhingomso Indwe Community Group
Sikhanyisile Home Based Care Group	Sikunye HCBC	Silindini HCBC
Silondolozi Mpilo	Siluncedo HCBC	Sinako
Sinako Wellness and Development Organization	Sinalo Itembalokupila	Sinethemba HBC



Sinethemba Organization	Sinovuyo HCBC	Siphakamise Revive Home Based Care
Sisonke HCHB	Sixolisile HCBC	Siyakhana Community Based Organization
Siyanceda Home Based Care	Siyaphila HBC	Siyazana
Siyazingca Ngenkcubeko Yethu Community Project	Sophila Sonke HCBC	Sunshine Coast Hospice
Thandisizwe HCBC	Tsomo Family Resource Centre	Tswaranang Northern Region Resource Centre
Tyhilulwazi Multi-purpose Centre	Umthombo Wesisa	Uncedo
Yinjongo Yethu	Yolisa HCBC	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities
Mobile Population
Safe Motherhood
TB
End-of-Program Evaluation
Family Planning

Budget Code Information

Mechanism ID:	9464		
Mechanism Name:	Africare		
Prime Partner Name:	Africare		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	170	140	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	170	140	Redacted



	1			1
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	170	140	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	170	140	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	169	140	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	170	140	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	50	40	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,216		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,425		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,481		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,925		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	936		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	1,635		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	90		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	10		Redacted



PMTCT_ARV_NGI	Sum of Regimen disaggregates	4,216		Redacted
	Sum of New and Current disaggregates	2,861		Redacted
	Number of HIV-positive pregnant women who received antiretrovirals to	_,		
PMTCT_ARV_TA	reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,216	4,216	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,425	4,425	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,481	2,481	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,925	1,925	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	936	936	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	1,635	1,635	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	90	90	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	10	10	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	4,216	4,216	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,861	2,861	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	160	160	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	169	169	Redacted
PMTCT_SITE	By site support type: Technical	160	160	Redacted



	1			1
	Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women			
PMTCT_SITE	Sum of Numerator Support Type disaggregates	160	160	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	169	169	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	169	169	Redacted
PMTCT_STAT_NG	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,554		Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	23,554		Redacted
PMTCT_STAT_NG	By: Known positives at entry	1,369		Redacted
PMTCT_STAT_NG	By: Number of new positives identified	3,056		Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	4,425		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,554	23,554	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	23,554	23,554	Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,369	1,369	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	3,056	3,056	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4,425	4,425	Redacted
HTC_TST_NGI	Number of individuals who received	120,174	120,174	Redacted



	<u> </u>			1
	T&C services for HIV and received their			
	test results during the past 12 months			
HTC_TST_NGI	By Test Result: Negative	110,766	110,766	Redacted
HTC_TST_NGI	By Test Result: Positive	9,408	9,408	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	120,174	120,174	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	10,266		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	30,798		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	19,777		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	59,333		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	30,043		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	90,131		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	120,174		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,174	144,218	Redacted
HTC_TST_TA	By Test Result: Negative	110,766	132,919	Redacted
HTC_TST_TA	By Test Result: Positive	9,408	11,299	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	120,174	144,218	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,266		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,798		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,777		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	59,333		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	30,043		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	90,131		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	120,174		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children	44,800	54,000	Redacted



	and families affected by HIV/AIDS			
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	128,243		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	4,520		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	3,549		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	72,104		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	48,070		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	128,243		Redacted
C2.1.D_TA	By Age: <15	8,069		Redacted
C2.1.D_TA	By Age: 15+	120,174		Redacted
C2.1.D_TA	Sum of Age disaggregates	128,243		Redacted
C2.1.D_TA	By Sex: Female	76,624		Redacted
C2.1.D_TA	By Sex: Male	51,619		Redacted
C2.1.D_TA	Sum of Sex disaggregates	128,243		Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	170	170	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	170	170	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	170	170	Redacted



	T I			1
CARE_SITE	Sum of Numerator Site Support Type disaggregates	170	170	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	170	170	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	170	170	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	170	140	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	170	140	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	170	140	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	170	140	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	170	140	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	170	140	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated	169	140	Redacted



	1			
	voluntary family planning services			
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	169	140	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	169	140	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	169	140	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	169	140	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	169	140	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	169	140	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	169	140	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	170	140	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	170	140	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity	170	140	Redacted



	1			
	completed that addresses clinical HIV			
	programs and has documented results			
	in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	170	140	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	170	140	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	170	140	Redacted

Implementing Mechanism Details

Mechanism ID: 7225	Mechanism Name: South African Democratic Teachers Union			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: South African Democratic Teachers Union				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 0					
FY 2013 Burn Rate: Redacted					
Funding Source	Funding Amount				
GHP-State	0				

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population Workplace Programs

Budget Code Information							
Mechanism ID:	7225						
Mechanism Name:	South African Democra	South African Democratic Teachers Union					
Prime Partner Name:	South African Democra	tic Teachers Union					
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Governance and	01100						
Systems	OHSS	0	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Prevention	HVAB	0	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Prevention	HVCT	0	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Prevention	HVOP	0	0				

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 7223	Mechanism Name: Masibambisane 1
--------------------	---------------------------------



Funding Agency: DOD	Procurement Type: Cooperative Agreement	
Prime Partner Name: South Africa Military Health Service		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,500,000		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	0	

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Military Population Workplace Programs

Budget Code Information

Mechanism ID:	7223		
Mechanism Name:	Masibambisane 1		
Prime Partner Name:	South Africa Military Health Service		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	НВНС	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,300	6,000
PP_PREV_DSD	Age/sex: 15-19 Male	500	1,000
PP_PREV_DSD	Age/sex: 20-24 Male	1,000	1,500
PP_PREV_DSD	Age/sex: 25-49 Male	500	1,000
PP_PREV_DSD	Age/sex: 15-19 Female	300	500
PP_PREV_DSD	Age/sex: 20-24 Female	500	1,000
PP_PREV_DSD	Age/sex: 25-49 Female	500	1,000
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,300	6,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,000	33,000



HTC_TST_DSD	Age/sex: 15-19 Male	5,000	6,000
HTC_TST_DSD	Age/sex: 20-24 Male	5,000	6,000
HTC_TST_DSD	Age/sex: 25-49 Male	5,000	5,000
HTC_TST_DSD	Age/sex: 50+ Male	1,000	1,000
HTC_TST_DSD	Age/sex: 15-19 Female	3,500	4,000
HTC_TST_DSD	Age/sex: 20-24 Female	5,000	5,500
HTC_TST_DSD	Age/sex: 25-49 Female	5,000	5,000
HTC_TST_DSD	Age/sex: 50+ Female	500	500
HTC_TST_DSD	Sum of Age/Sex disaggregates	30,000	33,000
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,000	13,200
C2.1.D_DSD	By Age/Sex: <15 Female	1,000	1,100
C2.1.D_DSD	By Age/Sex: <15 Male	2,000	2,200
C2.1.D_DSD	By Age/Sex: 15+ Female	3,000	3,300
C2.1.D_DSD	By Age/Sex: 15+ Male	6,000	6,600
C2.1.D_DSD	Sum of Age/Sex disaggregates	12,000	13,200
C2.1.D_DSD	By Age: <15	4,000	4,400
C2.1.D_DSD	By Age: 15+	8,000	8,800
C2.1.D_DSD	Sum of Age disaggregates	12,000	13,200
C2.1.D_DSD	By Sex: Female	4,000	4,400
C2.1.D_DSD	By Sex: Male	8,000	8,800
C2.1.D_DSD	Sum of Sex disaggregates	12,000	13,200
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	9,600	10,560
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,000	13,200
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,200	3,000



CARE_NEW_DSD	Age/sex: 15-19 Male	100	150
CARE_NEW_DSD	Age/sex: 20-24 Male	500	600
CARE_NEW_DSD	Age/sex: 25-49 Male	500	600
CARE_NEW_DSD	Age/sex: 50+ Male	200	200
CARE_NEW_DSD	Age/sex: 15-19 Female	100	200
CARE_NEW_DSD	Age/sex: 20-24 Female	300	500
CARE_NEW_DSD	Age/sex: 25-49 Female	300	500
CARE_NEW_DSD	Age/sex: 50+ Female	200	250
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,200	3,000
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,000	6,600
TX_CURR_DSD	Age/Sex: 15+ Male	4,000	4,400
TX_CURR_DSD	Age/Sex: 15+ Female	2,000	2,200
HRH_PRE	By Graduates: Other	10	20
HRH_PRE	Sum of Graduates disaggreagtes	10	20
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	10	20

mpromorming moonamen zotane		
Mechanism ID: 7221	Mechanism Name: TB Project	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

otal All Funding Sources: 0 Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0			
FY 2013 Burn Rate: Redacted			
Funding Source Funding Amount			
GHP-State	0		



Health Systems Trust	International Union Against TB	Johns Hophins Health and
l lealth Systems Trust	and Lung Disease	Education South Africa (JHHESA)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

ТВ

Workplace Programs

Budget Code Information

 Baagot Godo Information			
Mechanism ID:	7221		
Mechanism Name:	TB Project		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HVTB	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	1,268	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	1,268	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	380,000	



C2.1.D_DSD	By Age/Sex: <15 Female	7,600	
C2.1.D_DSD	By Age/Sex: <15 Male	7,600	
C2.1.D_DSD	By Age/Sex: 15+ Female	258,400	
C2.1.D_DSD	By Age/Sex: 15+ Male	106,400	
C2.1.D_DSD	Sum of Age/Sex disaggregates	380,000	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	380,000	
C2.1.D_NGI	By Age/Sex: <15 Female	7,600	
C2.1.D_NGI	By Age/Sex: <15 Male	7,600	
C2.1.D_NGI	By Age/Sex: 15+ Female	258,400	
C2.1.D_NGI	By Age/Sex: 15+ Male	106,400	
C2.1.D_NGI	Sum of Age/Sex disaggregates	380,000	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	323,000	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	380,000	



Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		270,211		Redacted	270,211	43,721
ICASS		328,500		Redacted	328,500	12,266
Institutional Contractors		900,000		Redacted	900,000	535,424
Management Meetings/Profes sional Developement		421,580		Redacted	421,580	4,309
Non-ICASS Administrative Costs		1,410,075		Redacted	1,410,075	156,138
Staff Program Travel		210,278		Redacted	210,278	166,325
USG Staff Salaries and Benefits		7,859,356		Redacted	7,859,356	1,604,255
Total	0	11,400,000	0	0	11,400,000	2,522,438

U.S. Agency for International Development Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	270,211	43,721



ICASS	(GHP-State	Redacted	328,500	12,266
Management Meetings/Prof essional Developement		GHP-State	Redacted	421,580	4,309
Non-ICASS Administrative Costs	(GHP-State	Redacted	1,410,075	156,138

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		0		Redacted	0	45,000
Non-ICASS Motor Vehicles		0		Redacted	0	100,000
Staff Program Travel				Redacted	0	55,000
USG Staff Salaries and Benefits				Redacted	0	200,000
Total	0	0	0	0	0	400,000

U.S. Department of Defense Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS	Administration	IGHP-State	Operational Support	Redacted	0	45,000
Non-ICASS Motor Vehicles	Office Vehicle		Vehicle purchase and maintenance	Redacted	0	100,000



U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Prevention						
Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing	1,008,788			Redacted	1,008,788	0
Computers/IT Services		1,021,375		Redacted	1,021,375	0
ICASS	1,425,513			Redacted	1,425,513	0
Institutional Contractors	1,015,699	0		Redacted	1,015,699	0
Management Meetings/Profes sional Developement		111,800		Redacted	111,800	0
Non-ICASS Administrative Costs		2,339,490		Redacted	2,339,490	0
Staff Program Travel	0	1,729,662		Redacted	1,729,662	0
USG Staff Salaries and Benefits	0	6,289,113		Redacted	6,289,113	0
Total	3,450,000	11,491,440	0	0	14,941,440	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	Item Funding	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
----------	--------------	-------------	------------------------------	--------	---------------------



Capital Security Cost		GAP	OBO Cost	Redacted	1,008,788	0
Sharing Computers/IT Services	Business Support: \$245050 & ITSO \$776,325	GHP-State		Redacted	1,021,375	0
ICASS		GAP		Redacted	1,425,513	0
Management Meetings/Prof essional Developement		GHP-State		Redacted	111,800	0
Non-ICASS Administrative Costs	USDH Res\$410,177; USDH Relocation \$150,000	GHP-State		Redacted	2,339,490	0

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		215,000		Redacted	215,000	0
Computers/IT Services		33,000		Redacted	33,000	30,834



Total	0	2,941,014	0		0 2,941,014	2,286,038
Benefits						
Salaries and		1,550,000			1,550,000	1,852,131
USG Staff				Redacted		
Staff Program Travel		199,928		Redacted	199,928	109,046
Administrative Costs		278,086			278,086	182,725
Non-ICASS				Redacted		
Developement						
Meetings/Profes sional		215,000			215,000	111,302
Management				Redacted		
ICASS		450,000		Redacted	450,000	0

U.S. Department of State Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	215,000	0
Computers/IT Services		GHP-State		Redacted	33,000	30,834
ICASS		GHP-State		Redacted	450,000	0
Management Meetings/Prof essional Developement		GHP-State		Redacted	215,000	111,302
Non-ICASS Administrative Costs	100,000 for PEPFAR PD activities to PAS	GHP-State	7400 phones,10660 recruit,39495 furn supplies,1290	Redacted	278,086	182,725



		printing,30318		
		5 contracts		

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		2,300		Redacted	2,300	0
Management Meetings/Profes sional Developement		10,000		Redacted	10,000	0
Non-ICASS Administrative Costs		195,200		Redacted	195,200	0
Peace Corps Volunteer Costs		1,245,800		Redacted	1,245,800	408,680
Staff Program Travel		20,600		Redacted	20,600	0
USG Staff Salaries and Benefits		476,100		Redacted	476,100	0
Total	0	1,950,000	0	0	1,950,000	408,680

U.S. Peace Corps Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As	Amount	Applied Pipeline
				Of Last Q1		- 1
Computers/IT Services		GHP-State		Redacted	2,300	0
Management		GHP-State		Redacted	10,000	0



Meetings/Prof essional					
Developement					
		60000	Redacted		
		facilities,			
Non ICASS		35000 equip&			
Non-ICASS Administrative	CLID Ctata	supplies,		195,200	
		40000			0
Costs		communicatio			
		ns, 60000			
		contracts			